Whsc1l1 Regulates Estrogen Receptor Activity In Sum44 Breast Cancer Cells by Irish, Jonathan Curtis
Wayne State University
Wayne State University Dissertations
1-1-2016
Whsc1l1 Regulates Estrogen Receptor Activity In
Sum44 Breast Cancer Cells
Jonathan Curtis Irish
Wayne State University,
Follow this and additional works at: https://digitalcommons.wayne.edu/oa_dissertations
Part of the Oncology Commons
This Open Access Dissertation is brought to you for free and open access by DigitalCommons@WayneState. It has been accepted for inclusion in
Wayne State University Dissertations by an authorized administrator of DigitalCommons@WayneState.
Recommended Citation
Irish, Jonathan Curtis, "Whsc1l1 Regulates Estrogen Receptor Activity In Sum44 Breast Cancer Cells" (2016). Wayne State University
Dissertations. 1641.
https://digitalcommons.wayne.edu/oa_dissertations/1641
WHSC1L1 REGULATES ESTROGEN RECEPTOR 
ACTIVITY IN SUM44 BREAST CANCER CELLS 
 
by 
JONATHAN CURTIS IRISH 
DISSERTATION 
Submitted to the Graduate School 
of Wayne State University, 
Detroit, Michigan 
in partial fulfillment of the requirements 
for the degree of  
DOCTOR OF PHILOSOPHY 
2016 
MAJOR: Cancer Biology 
Approved By: 
        
 Advisor                                  Date 
             
 
        
 
        
 
        
  
 
 
 
 
 
 
© COPYRIGHT BY 
 
JONATHAN CURTIS IRISH 
 
2016 
 
All Rights Reserved 
  ii 
DEDICATION 
 
 
I dedicate this work to my loving, patient wife Cesira. 
 
To my parents, Lori and Sean, who have been unwavering in their support of me 
and my family during my temporally and geographically long educational journey. 
 
 Finally, to my grandparents and aunt, Curtis, Norma, and Linda, for motivating 
me to study cancer. 
 
 
  iii 
ACKNOWLEDGEMENTS 
 
I would like to thank my mentor, Dr. Ethier, for providing an environment 
where I could learn think critically and become proficient at applying the scientific 
method to problems in biology. I owe my future in science in no small part to the 
time spent with Dr. Ethier and all of the members of the Ethier lab from whom I 
was able to learn so much. Thank you also to Dr. Wilson and the MUSC 
sequencing core for their patience and expertise during my struggles with my 
next-gen sequencing experiments. 
 
I also would like to thank Dr. Yang for his co-mentorship at Wayne State, 
and his support in helping me with my understanding of my work in the context of 
previous work performed by him and others in the Ethier lab, and especially with 
his help in organizing and structuring my writing for my dissertation.  
 
Thank you to Dr. Sheng for giving me my first chance in the lab, and for 
allowing me to develop my passion for developing the technical skills required to 
perform challenging experiments soundly.  
 
To my committee, particularly Dr. Matherly, and Dr. Brush, thank you so 
much for your guidance and patience. I could not have done this without your 
support. 
  iv 
TABLE OF CONTENTS 
DEDICATION	................................................................................................................	ii	
ACKNOWLEDGEMENTS	...............................................................................................	iii	
LIST	OF	TABLES	..........................................................................................................	viii	
LIST	OF	FIGURES	.........................................................................................................	ix	
LIST	OF	ABBREVIATIONS	.............................................................................................	xi	
CHAPTER	1				INTRODUCTION	......................................................................................	1	
1.1	General	Introduction	.....................................................................................................	1	
1.2	Genomic	basis	of	cancer	................................................................................................	4	
1.3	Breast	Cancer	Oncogenomics	.........................................................................................	7	
1.4	Epigenetic	Regulation	....................................................................................................	8	
1.4.1	DNA	Methylation	...........................................................................................................	9	
1.4.2	DNA	methylation	in	cancer	..........................................................................................	11	
1.4.3	Histone	Modification	...................................................................................................	12	
1.4.4	Histone	Variants	..........................................................................................................	14	
1.4.5	Histone	Tail	Modification	.............................................................................................	14	
1.4.6	Histone	Acetylation	.....................................................................................................	15	
1.4.7	Histone	Acetyltransferases	(HATs)	..............................................................................	16	
1.4.8	Histone	Phosphorylation	.............................................................................................	17	
1.5	Histone	Methylation	.....................................................................................................	19	
1.5.1	Histone	lysine	demethylases	.......................................................................................	21	
1.5.2	Histone	H3	methylation	on	lysine	4	.............................................................................	22	
1.5.3	H3K9	methylation	........................................................................................................	24	
  v 
1.5.4	H3K27	methylation	......................................................................................................	26	
1.5.5	H3K79	methylation	......................................................................................................	27	
1.6	NSD	family	of	histone	lysine	methyltransferases	..........................................................	29	
1.7	Epigenetic	Dysregulation	in	Breast	Cancer	....................................................................	32	
1.7.1	WHSC1L1	is	amplified	in	12-15%	of	Breast	Cancers	....................................................	34	
1.7.2	Breast	cancer	sub-types	...............................................................................................	37	
1.7.3	Histological	Subtyping	of	Breast	Cancer	......................................................................	38	
CHAPTER	2				KNOCKDOWN	OF	WHSC1L	IN	SUM44	CELLS	ALTERS	CELL	PROLIFERATION	
AND	GENE	EXPRESSION	.............................................................................................	44	
2.1	Introduction	.................................................................................................................	44	
2.2	Results	..........................................................................................................................	47	
2.2.1	WHSC1L1-short	is	the	major	expressed	isoform	in	breast	epithelial	cells	..................	47	
2.2.2	WHSC1L1-short	knockdown	reduces	cell	growth	........................................................	50	
2.2.3	Knockdown	of	WHSC1L1-short	alters	expression	of	several	genes	active	in	breast	
cancer	...................................................................................................................................	55	
2.2.4	SUM44	cells	respond	negatively	to	estrogen	..............................................................	60	
2.2.5	Gene	expression	profiling	of	SUM44	cells	after	treatment	with	estrogen	..................	66	
2.3	Discussion	....................................................................................................................	70	
2.4	Materials	and	Methods	................................................................................................	74	
2.4.1	shRNA	vectors	..............................................................................................................	74	
2.4.2	Lentiviral	infection	protocol	........................................................................................	74	
2.4.3	Antibodies	....................................................................................................................	74	
2.4.4	Cell	culture	...................................................................................................................	75	
2.4.5	Proliferation	assays	......................................................................................................	75	
2.4.6	Western	blotting	..........................................................................................................	76	
2.4.7	RNA	expression	profiling	.............................................................................................	76	
  vi 
2.4.8	Bioinformatics	and	Statistical	analysis	.........................................................................	77	
CHAPTER	3				ESTROGEN	RECEPTOR	ALPHA	BINDS	CHROMATIN	IN	THE	ABSENCE	OF	
ESTROGEN	IN	SUM44	CELLS	.......................................................................................	78	
3.1	Introduction	.................................................................................................................	78	
3.2	Results	..........................................................................................................................	79	
3.2.1	ERa	binds	chromatin	in	the	absence	of	estrogen	in	SUM44	cells	................................	79	
3.2.2	Motif	enrichment	at	ERa	binding	sites	........................................................................	84	
3.2.3	ERa	binding	decreases	upon	WHSC1L1-short	knockdown	..........................................	87	
3.3	Discussion	....................................................................................................................	89	
3.4	Materials	and	Methods	................................................................................................	92	
3.4.1	Chromatin	immunoprecipitation	followed	by	Illumina	sequencing	............................	92	
3.4.2	RNA	expression	profiling	.............................................................................................	93	
3.4.3	Bioinformatics	and	Statistical	analysis	.........................................................................	94	
CHAPTER	4				HISTONE	H3K4ME3	METHYLATION	IS	AFFECTED	GLOBALLY	AND	NOT	
LOCALLY	BY	WHSC1L1	KNOCKDOWN	.........................................................................	96	
4.1	Introduction	.................................................................................................................	96	
4.2	Results	..........................................................................................................................	97	
4.2.1	WHSC1L1-short	knockdown	increases	global	levels	of	histone	H3	.............................	97	
4.2.2	H3K4me3	ChIPseq	......................................................................................................	102	
4.3	Discussion	..................................................................................................................	107	
4.4	Materials	and	Methods	..............................................................................................	111	
4.4.1	Global	histone	methylation	western	blotting	............................................................	111	
4.4.2	Chromatin	Immunoprecipitation	followed	by	Illumina	sequencing	(ChIPseq)	..........	112	
CONCLUSIONS	.........................................................................................................	113	
The	effects	of	WHSC1L1	knockdown	on	transcript	expression	..........................................	117	
  vii 
WHSC1L1-short	expression	is	necessary	for	ERa	expression	in	SUM44	cells	.....................	119	
ER	binds	chromatin	extensively	in	SUM44	estrogen-free	cells	..........................................	119	
Final	Conclusions	................................................................................................................	121	
APPENDIX				SUM44	RNA-SEQ	DIFFERENTIAL	EXPRESSION	RESULTS	.........................	124	
REFERENCES	............................................................................................................	160	
ABSTRACT	...............................................................................................................	180	
AUTOBIOGRAPHICAL	STATEMENT	...........................................................................	186	
	
  
  viii 
LIST OF TABLES 
 
Table 1.1: Genes amplified in the 8p11-12 amplicon in breast cancer. .............. 36 
 
Table 2.1. Gene set enrichment analysis (GSEA) positively-enriched processes 
in SUM44 shWHSC1L1short vs shLacZ cells. .................................................... 63 
 
Table 2.2 GSEA negatively-enriched processes in SUM44 shWHSC1L1short vs 
shLacZ cells. ....................................................................................................... 64 
 
Table 2.3 GSEA positively-enriched processes in SUM44 cells treated with beta-
estradiol. .............................................................................................................. 65 
 
Table 4.1: Histone Transcripts significantly differentially expressed in SUM44 
shWHSC1L1short cells vs. shLacZ control. ...................................................... 101	
 
  
  ix 
LIST OF FIGURES 
 
Figure 2.1. WHSC1L1 cellular localization in tumor cell lines. ............................ 49 
 
Figure 2.2 WHSC1L1 expression patterns in breast cancer samples and in 
SUM44 and MCF10A. ......................................................................................... 52 
 
Figure 2.3 Knockdown of WHSC1L1 total and short isoform alone alters 
WHSC1L1 expression in SUM44 cells. ............................................................... 53 
 
Figure 2.4 Treatment with beta-estradiol affects proliferation of SUM44 cells. ... 54 
 
Figure 2.5 Knockdown of WHSC1L1short reduces the S-phase fraction in 
SUM44 cells. ....................................................................................................... 59 
 
Figure 2.6 Knockdown of WHSC1L1 total and short isoform alone alters 
expression of ESR1 transcript in SUM44 cells. ................................................... 62 
 
Figure 2.7 Knockdown of WHSC1L1 total and short isoform alone alters 
expression of ERa protein in SUM44 cells. ......................................................... 68 
 
Figure 2.8 SUM44 proliferation is sensitive to treatment with beta-estradiol. ..... 69 
 
Figure 3.1 ERa binding in SUM44 cells in estrogen-free conditions compared to 
treatment with beta-estradiol. .............................................................................. 81 
 
Figure 3.2 ERa binding in SUM44 cells in estrogen-free conditions and after 
10nM beta-estradiol treatment. ........................................................................... 82 
 
Figure 3.4 ERa binding in SUM44 shWHSC1L1short vs shLacZ cells after 
treatment with 10nM beta-estradiol. .................................................................... 88 
 
Figure 4.1 Global histone H3 methylation levels at lysines 4 and 36 in SUM44 
shWHSC1L1short and shWHSC1L1total vs shLacZ control cells. ...................... 98 
 
Figure 4.2 Histone H3K4me3 ChIPseq in SUM44 shWHSC1L1short vs shLacZ 
cells. .................................................................................................................... 99 
 
Figure 4.3 Genomic feature localization of histone H3K4me3 marks in SUM44 
cells. .................................................................................................................. 104 
 
  x 
Figure 4.4 Histone H3K4me3 patterns and mean intensity profiles for SUM44 
shWHSC1L1short vs shLacZ cells. ................................................................... 105	
 
 
  
  xi 
LIST OF ABBREVIATIONS 
 
BrCa   breast cancer 
ChIPseq  chromatin immunoprecipitation - next-gen DNA sequencing 
CpG   a cytosine followed by a guanine on the same DNA strand 
ERa   estrogen receptor alpha protein 
ESR1   estrogen receptor alpha gene 
FDR   false discovery rate  
GSEA   Gene Set Enrichment Analysis 
H1   histone subunit H1 gene 
H2A   histone subunit H2A gene 
H2B   histone subunit H2B gene 
H3   histone subunit H3 gene 
H3K4me1  histone H3 lysine 4 monomethylation 
H3K4me2  histone H3 lysine 4 dimethylation 
H3K4me3  histone H3 lysine 4 trimethylation 
H3K9me1  histone H3 lysine 9 monomethylation 
H3K9me2  histone H3 lysine 9 dimethylation 
H3K9me3  histone H3 lysine 9 trimethylation 
H3K36me1  histone H3 lysine 36 monomethylation 
H3K36me2  histone H3 lysine 36 dimethylation 
H3K36me3  histone H3 lysine 36 trimethylation 
  xii 
H4   histone subunit H4 gene 
HAT   histone acetyltransferase 
HDAC   histone deacetylase 
HER2   Erb-B2 Receptor Tyrosine Kinase 2 gene  
HMT   histone methyltransferase 
iPS   induced pluripotent stem cell 
KEGG  Kyoto Encyclopedia of Genes and Genomes  
KLF4   Kruppel-like factor 4 gene 
LacZ   beta-galactosidase gene 
NSD1   Nuclear SET Domain-containing 1 gene 
Oct4/POU5F1 POU class 5 homeobox 1 gene  
PR   progesterone receptor  
RNAseq  mRNA next-gen sequencing 
RTK   receptor tyrosine kinase  
SAM   s-adenosyl methionine  
SOX2   Sex Determining Region Y box 2 gene  
shRNA  short-hairpin RNA   
shWHshort  shRNA targeting the WHSC1L1 short isoform  
shWHlong  shRNA targeting the WHSC1L1 long isoform  
shWHtotal  shRNA targeting both long and short WHSC1L1 isoforms  
TCGA   The Cancer Genome Atlas  
WHSC1  Wolf Hirschhorn Syndrom Candidate gene  
  xiii 
WHSC1L1  Wolf Hirschhorn Syndrome Candidate 1-Like One gene  
WH-short  WHSC1L1 short isoform (catalytically inactive)  
WH-long  WHSC1L1 long isoform  
WH-total  both long and short WHSC1L1 isoforms 
  
1 
CHAPTER 1    INTRODUCTION 
 
1.1 General Introduction  
Breast cancer, or invasive carcinoma originating from epithelial tissue 
of the breast, is the most common cancer site in women (excluding skin 
cancers), and is second only to lung cancer as a cancer-related cause of death in 
women as of 2011 (placing breast cancer as the third most frequent cause of 
death in U.S women, behind heart disease and skin cancers, respectively) 
(SEER 2016). 
Breast cancer is estimated to account for 29% of all cancer diagnoses in U.S 
women as of 2015. While the breast cancer mortality rate has been decreasing at 
a steady but small rate over the past 25 years (approximately 1%), the rate of 
breast cancer incidence has remained essentially steady. In terms of odds, a 
woman living in the U.S. has a 1 in 8 chance of being diagnosed with breast 
cancer during her lifetime, and a 1 in 40 chance of dying from breast cancer 
(ACS 2016). 
Cancer is not a single disease, but rather a family of approximately 200 
illnesses sharing common genetic lesions and pathologies, classified into types 
primarily by the organ or tissue of origin of the primary tumor. As modern 
medicine has succeeded in eradicating or radically reducing infectious disease in 
countries such as the United States, cancer has become increasingly dominant 
as a cause of death and morbidity. 
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In summary, breast cancer is a major health issue for women in the United 
States, and even incremental improvements in the prevention, early diagnosis, 
and treatment of breast cancer could have a large positive effect on public 
health. 
All cancers have in common the basic property of uncontrolled 
proliferation of malignant cells derived from the tissue of the host organism, 
which no longer respond to host regulation of cell morphology, growth, 
proliferation, or programmed cell death. This uncontrolled proliferation of cells 
that no longer contribute to the function of their tissue of origin results in the 
pathology associated with cancer, namely that the increasing physical 
disruption caused by the rapidly growing cancer cells displaces normal tissue, 
interfering with normal physiology, as well as competing for nutrients and 
sometimes eliciting chronic inflammation due to the immune response attempting 
to clear the tumor cells. While primary tumors can be fatal due to obstruction or 
crowding out of normal tissue (brain tumors for example), most cancers cause 
death by metastasizing to organs and tissues distant from the site of the primary 
tumor, resulting in physical disruption of multiple organs and tissues throughout 
the body. As eloquently stated by Harold Varmus in his Nobel Banquet speech, 
cancer is not a foreign pathogen invading our bodies, but is instead "a distorted 
version of our normal selves", making the fight to eradicate cancer a fight against 
our own body, a fact that has profound implications when considering effective 
cancer treatments. Indeed, the fundamental strategy of classic chemotherapy is 
  
3 
to kill enough cancer cells to cause remission before killing so much good tissue 
that the patient dies from the chemotherapy. This is decidedly rudimentary, and 
yet classical cytotoxic chemotherapies targeting dividing cells have been the 
most successful therapies for human cancers to date. As the fields of molecular 
biology and genomics have matured, the search for targeted cancer therapies, 
which can be defined as therapies specifically targeting the biology of cancer 
cells, has become a top priority of cancer research. 
For targeted therapy to succeed, a basic requirement is the ability to 
sensitively and specifically discriminate between cancer cells and normal cells, 
and then develop targeted therapies that are both effective at killing or senescing 
cancer cells, while leaving normal cells and physiological processes intact. This 
basic requirement for the development of targeted cancer therapies is by itself an 
excellent reason for continued basic research of cancer genomics, as the 
defining characteristic differentiating a cancer cell from a normal cell is the 
presence of oncogenic and tumor suppressor inactivating mutations in cancer 
cells, and their absence in normal cells. As the rest of this thesis will describe, 
detailed characterization of specific oncogene-activating mutations that 
frequently occur in breast cancer is a critically important step in the 
understanding of the biology of breast cancer, and a basic requirement for the 
intelligent development of targeted therapies to treat cancer while minimizing 
side effects 
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1.2 Genomic basis of cancer 
Breast cancer, like all known malignancies, is a disease caused by the 
mutation of specific genes causing either loss of function or loss of regulation. 
Genes with loss of function upon mutation are termed tumor suppressor genes, 
and genes which gain constitutive activation or altered function after mutation are 
termed activated oncogenes. Modern understanding of cancer as a disease 
caused by mutations in genes occurred relatively recently. The seminal work by 
Bishop and Varmus in the early 1970s showed conclusively that one of the tumor 
viruses shown to cause cancer in chickens, v-src, was a mutated remnant of a 
gene originating in the chicken, c-src, which caused cancer when re-introduced 
by viral infection into a host chicken (Varmus, Weiss et al. 1972). They also 
made the connection that humans could and did develop cancer through 
stochastic mutations in SRC, the human ortholog of c-src, marking the beginning 
of modern oncogene research (Stehelin, Varmus et al. 1976, Spector, Varmus et 
al. 1978, Parker, Varmus et al. 1981).  
The human SRC proto-oncogene encodes a protein with non-receptor 
tyrosine kinase activity that interacts with several important mitogenic and cell 
cycle control signaling pathways. Oncogene activation of v-src occurs when 
mutations in tyrosine 527 or 416 inactivate the regulatory SH3 region of the 
protein, resulting in constitutive activation (Frame 2002). Human SRC has been 
shown to act as an oncogene in human cancers, however human SRC 
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oncogenic activity is usually activated by overexpression of the gene as opposed 
to a functional mutation in the protein (Wang, Fromowitz et al. 1991, Zheng, 
Wang et al. 1992). Similar to SRC, most oncogenes discovered have coded for 
proteins involved in some part of a cell signaling pathway promoting cell growth 
or division. 
While oncogene activation is accepted by most of the scientific community 
as a required step in development of malignant disease, it is necessary but not 
sufficient. Full malignancy in most if not all cancers occurs only after both a 
mutation activating at least one oncogene, and an additional inactivating 
mutation in at least one tumor suppressor gene. Tumor suppressor genes are 
classified as genes whose normal function is usually regulation of cell growth or 
proliferation, response to DNA damage, or regulation of apoptosis (programmed 
cell death). Tumor suppressor genes are defined by the fact that loss of function 
mutations contribute to malignancy, in contrast to oncogene activation, where 
mutation constitutively activates gene function and results in deregulated 
increased gene activity. A classic model for the development of malignant 
disease through multiple successive mutations in both tumor suppressor genes 
and proto-oncogenes is the model proposed by Burt Vogelstein et al, which 
modeled the development of colon cancer through the accumulation of mutations 
in multiple genes (Fearon, Hamilton et al. 1987, Fearon and Vogelstein 1990, 
Aguirre-Ghiso 2007). 
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Focusing on oncogenes, different categories of oncogenes can be 
classified based on function. As mentioned earlier, most "classical" oncogenes 
are members of signaling pathways promoting cell survival, growth, metabolism, 
or proliferation. Organized according to the structure of a cell (from exterior to 
interior), oncogenes could be classified into growth factors, receptor tyrosine 
kinases, non-receptor tyrosine kinases (intracellular), non-receptor 
serine/threonine kinases and associated co-regulators (intracellular), GTPases, 
and transcription factors (Cannistra 1990). 
It is important to the subject of this thesis to note that the canonical 
classification of oncogene functional groups does not include epigenetic 
regulators, genes that regulate chromatin structure and thus regulation of gene 
expression through accessibility of transcription factors to their target gene locus. 
Until relatively recently, chromatin modifiers were not considered to be 
oncogenic, as no driving oncogenes with epigenetic regulatory activity had been 
reported. While the mechanism of chromatin modifying enzymes and their role as 
oncogenes will be described and discussed elsewhere in this document, it is 
important to note that oncogenic chromatin modifiers, sometimes termed 
"oncomodifiers", represent a different class of oncogenes with biology distinct 
from the majority of well-characterized oncogenes.  
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1.3 Breast Cancer Oncogenomics 
While all cancers share generally similar patterns of mutations in specific 
classes of proto-oncogenes, the specific genes most often mutated and the 
mechanism of gene mutation are often specific to cancer types and sub-types. 
Recent studies of larger numbers of patient tumor samples from different cancer 
types, such as The Cancer Genome Atlas (TCGA) study, have provided a 
detailed ontology of mutations in different cancer types, with breast cancer 
benefitting from the collection of a large number of patient samples. The number 
of breast cancer samples collected exceeds 1000 samples, more than almost 
any other cancer type, providing unprecedented views into the nature of 
mutations in breast cancer. 
The 1105 breast cancer samples in the TCGA study portray gene 
amplification events as the second-most common mechanism of oncogene 
activation in breast cancers, second only to PIK3CA mutations at 31.3%, with 
amplifications in chromosomes 8 and 11 occurring most frequently. Notably, the 
most common point mutations found in breast cancers are loss-of-function (LOF) 
mutations in the TP53 gene (31.3%). A study by Ciriello et all on datasets 
collected by The Cancer Genome Atlas (TCGA) have shown that more than 75% 
of functional mutations found in breast cancer are the result of copy number 
alterations, and less than 15% of driving mutations are caused by point mutations 
(Ciriello, Miller et al. 2013). 
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1.4 Epigenetic Regulation 
Epigenetic regulation from a molecular and cell biological perspective can 
be defined as the set of structural attributes of chromatin that alter gene function 
without altering DNA sequence. Epigenetic changes are commonly capable of 
persisting across mitotic and meiotic events, although in modern definitions of 
epigenetic regulation, heritability of an epigenetic mark is not necessarily a 
defining characteristic (Waddington 2012, Felsenfeld 2014, Deans and Maggert 
2015). Unlike genetic changes, which are defined as changes in DNA sequence, 
epigenetic changes manifest as changes in the structure of chromatin in the form 
of covalent modifications to DNA or histones (Berger, Kouzarides et al. 2009). 
There are three main classes of epigenetic modification: DNA methylation, 
modulation of transcript availability by RNA, and histone modification. Both DNA 
methylation and histone modifications affect gene function by altering the 
physical accessibility of the DNA sequence coding for a gene, either allowing or 
preventing transcriptional machinery to bind and initiate transcription. RNA-
induced silencing acts between transcription and translation by either promoting 
degradation of the nascent mRNA transcript or sequestration of the transcript in a 
compartment where it cannot be translated into protein. While epigenetic 
regulation is most commonly thought of in terms of transcriptional regulation, 
DNA methylation and certain histone modifications also affect the rate of somatic 
mutation, which sometimes leads to genetic changes in gene expression or 
function, including oncogene activation or tumor suppressor inactivation. 
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1.4.1 DNA Methylation 
DNA methylation is defined as the covalent addition of a methyl group (-
CH3) to a cytosine base in a molecule of DNA. Canonical DNA methylation in 
humans occurs at so-called CpG sites, a term for a cytosine immediately 
followed by a guanine in the 3' direction (CpG is used to avoid confusion with 
CG, which when written without the “p'' refers to pairing of cytosine and guanine 
on complementary strands of DNA). Although most methylated cytosines in 
humans have a guanine base on their 3' side, there are other di-nucleotide and 
tri-nucleotide patterns that are subject to methylation in humans (and many other 
configurations in other organisms). Addition of a methyl group to cytosine 
converts the nucleotide to 5-methyl cytosine, methylating the DNA at that base.  
DNA methylation is generally a repressive mark, inhibiting transcription. CpG 
methylation of DNA has been shown to inhibit transcription by physically 
preventing binding of transcriptional enzymes (RNA polymerase and others) to 
the DNA, or by recruiting proteins that recognize and bind CpG-methylated DNA, 
recruiting other chromatin-modifying enzymes such as histone deacetylases and 
histone methyltransferases, resulting in heterochromatic structure at the site of 
CpG methylation (Bird 2002).  DNA methylation is most often found in gene 
promoter sequences in humans, and is one of the primary mechanisms of gene 
silencing in cells (Jones 2012). The promoters of most cell-specific genes that 
are responsible for the structure and function of other cell types are found to be 
heavily DNA methylated in differentiated cells (Riggs 1975). In particular, the 
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promoters of master regulators of pluripotency, namely Oct4 (POU5F1), SOX2, 
and KLF4 among others, are highly methylated and repressed in differentiated 
cells. Yamanaka, Jaenisch, and others discovered induced pluripotency in adult 
cells by overexpressing exogenous Oct4 (POU5F1), Sox2, Klf4, and Myc in 
differentiated cells (Takahashi and Yamanaka 2006, Wernig, Meissner et al. 
2007). Exogenous expression of these proteins induced a pluripotent stem cell 
(iPS) phenotype by removing DNA methylation at the promoters of the 
endogenous POU5F1 gene, resulting in the maintenance of an induced 
pluripotent phenotype, persisting after exogenous Oct4 expression was curtailed 
(and assuming no differentiation signals are present) (Maherali, Sridharan et al. 
2007). This was a remarkable discovery, as induced pluripotent stem cells 
appear to be indistinguishable from embryonic stem cells, and iPS cells can in 
fact be used to create chimeric organisms that develop normally. The fact that 
modulation of an epigenetic mark, in this case DNA methylation, can result in a 
change in phenotype to pluripotent stem cells, which can then differentiate into 
any phenotype, shows the incredible power of epigenetic regulation of gene 
expression. While a cell signaling response to stimuli in a cell's environment is 
capable of making diverse changes to gene expression, epigenetic regulation 
can render entire regions of the genome more or less accessible to 
transcriptional regulation. To use a crude analogy: if cell signaling represents the 
tactical playbook of a cell to its environment, then epigenetic regulation may 
represent the long-term strategy of the cell, operating within the constraints of the 
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rulebook spelled out by the genotype. In the case of DNA methylation, this 
analogy appears to largely hold; DNA methylation patterns in normal adult cells 
remain mostly constant in terminally differentiated cells, and induced 
pluripotency, as well as malignancy, are exceptions that prove the rule. 
1.4.2 DNA methylation in cancer 
Human cancers exhibit altered patterns of DNA methylation. Globally (at 
genome scale), most cancer cells are hypomethylated (decreased levels of DNA 
methylation), while specific gene promoter regions are hypermethylated 
(increased DNA methylation) (Feinberg and Vogelstein 1983). In mammalian 
cells, CpGs often occur in clustered groups of a few hundred to a few thousand 
bases, and have been named CpG-islands. The incidence of CpG dinucleotides 
in the human genome is ~1.7% of all nucleotides (based on the UCSC hg19 
genome assembly), thus potential CpG methylation sites make up a small 
proportion of dinucleotide sequences in the human genome.  
Despite the small number of CpGs genome-wide, the distribution of CpGs 
is not random; CpGs are enriched proximal to promoter regions in humans. 
Approximately 70% of human gene promoter regions contain CpG islands, 
enabling the prediction of unknown gene promoters based on local CpG content 
(Bird 1986). 
    In many cancers, promoters of genes that play a role in suppressing tumor 
growth and progression are found to be hypermethylated, resulting in 
suppression of gene expression. Methylation of DNA cytosines is catalyzed by a 
  
12 
family of proteins called DNA methyltransferases. The three known human DNA 
methyltransferases are DNMT1, DNMT3A, and DNMT3B (Meilinger, Fellinger et 
al. 2009). Inactivating mutations in DNMT3A have been found to promote 
oncogenesis, characterizing DNMT3A as a tumor suppressor.  
1.4.3 Histone Modification 
Histones are globular protein complexes that are found in the nuclei of 
eukaryotic cells (Van Holde, Sahasrabuddhe et al. 1974). Histones are normally 
found tightly associated with DNA: the strand of DNA composing each 
chromosome is wound around histones in a beads-on-a-string formation, with 
each histone surrounded by 147 nucleotides, and 50 nucleotides connecting 
each histone-DNA complex, which is called a nucleosome (Schalch, Duda et al. 
2005). The histone core is composed of 8 protein subunits: two each of H2A, 
H2B, H3, and H4 (Luger, Mader et al. 1997). The histone H1 subunit is not part 
of the globular core, but instead binds to the core proteins at either end, while 
holding the incoming and outgoing ends of the DNA strand against the globular 
core (Figure 0 [renumber]). Histones have a net basic charge, which aids in 
binding acidic DNA to the histone (Rohs, West et al. 2009). The wrapping 
of DNA around histones efficiently reduces the length and volume of the DNA in 
each eukaryotic cell, compacting the chromosomes to various degrees 
depending on the stage of the cell cycle. DNA that is tightly associated with 
histone is called heterochromatin, after the appearance of alternating dark and 
light bands in micrograph images when stained, while loosely associated 
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chromatin is called euchromatin. While the role histones play in compacting and 
organizing chromatin was apparent from simple observation, the complexity of 
the biology of histones and chromatin was not discovered until the advent of 
modern molecular biological methods. Since their discovery, it has been shown 
that histones are not simply passive scaffolding for DNA, but that the state of 
chromatin structure affects gene expression (Kayne, Kim et al. 1988). It was 
hypothesized early on that tightly packed chromatin was inaccessible to 
transcriptional machinery, meaning that heterochromatic DNA was not capable of 
being transcribed. The inactivation of one X chromosome in female cells is a 
prime example of this phenomenon: one of the two X chromosomes in each 
female cell is condensed tightly into heterochromatin, called a Barr body. The 
heterochromatic state of the second X chromosome prevents expression of the 
genes on the inactivated chromosome, which maintains the normal levels of 
proteins encoded by these genes, ensuring normal cell function. Barr bodies 
were discovered in 1949, prior to modern molecular biology techniques, yet 
Murray Barr correctly predicted that the function of Barr body formation was to 
prevent gene expression from more than one X chromosome per cell (Barr and 
Bertram 1949). As the field of molecular biology advanced, a virtuous cycle of 
structural and mechanistic discovery began, which has led to our current 
understanding of the process of histone modification, and the remarkable 
observation that covalent modification of specific amino acids just a few residues 
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apart on the histone core polypeptide can have opposing effects on transcription 
of gene loci proximal to the histone so modified. 
1.4.4 Histone Variants 
In addition to covalent modification of histones with different functional 
groups, alternate variants of the histone subunits themselves can be substituted 
for the canonical subunit variants. These alternative variants of the core histone 
subunits have slightly different amino acid content, and are substituted into 
specific regions of chromatin, where they alter chromatin conformation and 
function. The histone H3 variant H3.3 has been found to be present in chromatin 
containing gene loci that are actively transcribed, but more recently it was found 
at the pericentric and telomeric heterochromatin regions, representing silenced 
chromatin (Drane, Ouararhni et al. 2010). CENPA or cenH3 is a histone H3 
variant found in the cetromeric regions of chromosomes, and plays a critical role 
in kinetochore formation, specifically the binding of spindle fibers to chromatin for 
chromatid migration during anaphase (Howman, Fowler et al. 2000). 
1.4.5 Histone Tail Modification 
Histone modification is the term given to a class of reactions that catalyze 
the post-translational covalent addition or removal of small molecules to one of 
the histone core protein subunits, H2A, H2B, H3, or H4. The majority of these 
covalent modifications target the amino-terminal “tail'' of amino acids that 
protrudes from the tertiary structure of the core histone subunits, however amino 
acids in the globular region of the core histone subunits can also be covalently 
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modified. The first approximately 70 amino acids from the amino-terminal end of 
each histone subunit form the “tail'' region, a region with little or no secondary or 
tertiary structure that protrudes from the globular region of the histone complex. 
Because the tail regions of each histone subunit extend beyond the globular 
histone structure, they are free to interact with neighboring nucleosomes, 
transcription factors, or other chromatin-associated proteins. These tail regions 
are rich in basic amino acids, particularly lysine and arginine (Vidali, Gershey et 
al. 1968). 
1.4.6 Histone Acetylation 
In contrast to the indirect and relatively complex action of histone methyl 
marks, histone acetylation alters chromatin state in a more direct way: addition of 
acetyl groups to histone core tail lysines neutralizes the positive charge that 
attracts the negatively charged DNA backbone, resulting in decreased 
histone/DNA affinity, and ultimately dissociation of DNA from the histone to form 
euchromatin. The effect of histone acetylation on gene transcription was 
discovered by Vincent Allfrey in 1964 (Allfrey, Faulkner et al. 1964), however the 
mechanism for addition or removal of acetyl groups to histones was not known, 
nor was it known how the process was regulated. Histone acetylation was 
considered to be a general feature that resulted in euchromatin, while absence of 
acetylated histones resulted in heterochromatin. The first indication that a class 
of enzymes existed that catalyzed addition of acetyl groups to histones at specific 
amino acid residues started to become apparent in the early 90s, when C. David 
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Allis et al (early pioneers of chromatin immunoprecipitation) and others 
successfully characterized histone acetyltransferases (HATs) that targeted 
acetylation of specific lysine residues on specific histone subunits, as well as 
lysines on some other proteins, such as transcription factors (Sobel, Cook et al. 
1994, Brownell, Zhou et al. 1996, Vettese-Dadey, Grant et al. 1996). HATs 
catalyze the transfer of an acetyl group from Acetyl-coenzyme A (Ac-CoA) to a 
specific lysine on the histone subunit. Around the same time, histone deactylases 
(HDACs), the class of enzymes that catalyze the removal of acetyl groups from 
histones, were first characterized, including Rpd3 in yeast and HDAC1 in 
humans (Carmen, Rundlett et al. 1996, Taunton, Hassig et al. 1996). There are 
several HAT and HDAC classes, each of which contains several genes with 
relatively high sequence and structure homology, particularly in their catalytic 
domains. 
1.4.7 Histone Acetyltransferases (HATs) 
 The Gcn5-related family of histone methyltransferases (GNATs) includes 
the human genes PCAF, HAT1, ATF-2, and KAT2A. The family is named after 
the first histone acetylase to be characterized, Gcn5, a yeast HAT first described 
by Brownell et al in 1996. Human homologues include PCAF and HAT1. Proteins 
in this family contain a bromodomain that recognizes other acetylated proteins, 
as well as a catalytic HAT domain conserved across eukaryotes from yeast to 
human (Brownell, Zhou et al. 1996).  
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The MYST family of HATs includes MOZ, MOF, MORF, HBO1, and KAT5 
in humans. The name “MYST'' originates from the names of four of the early 
genes found in this family: MOZ, Ybf2 (later known as Sas3), Sas2, and Tip60 
(now known as KAT5). Structurally, MYST-family proteins usually contain zinc-
finger domains and chromodomains. MYST family proteins all share a motif in 
their HAT domain that is common to the GNAT family. The p300/CBP family 
consists of just two members, p300 and CBP. 
1.4.8 Histone Phosphorylation 
Like the phosphorylation of other proteins such as receptors and second 
messengers involved in cell signaling, histones are also phosphorylated, leading 
to the binding and activation of downstream effectors that promote various 
effects on chromatin conformation. Phosphorylation of histone residues is often 
accompanied by crosstalk with other histone modifications, which cooperate to 
alter chromatin conformation. Serine, threonine, and tyrosine are all 
phosphorylation substrates on histone subunits.  
The most well-characterized histone phosphorylation mark is 
phosphorylation of S139 the H2AX histone subunit in response to DNA damage, 
which results in recruitment of histone acetylases to promote relaxation of the 
chromatin surrounding the break (presumably to allow DNA repair machinery 
access to the DNA damage), and initiation of the DNA damage response 
checkpoint, which halts the cell in G1/S so that DNA repair can be completed. 
Phosphorylation of S139 on H2AX histones is catalyzed by the kinases ATM and 
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ATR, two well-known components of the DNA damage response pathway. 
Subsequent to phosphorylation of H2AX, which spans a multi-megabase region 
surrounding the DNA damage, the H4 subunits of histones in this region become 
acetylated, which leads to promotion of a euchromatic state in the chromatin 
proximal to the damage (Li, Li et al. 2011). Transition to euchromatin around the 
damaged DNA is probably necessary to allow DNA repair protein complexes to 
bind and repair the damage, and is not possible without this coordinated 
epigenetic transition in response to DNA damage (Goto, Tomono et al. 1999, 
Wei, Yu et al. 1999). 
Histone phosphorylation has also been shown to regulate transcription, 
particularly promotion of transcription. Several serines and tyrosines on histone 
subunits H2B and H3 have been found to be associated with changes in 
transcriptional regulation of several genes, particularly proliferation-associated 
proto-oncogenes such as c-myc. Among other mechanisms, phosphorylation of 
H2B and H3 will recruit histone acetyltransferases to the histone, which promotes 
euchromatin formation and generally an increase in transcription of proximal loci. 
Phosphorylation of H3 can also promote demethylation of repressive 
histone marks concomitantly with promotion of acetylation. Phosphorylation of 
Threonines 6 and 11 on histone H3 recruits GASC1, a histone demethylase, to 
the histone, where it catalyzes the removal of a transcriptionally repressive H3K9 
methyl mark. Phosphorylation of H3T6 and H3T11 is triggered by androgen 
receptor (AR) binding to the region, and the resulting histone phosphorylation 
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and demethylation is part of the mechanism of AR-dependent transcription 
(Metzger, Yin et al. 2008). 
1.4.9 Histone Ubiquitination 
Histone ubiquitination was discovered by Goldknopf in 1975, well before some 
other histone modifications, yet it remains one of the least characterized histone 
modifications in terms of function and genome-wide patterns (Busch and 
Goldknopf 1981). Histone ubiquitination state is linked to the levels of H3K4 and 
H3K36 methylation on a nucleosome. Interestingly, both serial addition and serial 
removal of a monoubiquitin residue to or from a histone can both promote 
activation of transcription, unlike other histone modifications where addition or 
removal of a particular mark usually have opposing effects on chromatin 
conformation (Zhang 2003, Weake and Workman 2008). 
1.5 Histone Methylation 
Histone methylation refers to the class of histone modifications that 
describe the substitution of a methyl group (-CH3) for one, two, or all three of the 
hydrogens in the amino (-NH3) group at the end of the R-group of lysine or 
arginine residues. These modifications are called mono-, di-, or tri-methylation, 
respectively. The methyl group added to the histone residue is sourced from S-
adenosyl methionine (SAM). Enzymes that catalyze the transfer of a methyl 
group from SAM to lysines or arginines are known as histone methyltransferases 
(HMT) or protein arginine methyltransferases (PRMT), respectively. Functionally, 
methylation of histone subunit lysines and arginines regulates chromatin 
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structure, transcriptional regulation, and DNA repair. While some histone 
methylation marks remain stable through cell divisions and even from one 
generation to the next, the process of histone methylation is actually quite 
dynamic.  
Unlike other covalent modifications of histone residues, histone 
methylation does not alter the net charge on the histone, and so does not appear 
to regulate chromatin structure or gene transcription through direct changes in 
histone/DNA affinity. Instead, histone methylation represents what has been 
proposed by some to be a “histone code'', a pattern of methylation marks that is 
read by large multi-protein complexes, which scan the methylation state of a 
group of histones and recruit, or block, transcriptional machinery, modifiers of 
chromatin structure, or other histone modifying complexes(Barski, Cuddapah et 
al. 2007). A model has been created to illustrate this concept, sometimes called 
the “read-write-erase'' model. This model classifies HMTs and PRMTs as 
“writers'', proteins which apply methyl marks to specific residues on histones. 
Histone modifications may then be read by histone ”readers”: proteins which are 
part of large multi-protein complexes that will catalyze additional histone 
modifications based on the existing pattern of histone modifications. HMTs and 
PRMTs are in fact members of such “reader'' complexes, and the proteins 
themselves often have specific protein domains that recognize protein-DNA 
complexes, as well as specific covalent modifications on histones. This can result 
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in a positive or negative feedback loop that maintains high or low levels of 
histone methylation at specific regions of the genome.  
There are two main classes of lysine histone methyltransferases: one 
class is named after the catalytic domain, named after 3 genes in model 
organisms where this class of HMTs was first discovered, Suppressor of 
Variegation, Enhancer of Zeste, Trithorax (SET). The other class encompasses 
all histone methyltransferases that have a non-SET catalytic domain. Methylation 
of specific residues only a few amino acids apart on the histone tail can have 
opposing effects on chromatin conformation or transcription: some promote 
transcription, while others inhibit. 
Known substrates for methylation on histones include lysines 4, 9, 27, 36, 
and 79 and arginines 8 and 17 on H3; and lysines 20 and 59, and arginine 3 on 
H4. Hypermethylation of lysines 4, 36, and 79 on histone H3 are associated with 
actively transcribed chromatin in the euchromatic state, while lysines 9 and 27 on 
histone H3 and lysine 20 on H4 are associated with transcriptional repression. 
Known arginine methylation substrates include arginines 8 and 17 on 
histone H3, and arginine 3 on histone H4. Histone H1 is also methylated on 
lysine 26. Below these histone methylation marks, the enzymes catalyzing their 
addition and removal, and their biological function will be described in detail. 
1.5.1 Histone lysine demethylases 
Histone demethylases represent of class of proteins that remove a methyl 
group from lysine residues, often on histones, but also from lysines of other 
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methylated proteins, both nuclear and cytosolic. Known histone demethylases 
are classified by their catalytic domains and required cofactors, and are 
organized into two families, the LSD family and the Jumonji family. The LSD 
family of lysine demethylases contains two members, LSD1 and LSD2. LSD 
family proteins contain an amine oxidase-like (AOL) domain, and a SWIRM 
domain (Hojfeldt, Agger et al. 2013). Flavin adenine dinucleotide (FAD) is 
reduced to FADH2, removing hydrogen from the methyl group, and then the 
carbon leaves the nitrogen on the lysine and combines with water to form 
formaldehyde. Because of the mechanism of lysine demethylation exhibited by 
LSD family proteins, they are not capable of demethylating tri-methylated lysine, 
but can demethylate di- and mono-methylated lysine. 
The second group of histone demethylases belongs to the Jumonji C 
(JMJC) family. This family of histone demethylases contain a Jumonji C catalytic 
domain which binds Fe2+ and α−ketoglutarate cofactors. The mechanism of 
JMJC lysine demethylases allows them to demethylate tri-methylated as well as 
di-methylated and mono-methylated lysine. 
1.5.2 Histone H3 methylation on lysine 4 
Lysine 4 is the most distal lysine on the histone H3 tail with evidence of 
methylation. A notation for communicating the level of methylation at a specific 
residue on histones: the histone subunit is noted, followed by the lysine number, 
and finally the level of methylation on that lysine. For example, mono-methylation 
of lysine 4 on the histone H3 subunit would be written as H3K4me1, and di-
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methylation and tri-methylation written as H3K4me2 and H3K4me3, respectively. 
H3K4 methylation is most often found on or near actively transcribed promoter 
regions, and mostly in the tri-methylated form, however H3K4me2 and H3K4me1 
marks are also commonly found proximal to active promoters. In many cell types, 
such as pluripotent stem cells in the process of differentiation during 
development, approximately 80% of actively transcribed promoters are marked 
by H3K4me3. H3K4me3 marks are found almost exclusively near the promoter 
regions of actively transcribed genes. 
While there are some reports of H3K4me2 marks playing a role in 
regulating de-methylation of DNA CpGs, the majority of H3K4me2 appears to co-
localize with H3K4me3 near promoters. H3K4me1, in contrast, appears to be a 
mark for distal enhancers, as it is often found marking distal enhancer regions for 
many genes, and is more evenly distributed genome-wide than either H3K4me2 
or H3K4me3. 
Histone methyltransferases that catalyze addition of methyl groups to H3K4 
include several proteins. Mixed Lymphocyte Leukemia 1 (MLL1), also known as 
lysine methyltransferase 2A (KMT2A), is a key histone methyltransferase that 
specifically tri-methylates lysine 4 on histone H3 (Ruthenburg, Allis et al.). 
MLL1 co-localizes with RNA polymerase II (Pol II) on the promoter regions 
of genes, the genomic region where almost all H3K4me3 marks are found. MLL1 
is part of a multi-protein complex called the MLL complex, which contains several 
histone-modifying enzymes in addition to MLL1. The MLL complex is involved in 
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the differentiation of hematopoietic stem cells to form lymphocytes. Mutations in 
MLL1 through chromosomal translocations result in activation of MLL1 into an 
oncogene in acute lymphoid and acute myelogenous leukemias. MLL1 
oncogenic activity is at least partially due to dysregulation of the HOXA family of 
genes, which, when prevented from tapering off their expression during 
hematopoesis, inhibit terminal differentiation of the lymphoid progenitor cells into 
mature white blood cells. MLL1 is paralogous to the Set1 gene in yeast. 
ASH1L (absent-small-homeotic-like-1) is another gene shown to methylate 
H3K4 residues, although H3K36 has also been reported as a substrate (Zhu, Li 
et al. 2016). ASH1L contains a SET domain, and is part of the SET family of 
HMTs. ASH1L also contains a PHD domain (Plant HomeoDomain) as well as a 
bromodomain, two domains common in proteins that recognize and bind 
chromatin. ASH1L is also involved in positively regulating HOX genes during 
development (Schuettengruber, Martinez et al. 2011). 
1.5.3 H3K9 methylation 
Hypermethylation of lysine 9 on histone H3 is generally associated with 
repression of transcription, however various levels of H3K9 methylation are found 
in both repressed and actively transcribed chromatin, and mono-, di-, and tri-
methylated H3K9 have been found to have diverse binding patterns and 
biological functions. H3K9me2 is reported to be mutually exclusive of H3K4 
methylation, and several protein complexes that contain H3K9 
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methyltransferases have been reported to be in complex with histone 
demethylases that target H3K4 methylation (Shi, Sun et al. 2011). 
Genome-wide, regions of H3K9 methylation are often much broader than 
other histone methylation marks, with some H3K9me2 regions spanning 
megabases of sequence in one contiguous region. H3K9me1 marks are often 
found localized to the promoter regions of actively transcribed genes; H3K9me2 
marks are often spread across broad regions. Constitutive heterochromatin, such 
as the chromatin found in inactive X chromosomes in female cells, possesses 
H3K9me2 marks on the majority histones. It has been shown that a region of 
H3K9me2 marks upstream of the Xist gene, the gene responsible for initiation of 
X-inactivation, serves as the starting point for the spread of H3K9me2 marks 
across the entire X chromosome that is in the process of inactivation. The spread 
of H3K9me2 marks, at least in the process of X-inactivation, is thought to be due 
to the recognition of existing H3K9me2 marks by the G9a-GLP-Wiz complex, 
causing a positive feedback loop that causes H3K9me2 to spread. Such auto-
recruitment of HMTs appears to be more general than just H3K9 methylation. 
The primary HMT for monomethylation and dimethylation of lysine 9 on 
histone H3 is actually a heterodimer of the G9a and GLP proteins, two SET-
domain containing proteins that can form homo-dimers, but are found in cells 
almost exclusively as G9a-GLP heterodimers (Tachibana, Sugimoto et al. 2001, 
Shankar, Bahirvani et al. 2013). Both G9a and GLP are members of the Suv39h 
family of proteins (Suv stands for Suppressor of Variegation, one of the three 
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protein families referred to in the name of the SET domain). G9a and GLP have 
very high homology, and have similar structure, differing only in the lengths of 
some domains. Mutant knockout experiments have shown that inactivation of the 
SET domain of G9a reduces histone H3K9me1 and H3K9me2 levels far more 
than mutation of the GLP SET-domain. G9a-GLP is joined by a third protein, Wiz, 
a zinc-finger protein that binds the SET domains of both G9a and GLP. 
Experiments by Ueda et all have shown that G9a-GLP-Wiz forms a more stable 
complex than either homodimer + Wiz complex, which may explain why the G9a-
GLP-Wiz trimeric complex is the only configuration found in vivo. 
As for other histone lysines, H3K9 methylation is a substrate for 
demethylation by histone lysine demethylases. One particular H3K9me3 
demethylase known to be involved in cancer is the GASC1 gene (KDM4C), 
which is amplified and overexpressed in breast cancers (Liu, Bollig-Fischer et al. 
2009). 
1.5.4 H3K27 methylation 
H3K27 hypermethylation is usually a strong mark of repressed chromatin, 
and is usually localized to the promoter regions of genes.  In developing 
progenitor and stem cells, it has been found that the promoters of several genes 
important in differentiation are bound by histones with both H3K4me3 and 
H3K27me3 marks. The presence of both of these marks with opposing functions 
(H3K4me3 is activating, H3K27me3 is repressive) on histones near a promoter 
are called bivalent chromatin marks, and are found proximal to the promoters of 
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genes that are not expressed, but will soon be expressed once cell differentiation 
begins (Bernstein, Mikkelsen et al. 2006, Ku, Koche et al. 2008). 
The hypothesis for bivalent chromatin marks is that, following the signal 
from a differentiation factor, a histone lysine demethylase will remove the 
H3K27me3 marks on the promoters, signaling activation of transcription due to 
the already present H3K4me3 marks on these promoters, allowing more rapid 
activation of transcription of these genes. While it is well established that these 
marks do occur at the promoters of several genes involved in cell differentiation, 
there is still some uncertainty about the role these bivalent domains play in the 
biology of differentiation, and whether H3K27 demethylation at bivalent chromatin 
marks actually result in rapid activation of these genes. 
1.5.5 H3K79 methylation 
Methylation of lysine 79 on histone H3 is catalyzed by a distinct class of 
histone methyltransferases known as the DOT1-like (DOT1L) family. The DOT1L 
family of HMTs do not contain a SET domain, but do share a different catalytic 
domain. DOT1L is the only known HMT that has lysine 79 on histone H3 as a 
substrate. DOT1L is capable of adding methyl groups to non-methylated, mono-
methylated, and di-methylated H3K79 (Vlaming and van Leeuwen 2016). 
Interestingly, di- and tri-methylation of H3K79 is not processive, meaning that 
DOT1L can transfer between one and three methyl groups to lysine 79. As such, 
it does not require independent step-wise additions of single methyl groups in 
separate reactions. H3K79 methylation was discovered in S. cerevisiae when the 
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deletion of the Dot1 gene in yeast resulted in the complete loss of H3K79 
methylation, which disrupted the normal silencing of telomeric genes (thus the 
name: Disruptor Of Telomere-1). DOT1L is the human homologue of Dot1 in 
yeast. 
The discovery of Dot1 function is an interesting study in the complexity of 
histone modifications and their biology. While the function of Dot1 is to methylate 
lysine 79 on histone H3, which results in activation of transcription, deletion of the 
gene had the opposite effect one would naively expect: transcription of telomeric 
genes increased when Dot1 was deleted. Paradoxically, overexpression of Dot1 
also increased telomeric gene expression. The hypothesis for this phenomenon 
is that methylation of K79 on non-telomeric histones by Dot1 maintained a small 
region at the telomere of the chromosome, which would be repressed by other 
histone modifications. High levels of Dot1 overexpression could inhibit the 
repression of telomeric gene expression, but total abrogation of Dot1 expression 
by gene deletion has a similar effect. When deleted, the lack of Dot1 activity and 
the resulting abrogation of all H3K79 methylation results in too many potential 
substrates for the telomeric repression machinery, diluting its activity, and 
resulting in de-repression of telomeric genes. While this phenomenon of both 
extremes of expression of a gene having similar biological effects may be a rare 
example, considering it is the sole HMT for lysine 79 on H3, Dot1/DOT1L serves 
as an important example of the complexity and counter-intuitive nature of the 
biology of histone modifications. 
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1.5.6 H3K36 methylation 
Methylation of lysine 36 on histone H3 is less understood than many other 
histone methyl marks, both in terms of H3K36 methylation patterns and 
characterization of the identity and activity of histone methyltransferases that 
target H3K36 as a substrate. H3K36 methylation has been reported as a mark of 
both transcriptional activation and repression for chromatin regions where it is 
found. Recent work has shown that H3K36 methylation generally occurs in broad 
regions spanning the bodies of genes, and often increases near the 3' end of the 
transcribed region of a gene (Wagner and Carpenter 2012). H3K36 methylation 
has also been shown to promote elongation of the nascent transcript as the 
transcriptional machinery leaves the promoter region immediately after initiation 
of transcription, and may also act as a marker for recently transcribed genes, 
preventing immediate re-association of the Pol II complex and initiation of a 
second round of transcription before the current transcript is complete (Bell, 
Wirbelauer et al. 2007, Berger 2007). 
1.6 NSD family of histone lysine methyltransferases 
NSD1 is the prototype for the nuclear SET domain-containing (NSD) 
family of histone lysine methyltransferases (HKMTs) named for their localization 
to the nucleus and their shared catalytic SET domain (Jaju, Fidler et al. 2001). 
There are three members, NSD1, WHSC1, and WHSC1L1, of which NSD1 and 
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WHSC1L1 are both known to be oncogenic (Kim, Kee et al. 2006, Kim, Kee et al. 
2007). The NSD1 gene is located on the long arm of chromosome 5, and codes 
for three known transcript isoforms. The longest isoform codes for a 2696 amino-
acid protein containing a catalytic SET domain, a post-SET domain, and several 
PHD, zinc finger, and PWWP chromatin interaction domains(Vougiouklakis). 
Mutations in NSD1 are associated with Sotos syndrome, a genetic 
overgrowth disease that causes overgrowth in children between 1 and 2 years 
old. The disease is caused by a decrease in the levels of NSD1 protein due to 
loss-of-function mutations in one copy of the NSD1 gene (Kurotaki, Imaizumi et 
al. 2002, Douglas, Hanks et al. 2003, Wernig, Meissner et al. 2007). 
Translocations with breakpoints within the NSD1 gene are found in some 
childhood leukemias, and NSD1 has been shown to be a driving oncogene in 
these cancers. NSD1 sometimes fuses with NUP98, resulting in constitutive 
activation of the histone methyltransferase activity of NSD1 (Jaju, Fidler et al. 
2001). Lysine 36 on the histone H3 subunit has been reported as the primary 
substrate for NSD1 methylation. NSD1 has also been shown to interact with the 
androgen receptor (AR), specifically the ligand binding domain and the DNA-
interaction domain of AR. 
WHSC1 is the second member of the NSD family, and is located on the 
short arm of chromosome 4. Loss of function mutations (usually small deletions) 
in WHSC1 cause Wolf-Hirschhorn Syndrome, a disease characterized by 
microcephaly, mental deficiency, low muscle tone, and other defects in growth, 
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presenting at birth. Several of the symptoms of Wolf-Hirschhorn Syndrome are 
opposites of the symptoms observed in Sotos syndrome, a disease caused by 
loss of function of NSD1 (Douglas, Hanks et al. 2003, Douglas, Coleman et al. 
2005). WHSC1 has high homology with WHSC1L1, with both proteins containing 
many of the same PWWP and PHD domains, the catalytic SET domain followed 
by post-SET domain. WHSC1 also contains as AWS domain, which WHSC1L1 
lacks. The primary substrate of WHSC1 has been reported to be lysine 36 on 
histone H3, where it adds a tri-methyl mark (Nimura, Ura et al. 2009).  
While there are six known isoforms coded for by WHSC1, they fall into two 
main classes. The long isoforms encode for a 1365 amino-acid protein that 
contains the catalytic SET domain, while the short isoforms encode for a 627 
amino-acid protein that lacks a catalytic SET domain.  WHSC1 translocations 
have been found to be driving oncogenes in multiple myelomas (Huang, Wu et 
al. 2013, Min, Ezponda et al. 2013). 
The Wolf Hirschhorn Syndrome Candidate 1-Like 1 (WHSC1L1) 
gene is located on the short arm of chromosome 8, in the 8p11-p12 band. 
WHSC1L1 is the third gene in the NSD family of SET-domain containing histone-
lysine methyltransferases (HKMTs), the other members consisting of Nuclear 
SET domain-containing protein 1 (NSD1) and Wolf Hirschhorn Syndrome 
Candidate 1 (WHSC1) (Stec, van Ommen et al. 2001). WHSC1L1 has the 
greatest protein sequence homology with WHSC1, although all three proteins 
contain similar domains, including a catalytic SET domain, a post-SET domain, 
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and one or more PWWP and PHD domains (He, Li et al. 2013). The WHSC1L1 
gene codes for two known isoforms; the first isoform codes for the full-length 
1437 amino-acid protein (NM_023034) containing the catalytic SET domain, and 
the second isoform (NM_017778) codes for a shorter protein that consists of the 
first 647 amino-acids of the long isoform. 
The short isoform of WHSC1L1 (WHSC1L1short) contains only a single 
PWWP domain, and lacks the catalytic SET domain, PHD domains, and other 
PWWP domains (Angrand, Apiou et al. 2001). WHSC1L1 expression is localized 
to the nucleus (Figure 2.1). While the long isoform of WHSC1L1 is much more 
rich in functional motifs than the relatively simple short isoform, WHSC1L1-short 
is the predominantly expressed isoform in most normal breast epithelial samples 
as well as tumor samples from most breast cancers. 
1.7 Epigenetic Dysregulation in Breast Cancer 
For several decades following the initial discovery by Bishop and Varmus 
that the transforming oncogenes found in tumor viruses are actually remnants of 
human genes that also act as oncogenes when mutated in human cells, most 
oncogenes discovered belonged to a few functional classes. Common functions 
of classical oncogenes include receptor tyrosine kinases (RTKs), second-
messengers downstream of RTKs, transcription factors, and a few other classes 
of proteins involved in cell signaling pathways. The discovery that genes 
encoding histone modifiers and other epigenetic regulators could act as 
oncogenes is fairly recent, and dramatically increases the potential complexity of 
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oncogenesis, both as a somatic disease and as a product of germline 
predisposition. It is important when discussing the oncogenic potential of histone 
modifiers and other epigenetic regulatory genes that the concept of epigenetics, 
specifically the heritability of epigenetic marks, is not conflated with the role 
mutated chromatin-modifying enzymes play in driving cancer through altering the 
marks on chromatin that confer heritable patterns of gene expression. While the 
effect of inherited epigenetic marks on the development of cancer has been 
studied, the subject of this work describes the dysregulation of a histone 
methyltransferase that acts as an oncogene through overexpression as a result 
of a somatic event that resulted in gene amplification of the histone 
methyltransferase WHSC1L1. 
Several other genes that code for histone modifying enzymes have also 
been described as oncogenes when mutated, and these mutations have been 
somatic. It should be stressed that these are somatic events that then proceed to 
act as oncogenes through dysregulation of epigenetic marks, and are not 
inherited epigenetic marks that lead to cancer in the individual, nor are these 
mutations and their resulting epigenetic changes themselves heritable. For this 
reason, the term “epigenetic'' will be used as sparingly as possible going forward, 
as the definition of the term epigenetics is more closely aligned with the heritable 
transfer of phenotypic traits through regulation of gene expression that is not 
encoded by DNA sequence, the key word being heritable. 
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1.7.1 WHSC1L1 is amplified in 12-15% of Breast Cancers 
Investigation of patterns of amplification on the short arm of chromosome 
8 resulted in detailed mapping of copy number changes. Using array comparative 
genomic hybridization (aCGH) and microarray expression analysis, Gelsi-Boyer 
et al conducted a detailed investigation of the 8p11-p12 amplicon on a panel of 
breast cancer tissue samples breast cancer cell lines, identifying four distinct 
regions of amplification in the 8p11-p12 amplicon (Gelsi-Boyer, Orsetti et al. 
2005, Pole, Courtay-Cahen et al. 2006). These regions were labeled A1, A2, A3, 
and A4; regions were characterized by the common co-amplification of the “core'' 
genes in each region in several samples in the panel. The WHSC1L1 locus was 
identified as one of 11 core genes in the A2 region of the 8p11-12 amplicon, 
together with part of ASH2L, STAR, LSM1, BAG4, DDHD2, PPAPDC1B, LETM2, 
FGFR1, C8orf86, and TACC1. 
Bilal et al have found amplification of chromosomes 8 and 17 to be 
predictive of tumor recurrence and poor outcome in ER+ breast cancers with 
these amplifications (Bilal, Vassallo et al. 2012). 
Previous work by the Ethier lab and several other groups has identified 
several driving oncogenes in the 8p11-p12 amplicon (Table 1.1), several of which 
have chromatin-modifying activity. These include, among others, MYST3 
(KAT6A), ASH2L, WHSC1L1 (Forozan, Veldman et al. 1999, Forozan, 
Mahlamaki et al. 2000, Garcia, Pole et al. 2005, Yang, Streicher et al. 2006, 
Yang, Liu et al. 2010). As mentioned above, a key question this project 
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attempted to answer is whether there are multiple driving oncogenes within an 
amplicon, or conversely, one primary driving oncogene surrounded by passenger 
genes that are present as an artifact of the mechanism of amplification. 
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Table 1.1: Genes amplified in the 8p11-12 amplicon in breast cancer. 
  
gene symbol sub-amplicon cluster
PROSC A1
DDHD2 A2
RAB11FIP1 A1
LSM1 A2
BRF2 A1
PPAPDC1B -
WHSC1L1 A2
FGFR1 A2
TM2D2 A2
AP3M2 A4
ASH2L A1;A2
BAG4 A1;A2
FUT10 A3
EIF4EBP1 A1;A2
LETM2 A2
AGPAT6 A3;A4
POLB A4
VDAC3 A4
HOOK3 -
TACC1 A2
KAT6A (MYST3) A4
ERLIN2 A1
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1.7.2 Breast cancer sub-types 
Classification of cancer types is fundamental to the detailed description of 
a specific cancer, and this identification of cancer type provides a foundation 
upon which almost all cancer research and treatment is built (Song, Merajver et 
al. 2015). 
Before the development of modern molecular biology techniques, the features 
used to classify a cancer were the organ where the primary tumor was found, 
followed by the type of tissue constituting the majority of the tumor mass, and 
lastly the presence or absence of tumor cells in lymphatic tissue and/or 
metastasis. 
Other than blood cancers (which are classified by cell type rather than tissue 
type), most if not all cancers are described by tissue type and organ or region of 
origin, e.g. breast carcinoma, lung carcinoma, or osteosarcoma. 
While anatomical and histological features were some of the earliest 
methods used to classify cancers (according to the modern definition of 
malignant disease), these methods persist as the primary classifiers of cancer 
today. Despite the distortion wrought by oncogenesis, the origin of the tumor 
cells remains some of the most important information used to diagnose a cancer, 
make a prognosis, and determine the appropriate treatment. Indeed, the location 
of a patient's primary tumor determines which specialist they will see to be 
treated for their disease: oncologists and basic researchers specialize in one or a 
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small number of types of cancer, based on anatomical location and histological 
type. 
1.7.3 Histological Subtyping of Breast Cancer 
While classification of tumor types by organ and tissue of origin have 
some prognostic value, depending on the cancer type, the advent of cancer sub-
typing by molecular marker detection brought forth a new era in cancer 
classification. Breast cancer is an excellent example of the development of 
classifications of distinct sub-types within the more general diagnosis of breast 
carcinoma. McGuire et al used dextran coated charcoal (DCC) and sucrose 
gradient centrifugation to quantitatively detect levels of ERa in samples from 64 
primary and metastatic breast tumors, showing that expression of ERa varied 
widely in expression among the samples (McGuire 1973). The authors 
hypothesized that one of several plausible explanations for the broad range in 
ERa expression was that some breast cancers did not express ERa (which we 
now know to be the case). It was already known in sheep that oophorectomy 
(removal of the ovaries) could slow the growth of some breast tumors, but had 
little or no effect on others. The observed range in ERa expression in the breast 
tumor cohort suggested that classification of breast tumors by ERa status might 
be able to predict response to estrogen ablation therapy. 
By 1974, several studies had shown that measurement of ERa in a patient 
tumor sample was predictive of the patient's response to anti-estrogen therapy. 
Later, it was determined that hormone receptor status was both predictive of 
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response to hormone therapies, and prognostic in that patients positive for ERa 
were more likely to survive in the short term (approximately 15 years) than breast 
cancer patients that lacked hormone receptor expression. The end result of this 
progress in molecular sub-typing was the establishment of two main sub-types of 
breast carcinoma: ER-positive and ER-negative. 
Progesterone receptor testing was also developed, and added to ERa 
testing after it was determined that testing for the progesterone receptor could 
further sub-divide the ER-positive sub-type (Shyamala, Chou et al. 2002). The 
resolution of breast cancer sub-typing increased again with the discovery that the 
human epidermal growth factor receptor (HER2) gene is amplified in ~20% of 
human breast cancers (King, Kraus et al. 1985) by Stu Aaronson and colleagues, 
followed by the work by Slamon and others showing a strong correlation between 
levels of HER2 expression in breast cancers and the aggressiveness of the 
disease (Slamon, Clark et al. 1987, Ignatoski, Lapointe et al. 1999). This work led 
to the addition of a third molecular sub-type of breast cancer: HER2-amplified. 
Importantly, this work to identify the HER2-amplified breast cancer subtype was 
driven by the concurrent development of a targeted antibody therapy against 
HER2 activity, trastuzumab (brand name Herceptin), developed by Micheal 
Shepard and others at Genentech (Lewis, Figari et al. 1993). 
The development of HER2 testing brought the number of breast cancer 
sub-types to three: ER/PR positive, HER2-amplified, and so-called triple-
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negative, after the fact that these tumors would test negatively for all the 
molecular markers. 
By testing patient breast tumor samples for these molecular markers, 
physicians were able to make much more accurate prognoses, and accurately 
predict response to either hormone therapy or treatment with trastuzumab. 
Patients with the triple-negative sub-type occupy a difficult corner of the breast 
cancer classification space: triple-negative breast cancers are particularly 
aggressive, with a mean 5-year survival rate as low as 22% for patients with 
metastatic disease, and the molecular profile characteristic of these tumors 
predicts that they will respond poorly or not at all to hormone therapy or 
treatment with HER2 inhibitors. However, triple-negative breast cancers are 
sometimes more sensitive initially to chemotherapy than hormone-receptor 
positive or HER2-amplified breast cancers, reinforcing the advantage of adding 
molecular screening to the anatomical and histological diagnostic procedures 
(Baselga, Norton et al. 1998, Bagaria, Ray et al. 2014). 
Confirmation that testing for molecular biomarkers in patient tumors has 
predictive and prognostic value increased the clinical importance of more finely 
classifying breast cancers into sub-types, and supported the hypothesis that 
cancer is a highly heterogeneous collection of related diseases (Sorlie, Perou et 
al. 2001, Curtis, Shah et al. 2012). The implication of such heterogeneity at the 
level of protein expression is that increased knowledge of the specific molecular 
profile of a patient's tumor will increase the predictive and prognostic power of 
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physicians when treating breast cancer, as well as leading to more focused 
research that might lead to new therapies, particularly for triple-negative breast 
cancer patients, and increased understanding of cancer biology. This potential, 
together with new microarray technology that enabled the measurement of 
mRNA expression levels of thousands of genes from a single whole mRNA 
sample, led to the molecular profiling experiments that enable our current 
classification system of five breast cancer sub-types: luminal A, luminal B, triple-
negative (sometimes called basal), HER2-amplified, and claudin-low (Perou, 
Sorlie et al. 2000, Bertucci, Orsetti et al. 2008, Prat and Perou 2011). 
Some tests to determine breast cancer sub-type have already made a 
great improvement in the quality of care for a patient. The targeted treatments for 
patients with HER2 amplified breast cancers are a prime example. Before the 
test for HER2 amplification and the development of the targeted therapy 
Herceptin, breast cancer patients with HER2 amplifications were suffering poorer 
outcomes than patients with normal HER2 status due to the increased 
aggressiveness exhibited by HER2 amplified tumors. With the availability of 
trastuzumab and the routine testing of breast tumor biopsies or mastectomy 
tissue for HER2 amplification, these patients now have up to a 35% response 
rate to trastuzumab, disease-free survival (DFS) increased from 62.2% to 73.7%, 
and overall survival (OS) increased from 75.2% to 84% (Callahan and Hurvitz 
2011, Perez, Romond et al. 2014). 
  
42 
For luminal breast cancer sub-types, IHC-based testing for hormone 
receptor status has also been an important advance, leading to targeted 
hormone therapies and sometimes less aggressive treatment of patients due to 
the knowledge that their tumors would be likely to respond completely to 
hormone therapy and surgery, saving them from the morbidity associated with 
traditional chemotherapy. However, the discovery of two major sub-types of 
hormone positive breast cancer, Luminal A and Luminal B, has made it clear that 
the probability of response to hormone therapy is lower and the risk of recurrence 
higher for those patients with disease classified as Luminal B (Sotiriou and 
Pusztai 2009). This suggests that continuing to develop classification techniques 
based on gene expression signatures will further advance our understanding of 
breast cancer, and will likely further sub-divide current breast cancer sub-types 
into additional meaningful classes, each with their own indications for treatment. 
While we are currently in the age of classifying breast cancers based on 
the aforementioned staging and grading of the tumor, IHC and FISH testing for 
hormone receptor status and HER2 amplification, and now transcriptome 
signatures such as the PAM50 breast cancer panel, the next logical step in 
classification methodology may soon be whole-exome or whole-genome DNA 
sequencing of both the primary tumor and a patient blood sample to determine all 
somatic and germline mutations present in the tumor compared to the patient's 
normal tissue. Costs for next-generation sequencing such as Illumina paired-end 
short read sequencing or long read sequencing as performed by Pacific 
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Biosciences are becoming affordable enough to be used to collect genome-wide 
mutation, copy number alteration, variation, and transcript expression data for 
every patient tumor biopsied with the intention to diagnose or rule out cancer. 
While gene expression signatures such as PAM50 have already increased 
our knowledge of breast cancer sub-types to the point where we can differentiate 
between luminal A and luminal B cancers, current methodologies for clinical 
testing of patients suspected of having breast cancer still do not attempt to detect 
all mutations or copy number alterations (CNAs) in a patient's tumor. If basic 
cancer research has shown one thing, it is that every cancer is slightly different. 
The discovery of oncomodifiers has shown that, together with the unique 
combination of driving mutations present in a given cancer, inherited or 
oncogene-driven epigenetic states provide an additional layer of complexity 
contributing to the cancer phenotype (Al-Hajj, Wicha et al. 2003, Dontu, Abdallah 
et al. 2003, Dontu, Jackson et al. 2004). 
This dissertation will aim to expand on knowledge of transforming 
properties of the 8p11-12 amplicon in breast cancer, specifically the role of 
WHSC1L1 amplification and overexpression on the regulation of tumor cell 
prolifεραtion, target gene expression, and chromatin binding events, both 
epigenetic marks and transcription factor binding. 
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CHAPTER 2    KNOCKDOWN OF WHSC1L IN SUM44 
CELLS ALTERS CELL PROLIFERATION AND GENE 
EXPRESSION 
 
2.1 Introduction 
Previous work in the Ethier lab and by others has established that 
WHSC1L1 is amplified and overexpressed as part of an amplified region called 
the 8p11-p12 amplicon, a 30-50 gene region amplified in 12-15% of breast 
cancers, and that WHSC1L1 acts as a driving oncogene in these cells. 
Additionally, other genes in the 8p11-p12 amplicon often found co-amplified with 
WHSC1L1 include ASH2L and MYST3 (KAT6A), both of which are chromatin 
modifiers. Among the candidate driving oncogenes present in the 8p11-p12 
amplicon is FGFR1, which was initially predicted to be the principle driver in the 
amplicon, however it has been shown that in many breast cancers with the 8p11-
p12 amplicon, FGFR1 is not highly expressed and FGFR1 expression does not 
appear to be necessary for maintenance of a tumor phenotype in these cells. 
To determine which genes were the strongest candidate driver oncogenes 
in cells with the 8p11-p12 amplicon, Yang and others in the Ethier lab performed 
a functional screen of individual genes in the amplicon by overexpressing each 
candidate oncogene in MCF10A cells and testing for a transformed phenotype by 
soft-agar colony formation, 3D colony morphology, and proliferation. A 
complementary screen was performed by shRNA knockdown of each candidate 
oncogene in the SUM44 breast cancer cell line, measuring loss of cell 
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proliferation and loss of soft-agar colony formation (add cite)[Yang06, Yang10}. 
In these studies, it was found that WHSC1L1-short was sufficient to induce a 
transformed phenotype in MCF10A cells when overexpressed by lentiviral 
transduction. 
Tests for induction of a transformed phenotype included colony formation 
of MCF10A cells in the absence of insulin on 60mm culture plates, as well as 
soft-agar colony formation, and finally colony morphology when cultured in 3D 
Matrigel. These experiments clearly indicated that MCF10A-WHSC1L1-short 
cells formed the largest and highest number of colonies in the absence of insulin, 
demonstrating growth factor independent growth, as well as forming the largest 
number of soft-agar colonies, and finally showing obvious disorganized colony 
morphology in 3D Matrigel. Additionally, in SUM44 cells, two different shRNAs 
knocking down total WHSC1L1 (both short and long isoforms of WHSC1L1) 
resulted in significantly reduced proliferation and reduced colony size and 
number in SUM44. Proliferation was also reduced in one SUM52-
shWHSC1L1total cell line, transduced with the same shRNA that had the 
strongest effect in SUM44. It should be noted that these WHSC1L1 knockdown 
experiments in SUM44 used pGIPZ shRNA vectors against total WHSC1L1, 
while the experiments shown here used pLKO lentiviral shRNA vectors 
purchased from Sigma. 
As WHSC1L1 was the strongest candidate driver oncogene of the 8p11-
p12 amplified and overexpressed genes tested, it was a suitable target for further 
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investigation. The initial objective was to develop a model of WHSC1L1 
expression loss in SUM44 cells, and measure the effect of either specific shRNA 
knockdown of WHSC1L1-short, or knockdown of total WHSC1L1 on cells 
proliferation and the expression profile of the transcriptome in the WH-
knockdown cells vs. a control condition (a vector containing shRNA for LacZ, a 
bacterial transcript that should have no effect on any human transcript). Use of 
off-the-shelf vectors enabled expeditious screening for the best knockdown 
among several shRNAs and selection of the best vectors for knockdown of total 
WHSC1L1 or WHSC1L1-short. 
The first set of experiments was designed to establish stable knockdown 
of either both the long and short isoforms of WHSC1L1, or the short isoform only, 
in SUM44 cells. The use of the 3'UTR-specific WHSC1L1-short shRNAs was key 
to achieving specific knockdown, as the coding sequence of WHSC1L1-short is 
identical to the long isoform until the splicing of an alternate exon 10, which 
contains the short isoform-specific 3' UTR region targeted by the WHSC1L1-
short shRNAs. Once stable knockdown could be confirmed, the objectives were 
to study the effect of knockdown of WHSC1L1 on cell proliferation and on gene 
expression, specifically the effect of knockdown of WHSC1L1-short alone, to 
determine whether we would observe similar effects to previous experiments with 
total WHSC1L1 knockdown when only the short isoform was depleted. 
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2.2 Results 
2.2.1 WHSC1L1-short is the major expressed isoform in breast epithelial 
cells 
As previously mentioned, WHSC1L1 is known to have histone 
methyltransferase activity targeting histone H3 lysines as substrate. To support 
our hypothesis that overexpression of WHSC1L1-short alters histone methylation 
patterns in key genes that leads to promotion and maintenance of an oncogenic 
phenotype, we first sought to identify basic properties of WHSC1L1, such as the 
cellular localization of the protein isoforms, and the relative abundance of the 
long and short isoforms at the transcript and protein level. We would expect 
WHSC1L1 to be localized to the nucleus if it is in fact binding histone proteins as 
a substrate, and, while little can be directly interpreted from relative isoforms 
abundance, it is important to determine whether each isoform is actually 
expressed at significant levels. 
To determine the subcellular localization of WHSC1L1 protein in breast 
epithelial cells, we cultured primary human mammary epithelial cells (HMEC) 
immortalized with viral E6/E7 proteins and MCF10A cells, both of which were 
lentivirally transduced with the pLenti6.3-WHshortV5 construct, then exposed to 
polyclonal WHSC1L1 antibody followed by FITC-conjugated secondary antibody. 
The nuclei of both HMEC-E6/E7-pL6.3-WHshort and MCF10A-pL6.3-WHshort 
cells exhibited strong green fluorescence in the nuclei of many cells (nuclei 
stained with DAPI), while cytoplasmic green fluorescence is not detected (Figure 
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2.1). This indicates that WHSC1L1 is expressed in the nucleus of these models 
of breast epithelial cells in culture. 
To find the relative expression of WHSC1L1 transcript for the short and 
long isoforms of WHSC1L1 in breast tissue, RNAseq whole RNA expression data 
from The Cancer Genome Atlas Breast Cancer dataset was used to determine 
the expression levels of WHSC1L1-short and WHSC1L1-long. A boxplot of the 
distribution of expression levels for each isoform for all TCGA BrCa samples 
(Figure 2.2a) shows that the mean expression of the short isoform of WHSC1L1 
is higher than the mean expression of the long isoform. Immunobloting for 
WHSC1L1 protein in SUM44 luminal B breast cancer cells and MCF10A breast 
epithelial cells (Figure 2.2b) indicates that WHSC1L1 protein expression in these 
cell lines is concordant with observed WHSC1L1 mRNA expression levels in 
TCGA breast cancer samples. Of note, WHSC1L1-short transcript expression 
was also higher than WHSC1L1-long expression in the normal breast tissue 
samples collected by TCGA (data not shown). 
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Figure 0.2 HELP 
     
 
 
 
  
Figure 2.1. WHSC1L1 cellular localization in tumor cell lines.  
Immunofluorescence micrographs of human mammary epithelial cells 
immortalized with viral E6/E7 and MCF10A breast epithelial cells lentivirally 
transduced with WHSC1L1-short. WHSC1L1 antibody visualized with anti-
rabbit FITC and nuclei stained with DAPI. 
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2.2.2 WHSC1L1-short knockdown reduces cell growth 
To confirm that knockdown of WHSC1L1 reduces SUM44 proliferation, 
and to determine the effect of WHSC1L1-short knockdown, SUM44 cells were 
lentivirally transduced with shLacZ (control), shWHtotal or shWHshort short-
hairpin RNA (shRNA). Of the five WHtotal shRNAs and two WHshort shRNAs, 
shWHtotal_2 and shWHshort_1 achieved the greatest reduction in WHSC1L1 
transcript levels when measured by real-time PCR (Figure 2.1). Knockdown of 
WHSC1L1 expression was validated by western blot. Both shWHtotal_1 and 
shWHtotal_2 reduced levels of WHSC1L1 (Figure 2.3a), with the most 
knockdown occurring in the short isoform. The shWHtotal_2 cells exhibited better 
knockdown of both isoforms of WHSC1L1; this shRNA vector was chosen for use 
in later experiments. Both of the shWHshort vectors knocked down WHSC1L1-
short levels (Figure 2.3b), however shWHshort\_1 consistently had greater 
knockdown of the short isoform, and was used for later 
experiments. 
With a working WHSC1L1-knockdown model in SUM44 cells, we next 
investigated the effect of WHSC1L1total and WHSC1L1-short knockdown on cell 
proliferation. A proliferation assay was performed to measure changes in 
proliferation after knockdown of WHSC1L1 over a period of 10 days. SUM44 
shLacZ cells exhibited an 8.8-fold increase in cell number over the 10-day culture 
period, while the shWHtotal cell number increased 5.6-fold, and the shWHshort 
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cells increased 3.8-fold (Figure 2.4a). While both the shWHtotal and the 
shWHshort cells proliferated more slowly than the shLacZ controls, knockdown of 
the short isoform of WHSC1L1 had the greatest negative effect on growth. 
A boxplot of the distribution of the fold-increase in cell number for 3 
repeats of the proliferation assay comparing growth of SUM44 shWHtotal and 
shWHshort vs shLacZ cells (Figure 2.4b) shows that the interquartile range (IQR) 
of the SUM44 shLacZ cell number for the three experiment replicates is higher 
than the IQR for SUM44 shWHshort. 
Proliferation of SUM44 slowed with WHSC1L1-short knockdown, but 
did not stop. Observing this decrease in proliferation upon knockdown of 
WHSC1L1-short, we became interested in whether there was a buildup of cells in 
either G1 or G2 in the SUM44 shWHshort cells. The DNA content flow cytometry 
plot (Figure 2.5) shows DNA content in SUM44 shLacZ and shWHshort by flow-
cytometry. The fraction of S-phase cells (blue shaded region) was reduced in the 
shWHshort cells, and there were increases in both the G1 and G2 phase 
populations compared to shLacZ control. 
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Figure 6.2 WHSC1L1 expression patterns in breast cancer samples and in 
SUM44 and MCF10A. 
a. Transcript expression levels of WHSC11L1 short and long in TCGA breast 
cancer samples. b. Immunoblot for WHSC1L1 in SUM44 breast cancer cells 
and in MCF10A cells, a model of non-malignant breast epithelial tissue. 
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Figure 2.3 Knockdown of WHSC1L1 total and short isoform alone alters 
WHSC1L1 expression in SUM44 cells.  
a. Immunoblot of WHSC1L1 from whole cell lysate of SUM44 shLacZ and 
shWHSC1L1total cells. b. WHSC1L1 immunoblot from whole cell lysate of 
SUM44 shLacZ and shWHSC1L1short cell lines.  
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Figure 2.4 Treatment with beta-estradiol affects proliferation of SUM44 
cells. 
a. Proliferation of SUM44 shWHSC1L1total and shWHSC1L1short cells vs 
shLacZ control on days 0 and 12. Error bars represent 1.98 * standard error 
mean (SEM) of 3 experiments. b. Boxplot showing the distribution of the fold-
increase in cell number in SUM44 shWHSC1L1short vs shLacZ cells after 12 
days. Error bars represent 3 experiments. 
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2.2.3 Knockdown of WHSC1L1-short alters expression of several genes 
active in breast cancer 
WHSC1L1-long possesses histone methyltransferase activity, promoting 
hypermethylation of histone H3K36. H3 lysine 36 di- and tri-methylation has been 
shown to promote transcriptional elongation, thus promoting expression of gene 
loci with these histone marks. While this mechanistic knowledge of WHSC1L1 
activity is evidence that WHSC1L1 can be a transcriptional activator, little is 
known about the effect of WHSC1L1 expression level on the regulation of target 
gene expression, particularly in the setting of gene amplification. Further, it is not 
known how WHSC1L1-short, lacking the catalytic SET domain and thus direct 
methyltranferase activity, regulates gene expression, or whether both isoforms of 
WHSC1L1 regulate the same target genes. As the target genes regulated by 
WHSC1L1 expression are not well understood in normal cells, nor in cancer cells 
where WHSC1L1 is amplified and over expressed, we performed a series of 
experiments to investigate the effect of WHSC1L1-short and WHSC1L1-total 
knockdown on the gene expression profile of SUM44 cells. 
To carry out these experiments, we first performed expression profiling of 
SUM44 shWHtotal cells to identify genes regulated by WHSC1L1 expression. 
SUM44 cells were transduced with pGIPZ shWHtotal lentivirus and selected for 
Puromycin resistance. Total mRNA extracted from shLacZ and shWHtotal 
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SUM44 cells was hybridized to an Agilent 2-color microarray and the expression 
profiles for the two conditions were compared. Knockdown of total WHSC1L1 
resulted in significant changes in gene expression (Supplementary Table 1). 
Among genes with significant transcript downregulation in SUM44 shWHtotal 
knockdown cells, we identified several that were interesting in the context of ER-
positive Luminal B breast cancers, including ESR1, ERBB4, MYCN, CD24, and 
CD44. 
As SUM44 cells express high levels of ER-alpha, we focused on ESR1 
and HER4, and validated the microarray data by RT-PCR (data not shown). 
To confirm and extend the results obtained from the microarray 
experiments, we next performed RNAseq expression profiling analysis following 
knockdown of WHSC1L1-total or WHSC1L1-short.  The expression profiles of 
SUM44 shLacZ, SUM44 shWHtotal, and SUM44 shWHshort cells were 
measured by Illumina 151 base-pair paired-end sequencing of whole mRNA 
extracts from each cell line, followed by differential expression analysis using the 
DESeq2 Bioconductor package to identify significantly differentially expressed 
genes between SUM44 shLacZ and either SUM44 WHSC1L1 knockdown 
sample. A plot of RNAseq results (Figure 2.6) shows log2foldchange values for 
ESR1 in SUM44 shWHshort vs shLacZ DESeq2 differential expression analysis 
of RNAseq expression data. As shown in the plot, there was a 1.06-fold decrease 
in ESR1 in shWHtotal cells (FDR 0.97), and a 1.78-fold decrease in ESR1 in 
shWHshort cells (FDR 0.13). 
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With confirmation by both microarray and RNAseq that WHSC1L1 
knockdown significantly reduced ESR1 expression, we wanted to know whether 
the downregulation of ESR1 transcript observed in the expression profiling data 
would correspond to a reduction in levels of ER-alpha protein upon knockdown of 
WHSC1L1, particularly WHSC1L1-short. ER-alpha protein levels in whole cell 
lysates from SUM44 shLacZ, shWHtotal, and shWHshort were measured by 
immunoblot (Figure 2.7a). As seen in the figure, both HER4 and ER-alpha 
protein levels were markedly reduced in the shWHtotal SUM44 cells. ER-alpha 
levels were even further reduced in SUM44 shWHshort cells (Figure 2.7b). 
These data indicate that the amplification and overexpression of the short 
isoform of WHSC1L1 observed in SUM44 cells is necessary for the high levels of 
ERa transcript and protein expression in these cells, which is greater than ERa 
expression in MCF7, the prototypical ER+ breast cancer model cell line (Figure 
2.7c). 
RNAseq expression profiling of SUM44 shWHshort cells compared to 
SUM44 shLacZ control identified 1130 significantly differentially expressed genes 
(p-value < 0.05, FDR < 0.15). Of those 1130 genes, 622 were upregulated and 
508 were downregulated in the shWHshort knockdown cells relative to shLacZ 
control. A total of 237 genes were differentially expressed in SUM44 shWHtotal 
cells compared to SUM44 shLacZ controls; 114 were upregulated, and 123 
downregulated. A total of 63 genes were significantly differentially expressed in 
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both WHshort and WHtotal knockdown samples compared to shLacZ control. 
The differentially expressed genes for each condition are shown in the Appendix. 
To identify patterns of biological significance in the differentially expressed 
genes, we ran gene set enrichment analysis (GSEA) on the expression values of 
all genes measured by RNAseq in SUM44 WHSC1L1 knockdown cells 
compared to shLacZ controls. A false discovery rate (FDR) of 0.25 was chosen 
as the cutoff for significant gene set enrichment, and the Kyoto Encyclopedia of 
Genes and Genomes (KEGG) gene set list was selected to query for enrichment. 
GSEA of the SUM44 shWHSC1L1-short vs. shLacZ samples identified 10 KEGG 
pathway gene sets significantly enriched in SUM44 shWHSC1L1-short relative to 
shLacZ (Table 2.1). Top hits included gene sets involved in DNA replication and 
DNA repair, as well as steroid biosynthesis. 
As shown in Table 2.2, only 3 KEGG pathway gene sets were significantly 
negatively enriched in SUM44 shWHSC1L1-short cells compared to shLacZ 
cells. 
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Figure 2.5 Knockdown of WHSC1L1short reduces the S-phase fraction in 
SUM44 cells.  
DNA content assays by flow cytometry of SUM44 shLacZ (left panel) and 
shWHSC1L1short (right panel). 
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2.2.4 SUM44 cells respond negatively to estrogen 
SUM44 cells express high levels of estrogen receptor alpha, in fact at 
significantly higher levels than in MCF7, the prototype cell line for ER-positive 
breast cancer. Both MCF7 and SUM44 were isolated from pleural effusion 
metastases in patients with late stage breast cancer. While the sensitivity of 
MCF7 cells in vitro to estradiol has been comprehensively described in the 
literature, it remains one of the few ER-positive breast cancer cell line models, 
and represents the Luminal-B subtype. Upon observing the effect of WH 
knockdown on ER-alpha protein expression levels, we became interested in the 
response of SUM44 cells to treatment with estrogens, and whether WH 
knockdown would affect the SUM44 response to estrogen. 
Proliferation assays were conducted on SUM44 shLacZ, shWHtotal, and 
shWHshort cells. The cells were cultured in serum-free media that did not contain 
phenol red, and were treated with either vehicle control or varying concentrations 
of beta-estradiol. A plot of cell proliferation (Figure 2.8) shows SUM44 shLacZ 
and shWHshort cell numbers after 11 days of culture in increasing concentrations 
of beta-estradiol. SUM44 shLacZ cell proliferation began to decrease at 1pM 
beta-estradiol, and decreased in a dose-dependent manner through 1nM, 
indicating that picomolar concentrations of estrogen have an inhibitory effect on 
SUM44 proliferation. In contrast, proliferation of SUM44 shWHshort cells 
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increased in 1pM estrogen, and further increased at 10pM, then steadily 
decreased at 100pM and 1nM beta-estradiol, in parallel with the proliferation 
decrease seen in the shLacZ cells. 
 
  
  
62 
 
  
Figure 2.6 Knockdown of WHSC1L1 total and short isoform alone alters 
expression of ESR1 transcript in SUM44 cells.  
RNAseq differential expression of ESR1 transcript levels in SUM44 
shWHSC1L1short vs shLacZ control cells. Experiment performed in duplicate 
with differential expression performed using DESeq2. 
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Table 2.1. Gene set enrichment analysis (GSEA) positively-enriched 
processes in SUM44 shWHSC1L1short vs shLacZ cells. 
 
  
RANK DETAILS SIZE NES FDR
1 DNA REPLICATION 36 2.23 0.0
2 ANTIGEN PROCESSING AND PRESENTATION 88 2.0 0.002
3 CELL CYCLE 124 1.94 0.003
4 SYSTEMIC LUPUS ERYTHEMATOSUS 134 1.93 0.003
5 SPLICEOSOME 125 1.92 0.003
6 STEROID BIOSYNTHESIS 16 1.84 0.008
7 HOMOLOGOUS RECOMBINATION 28 1.82 0.01
8 MISMATCH REPAIR 23 1.81 0.01
9 CITRATE CYCLE TCA CYCLE 30 1.75 0.018
10 PYRIMIDINE METABOLISM 96 1.75 0.017
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Table 2.2 GSEA negatively-enriched processes in SUM44 
shWHSC1L1short vs shLacZ cells. 
 
 
  
RANK DETAILS SIZE NES FDR
1 DNA RIBOSOME 86 -3.23 0
2 ARACHIDONIC ACID METABOLISM 58 -1.66 0.101
3 NITROGEN METABOLISM 23 -1.58 0.134
  
65 
 
 
 
 
 
 
 
 
 
 
Table 2.3 GSEA positively-enriched processes in SUM44 cells treated 
with beta-estradiol. 
  
RANK DETAILS SIZE NES FDR
1 CELL CYCLE 123 2.8 0.0
2 DNA REPLICATION 35 2.44 0.0
3 OOCYTE MEIOSIS 102 2.12 0.001
4 MISMATCH REPAIR 22 2.09 0.001
5 HOMOLOGOUS RECOMBINATION 27 2.02 0.003
6 PYRIMIDINE METABOLISM 92 1.98 0.003
7 SPLICEOSOME 125 1.96 0.004
8 NUCLEOTIDE EXCISION REPAIR 43 1.93 0.005
9 PROTEASOME 41 1.9 0.007
10 STEROID BIOSYNTHESIS 16 1.9 0.006
11 FOLATE BIOSYNTHESIS 11 1.89 0.006
12 P53 SIGNALING PATHWAY 66 1.87 0.007
13 SYSTEMIC LUPUS ERYTHEMATOSUS 99 1.87 0.007
14 GALACTOSE METABOLISM 23 1.84 0.01
15 PROGESTERONE MEDIATED OOCYTE MATURATION 79 1.82 0.011
16 CITRATE CYCLE TCA CYCLE 29 1.77 0.018
17 BASE EXCISION REPAIR 33 1.77 0.017
18 PENTOSE PHOSPHATE PATHWAY 25 1.7 0.03
19 RNA DEGRADATION 56 1.69 0.032
20 BIOSYNTHESIS OF UNSATURATED FATTY ACIDS 21 1.64 0.045
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2.2.5 Gene expression profiling of SUM44 cells after treatment with 
estrogen 
SUM44 cells represent a model of highly ER-positive luminal B breast 
cancer. As shown above, SUM44 cells are exquisitely sensitive to estrogen, 
responding to as little as 10pM beta-estradiol, and actually reducing their 
proliferation rate upon treatment with greater than 10pM beta-estradiol. Given 
this extraordinary response to estrogen, we became interested in the effect of 
estrogen treatment on gene expression in SUM44 cells. 
To determine the effect of estrogen treatment on SUM44 gene expression, 
we cultured the cells in estrogen-free conditions for 72 hours, then added 10nM 
beta-estradiol and waited 6, 12, and 24 hours after treatment before harvesting 
whole mRNA and measuring transcript expression by RNAseq. We then 
performed GSEA on the expression profiling data to determine which KEGG 
pathways were positively or negatively enriched in SUM44 estrogen-treated cells 
compared to SUM44 cells grown in normal conditions. As shown in Table 2.3, 
treatment with estrogen for 6 hours resulted in positive enrichment of cell-cycle, 
DNA replication, meiosis, and DNA mismatch repair KEGG pathway gene sets. 
Interestingly, with the exception of the lupus erythematosus and antigen 
processing and presentation gene sets, all of the gene sets positively enriched in 
SUM44 shWHshort cells were also positively enriched after treating SUM44 cells 
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with estrogen. In addition to the common gene sets, several additional gene sets 
were positively enriched, including several pathways related to steroid hormone 
receptor activation. The p53 pathway was also positively enriched upon 
treatment of SUM44 with estrogen. Overall, a total of 20 gene sets were enriched 
with an FDR less than or equal to 0.05. 
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Figure 2.7 Knockdown of WHSC1L1 total and short isoform alone alters 
expression of ERa protein in SUM44 cells.  
a. Immunoblot of ERa from whole cell lysate of SUM44 shLacZ and 
shWHSC1L1total cells. b. ERa immunoblot of whole cell lysate from SUM44 
shLacZ and shWHSC1L1short cells. c. ERa immunoblot of MCF7 and SUM44 
whole cell lysate. 
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Figure 2.8 SUM44 proliferation is sensitive to treatment with beta-estradiol.  
Proliferation of SUM44 shWHSC1L1short and shLacZ cells in response to 
increasing amounts of beta-estradiol. Error bars show 1.8 * SEM for 3 
experiments. 
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2.3 Discussion 
We were able to successfully create WHSC1L1-total and 
WHSC1L1-short knockdown models using a lentiviral shRNA expression vector 
stably transduced in SUM44 cells, achieving a reduction in both transcript and 
protein levels of WHSC1L1-long and WHSC1L1-short as shown by real-time 
PCR and western blotting, respectively. As previously shown, knockdown of total 
WHSC1L1 negatively affected SUM44 cell proliferation, and our results with 
WHSC1L1-short knockdown indicated an even greater negative effect on 
proliferation when only the short isoform was knocked down. The lack of a model 
that knocked down the long isoform of WHSC1L1 alone complicates the 
interpretation of the proliferation experiments, however the data with the total and 
short-only WHSC1L1 knockdown could support a model where the activities of 
the long and short isoforms of WHSC1L1 are opposed. While shRNA knockdown 
of total WHSC1L1 resulted in successful knockdown of both isoforms of 
WHSC1L1, knockdown of WHSC1L1-short with the short isoform-specific shRNA 
appeared to achieve a greater knockdown of WHSC1L1-short than knockdown of 
either isoform in the shWHtotal cell lines.  
Also, interestingly, in the SUM44 shWHshort-1 cells, which achieved the 
greatest knockdown of WHSC1L1-short, the level of WHSC1L1-long appears to 
increase noticeably. This increase can also be observed at the mRNA level in the 
RNAseq expression profiling data (Appendix). These results suggest 
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autoregulation of WHSC1L1 expression by WHSC1L1-short, and the increased 
level of WHSC1L1-long in the SUM44 shWHshort cells, together with the much 
greater number of significantly differentially expressed genes upon WHSC1L1-
short knockdown, suggests that SUM44 cells are much more sensitive to 
expression levels of the short isoform of WHSC1L1. It would be interesting to 
investigate whether changes in WHSC1L1-short expression cause a greater 
magnitude of changes compared to changes in WHSC1L1-long in other cell lines 
as well. 
Knockdown of WHSC1L1 resulted in differential expression of many 
genes known to be interesting in breast cancer and notably resulted in significant 
downregulation of ESR1 transcript, which in turn resulted in a decrease in ERa 
expression. In addition to ERa, HER4 mRNA and protein levels were reduced in 
SUM44 shWHSC1L1-short cells relative to shLacZ control. 
While we chose to focus on ERa downregulation due to the importance of 
the estrogen receptor in breast cancer and specifically the high ERa levels 
observed in SUM44 cells, several other interesting genes were differentially 
expressed upon WHSC1L1 knockdown, and the mechanism of regulation of 
these genes by WHSC1L1 should be investigated. One important general 
conclusion that can be made from the RNAseq expression profiling data is that 
knockdown of WHSC1L1-short had a positive overall effect on gene expression, 
increasing the expression level of over 600 genes, while downregulating 
approximately 500. It should also be noted that the total number of significantly 
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differentially regulated genes in the SUM44 shWHSC1L1total cells was much 
smaller than the number that were significantly altered in SUM44 
shWHSC1L1short. 
One possible interpretation of this finding is that the long isoform and short 
isoform of WHSC1L1 have opposing effects on the set of target genes shared by 
both isoforms. Also, the observation that WHSC1L1-long increased upon 
knockdown of WHSC1L1-short supports the possibility that the two isoforms of 
WHSC1L1 reciprocally regulate each others' expression. The net increase in 
expression upon WHSC1L1-short knockdown could indicate that the effect of 
WHSC1L1 amplification and overexpression in SUM44 cells has a net 
suppressive effect on gene expression, which would be counterintuitive to the 
effects of most oncogenes, which generally upregulate pathways involved in cell 
growth, proliferation, and survival. Indeed, the fact that TP53 is mildly 
upregulated upon knockdown of WHSC1L1-short, along with positive enrichment 
for DNA damage repair pathways, may indicate that WHSC1L1 amplification 
plays a role in suppression of tumor suppressor pathways in SUM44. The fact 
that the same pathways are upregulated upon treatment of SUM44 with estrogen 
is admittedly baffling, although extremely interesting. 
There is not enough data from these experiments to propose a model for 
the similar response of SUM44 cells to WHSC1L1-short knockdown and 
treatment with estrogen, however the evidence strongly suggests that treatment 
of SUM44 cells with estrogen has a similar effect as downregulating ERa 
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expression (as has been shown to occur when WHSC1L1-short is knocked 
down). This is a surprising finding, and one that needs to be repeated in SUM44 
and additional ER-positive breast cancer cell lines with WHSC1L1 
overexpression. The possible relationship between WHSC1L1-short 
overexpression and the response of this highly ER-positive cell line to estrogen 
suggest that SUM44 may be an informative model for increasing our 
understanding of mechanisms for endocrine resistance in breast cancer (Gururaj, 
Rayala et al. 2006). 
It should be noted that mRNA for the TSKU gene was the fourth most 
abundant transcript found in SUM44 shLacZ cells, and was also significantly 
upregulated in SUM44 shWHSC1L1-short cells. This is interesting considering 
the fact that the TSKU locus is part of an amplified region on the long arm of 
chromosome 11 that is also amplified in SUM44 cells. The high expression of 
TSKU is expected, given the gene amplification. However, the fact that TSKU 
expression appears to be regulated by expression of WHSC1L1-short, a 
transcript coded for by another amplified region on a different chromosome, 
suggests that there may be functional cooperation among genes in different 
amplified regions that co-occur in breast cancer. The question whether co-
amplified genes share common regulatory pathways is an important question in 
cancer. It's logical that the presence of multiple amplified regions in a cancer is 
due to selection for the co-amplification of these regions, as they are presumably 
rare events that would not be expected to co-occur without selective pressure. 
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2.4 Materials and Methods 
2.4.1 shRNA vectors 
Lentiviral shRNA expression vectors were from the pLKO shRNA catalog 
purchased from Sigma. Vectors used include TRCN0000415241 (WHSC1L1-
short), and the WHSC1L1-total vectors, TRCN0000425711, TRCN0000015615, 
and TRCN0000015616. 
2.4.2 Lentiviral infection protocol 
Lentivirus for lentiviral transduction of shRNAs into SUM44 cells was 
prepared using the Sigma Mission lentiviral packaging system (Sigma, shp-001) 
in 293FT packaging cells following the manufacturer's protocol. Briefly, each 
construct was co-transfected into 293FT cells with Sigma pLKO shRNA vectors 
and virus was harvested according to the manufacturer's instructions. Target 
cells were transduced with packaged virus in growth media supplemented with 5 
ug/ml polybrene. Cells were cultured for three days to allow for expression of the 
resistance marker. Non-transduced cells were eliminated from the culture by 
addition of the selection agent puromycin (3ug/mL). 
2.4.3 Antibodies 
Antibody for WHSC1L1 was purchased from ProteinTech Group Inc. (Cat. 
No.11345-1-AP). Estrogen receptor alpha antibody was purchase from Bethyl 
Labs (Cat. No. A300-498A). ChIP-grade anti-estrogen receptor alpha antibodies 
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were purchased from Santa Cruz (sc-543x) and Thermo Scientific (MA5-13065). 
ChIP-grade histone antibodies were used for both ChIP and immunoblotting, and 
were purchased from Abcam and Millipore: total H3 (Abcam ab1791), H3K36me3 
(Abcam ab9050), H3K36me2 (Abcam ab9049), and H3K4me3 (Millipore 17-678). 
2.4.4 Cell culture 
SUM44PE cells were cultured in serum-free Ham's F-12 with supplements 
(Ham's F-12 with 1ug/ml hydrocortisone, 1 mg/ml bovine serum albumin, 10 mM 
Hepes, 5 mM ethanolamine, 5ug/ml transferrin, 10 nM triiodothyronine, 50 nm 
sodium selenate, 25ug/ml gentamicin, 2.5ug/ml fungizone, and 5ug/ml insulin), 
as described previously (Ethier, Chiodino et al. 1990). For estrogen-free culture 
conditions, phenol red-free Ham's F-12 media was substituted for normal Ham's 
F-12; all supplements were as in normal media. Cells transduced with lentiviral 
shRNAs were selected and maintained in 3 ug/mL puromycin. 
2.4.5 Proliferation assays 
Proliferation assays were performed in 6-well culture plates seeded with 
5x105 cells per well. At 24 hours and 10 days after seeding, cells were washed 
three times with PBS and agitated on a rocker table with 0.5 ml of a 
HEPES/MgCl2 buffer (0.01 M HEPES and 0.015 M MgCl2) for 5 minutes. Cells 
were then lysed for 10 minutes with a solution of ethyl 
hexadecyldimethylammonium, and the nuclei were counted using a Z1 Coulter 
Counter (Beckman Coulter, Brea, CA, USA). 
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2.4.6 Western blotting 
Cells were plated and grown to 90% confluency.  Where indicated, the 
cells were treated with 500 nM gefitinib for the indicated times.  Cells were then 
lysed in a buffer containing 20 mM Tris-HCl (pH 8.0), 137 mM NaCl, 1% NP40, 
10% glycerol, 1 mM Na3VO4, and 1X Protease Inhibitor cocktail (Calbiochem, 
539131), and protein concentrations were measured by Bradford assay (Bio-
Rad). Laemmli sample buffer was added to the lysates and the samples were 
boiled for 5 minutes before being separated by electrophoresis on SDS-
polyacrylamide gels (Bio-Rad). After transferring the proteins to polyvinylidene 
difluoride (PVDF) membranes, blots were probed overnight at 4° Celsius with the 
indicated antibodies. 
2.4.7 RNA expression profiling 
Total RNA was prepared using a Qiagen RNeasy Plus Mini Kit and 
processed by the MUSC Genomics core for 2x101 cycles, paired-end RNA 
sequencing on an Illumina HiScanSQ. RNA integrity was verified on an Agilent 
2200 TapeStation (Agilent Technologies, Palo Alto, CA). A total of 100-200 ng of 
total RNA was used to prepare RNA-Seq libraries using the TruSeq RNA Sample 
Prep kit following the protocol described by the manufacturer (Illumina, San 
Diego, CA). Sequencing was performed on an Illumina HiScanSQ. Samples were 
demultiplexed using CASAVA (Illumina, San Diego, CA). Fastq files were used to 
map reads to the human genome (hg19, UCSC) utilizing Tophat2 with default 
settings.  A total of 100-200 ng of total RNA was used to prepare RNA-Seq 
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libraries using the TruSeq RNA Sample Prep kit following the protocol described 
by the manufacturer (Illumina, San Diego, CA). 
2.4.8 Bioinformatics and Statistical analysis 
Paired end sequencing of 151 base-pair reads was performed on RNA 
samples using an Illumina HiSeq2500 with each sample sequenced to a depth of 
approximately 10 million reads. Data was subjected to Illumina quality control 
(QC) procedures (>80% of the data yielded a Phred score of 30), and 
preprocessing using Trimmomatic which removed adapter sequences and 
filtered low quality reads (Bolger, Lohse et al. 2014). Further data QC was 
performed using FastQC, prior to aligning the reads to the human genome HG19 
using Tophat2 (Kim, Pertea et al. 2013). The resulting SAM files were inputted 
into the Python package HTSeq and quantitative readouts for each sample 
obtained in the form of count data. In order to infer differential signal within the 
data sets with robust statistical power, we utilize DEseq2, a method which tests 
for differential expression based on a model using negative binomial distribution 
(Love, Huber et al. 2014). Transcript count data from DESeq2 analysis was 
ranked according to q-value, which is the smallest false discovery rate (FDR) at 
which a transcript is called significant. Statistical analysis of Pathways and Gene 
Ontology terms was carried out using this sorted transcript list (Subramanian, 
Tamayo et al. 2005) which was subjected to Gene Set Enrichment Analysis 
(GSEA) using the ToppGene Suite (Chen, Bardes et al. 2009). 
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CHAPTER 3    ESTROGEN RECEPTOR ALPHA BINDS 
CHROMATIN IN THE ABSENCE OF ESTROGEN IN 
SUM44 CELLS 
 
3.1 Introduction 
Estrogen receptor signaling is important in the growth and development of 
tissue, and plays a key role in ER+ breast cancer. The presence or absence of 
ERa expression in a malignant breast tumor has a profound effect on the 
aggressiveness of a malignant breast tumor, affects the options for treatment, 
and influences the overall prognosis. ERa testing, together with tests 
for progesterone receptor expression and HER2 amplification/overexpression are 
the primary molecular markers used to classify breast cancers at diagnosis. 
Nearly 75% of breast cancers diagnosed are found to be positive for ERa 
expression, and treatments that inhibit activation of the estrogen receptor are 
effective in most patients with ER+ disease (Rose, Kamby et al. 1986).  
Given the importance of estrogen signaling in ER+ breast cancers, there is 
high demand in basic cancer research for a cell line that models ER+ breast 
cancer in the lab. The MCF7 cell line, developed in 1973 at the Michigan Cancer 
Foundation (now Karmanos Cancer Institute) in Detroit, was one of the first cell 
line models of human breast cancer that could be cultured indefinitely, and 
remains essentially the sole model of ER+ breast cancer used for basic research 
as of 2015. One active area of basic research using MCF7 cells is the study of 
cellular response to inhibition of estrogen signaling, specifically inactivation of 
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estrogen receptor alpha. The majority of our current understanding of the cellular 
response of ER+ breast cancer cells to estrogen agonists and antagonists is 
based on research conducted with MCF7 cells. While the research conducted so 
far is invaluable to our understanding of ER biology in ER+ breast cancers, 
investigation of ERa biology in additional breast cancer cell lines will most likely 
strengthen some findings, while possibly contradicting others, eventually leading 
to a more complete understanding of the role of ERa in breast cancer biology. 
3.2 Results 
3.2.1 ERa binds chromatin in the absence of estrogen in SUM44 cells 
The high levels of ERa protein expression in SUM44 cells and the cells' 
lack of response to exogenous estrogen suggest that estrogen receptor activity is 
an important driver of the biology of these cells in the absence of estradiol. We 
next sought to determine ERa binding sites in SUM44 cells, and to measure the 
relative binding intensity of ERa in estrogen-free and estrogen-containing 
conditions. To measure ERa binding to chromatin in SUM44, we cultured cells in 
phenol red-free SFIH media for 72hrs to maintain estrogen-free culture 
conditions, and treated with either vehicle or 10nM beta-estradiol for 45 minutes 
immediately before harvesting the cells for chromatin immunoprecipitation. We 
then chromatin immunoprecipitated the fragmented chromatin with anti-ERa 
antibody and sequenced the ChIP'd DNA on an Illumina Hi-Seq 2500 (Goren, 
Ozsolak et al. 2010). Three biological replicates of each sample type, vehicle and 
10nM beta-estradiol, were prepared and sequenced. After alignment and peak 
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calling with two different peak callers, Homer's findPeaks and MACS2, we 
identified a consensus peakset containing the binding regions found to be 
present in at least 2 of the 3 replicates for each condition. We found 20820 ERa 
binding regions present in estrogen-free SUM44 shLacZ samples, and 33121 
ERa peaks in the SUM44 plus 10nM estrogen samples. 
To determine the effect of estrogen treatment on ERa binding in SUM44 
cells, we next performed differential occupancy and differential binding analyses 
on SUM44 shLacZ 10nM estradiol vs estrogen-free cells using the DiffBind 
package by Anders et al. There was a large overlap of 17661 peaks shared 
between the estrogen-free and 10nM estrogen samples (Figure 3.1a), however 
the presence of a large number of peaks in the absence of estrogen is 
particularly interesting. The peaks in each of the three groups, estrogen-free 
only, estrogen-containing only, and plus/minus estrogen, were annotated to find 
nearby genes, and the gene annotations were grouped according to the three 
conditions: estrogen-free ERa binding, estrogen-rich ERa binding, and ERa 
binding under both conditions. The majority of the 6246 ERa-bound genes in 
SUM44 were bound by ERa in both estrogen-free and estrogen-rich conditions: 
4761 genes with 17661 ERa binding sites (Figure 3.1b). In addition to an 
occupancy analysis of the ERa binding sites in 10nM estrogen vs. estrogen-free 
conditions, a differential binding analysis of the  
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 Figure 3.1 ERa binding in SUM44 cells in estrogen-free 
conditions compared to treatment with beta-estradiol. 
 a. Venn diagram of ERa binding sites in SUM44 cells treated with 
10nM beta-estradiol vs. cells cultured in estrogen-free conditions, as 
measured by ERa ChIPseq. b. Venn diagram ERa-bound genes by 
ERa ChIPseq in estrogen-free vs 10nM beta-estradiol conditions for 
SUM44 cells. c. MA-plot showing plotting the fold change in ERa 
binding vs. mean peak intensity after treatment of SUM44 cells 
under estrogen free conditions with 10nM beta-estradiol for 45 
minutes before performing ERa ChIPseq.  
C 
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 Figure 3.2 ERa binding in SUM44 cells in estrogen-free conditions and after 
10nM beta-estradiol treatment.  
a. Kernel density estimate plot of the distribution of ERa binding site distances 
from a transcription start site (TSS). b. Heatmap of ERa binding for all ERa 
binding sites in non-treated SUM44 cells over a 10kb window centered on the 
peak maximum. 
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ERa binding sites present in both conditions was performed. Figure 3.1c shows 
an MA plot of ERa binding in SUM44 cells treated with 10nM beta-estradiol 
relative to SUM44 cells in estrogen free conditions. This plot shows the fold-
change in significantly differentially bound ERa binding sites (pink data points) as 
a function of overall peak intensity (x-axis). The plot shows that there were 7574 
ERa binding sites with significant changes in ERa binding, and that most sites 
common to both conditions with moderate initial binding intensity showed an 
increase in ERa binding in the presence of estrogen. As seen in the MA-plot, the 
ERa binding sites that did decrease after treatment with estrogen exhibited 
relatively weak binding. 
While the above differential ERa binding analysis showed that most 
changes to ERa binding upon treatment of SUM44 cells with estrogen 
manifested as increased binding intensity to sites already bound by ERa in 
estrogen-free conditions, we were also interested in whether there was a shift in 
peak intensity based on distance of the peak from the TSS of the most proximal 
gene. To investigate the distribution of peak area as a function of distance from 
the transcription start sites of all ER-bound genes, a kernel density estimate plot 
was created based on the distributions of all ERa consensus peaks in SUM44 
cells grown in estrogen-free conditions and SUM44 +10nM estrogen cells. Figure 
3.2a shows the distribution of ERa peaks in SUM44 estrogen-free cells (the blue 
line) compared to SUM44 cells treated with 10nM beta-estradiol (green line). In 
the estrogen-starved SUM44 cells, most ERa-bound regions are within 10kb of a 
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TSS. In contrast, the ERa bound to chromatin in the estrogen-treated SUM44 
cells is much more spread out, with a lower proportion within 10kb of a TSS. 
Figure 3.2b shows that the profile of most ERa binding sites is unimodal and 
narrow, with the base of the peak covering less than 1kb. As seen at the bottom 
of the heatmap, there is a subset of ERa peaks that are wider, however these 
peaks are in the minority.  
3.2.2 Motif enrichment at ERa binding sites 
Motif enrichment analysis was run on the ERa binding sites unique to 
each condition to determine if there were changes in the motifs bound by ERa in 
the presence or absence of estrogen. As shown in Figure 3.3, the top 3 motifs 
enriched by ERa binding sites common to both estrogen-free and estrogen-
containing SUM44 cells are ERE, FOXA1, and Foxa2. The ERa binding sites 
unique to plus estrogen conditions also enrich ERE motifs most strongly, 
followed by Esrrb, then FOXA1. Interestingly, the ERa binding regions unique to 
estrogen-free conditions do not enrich for ERE motifs; the top three motifs 
enriched in SUM44 estrogen-free ERa binding sites are Foxa2, FOXA1, and 
Fox:Ebox motifs.  
 While the strength of enrichment for a given motif, shown by p-value, 
changed the ranking of the top three motifs enriched for a given condition, the 
actual percentage of ERa binding sites bound to a given motif exhibited a 
different pattern. As shown in the lower panel of Figure 3.3, the percentage of 
ERa peaks bound to ERE motifs increased from 17.8% of the ERa peaks 
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common to both estrogen conditions to 27.7% of peaks unique to the 10nM 
estrogen condition. In contrast, the ERa peaks unique to the estrogen-free 
conditions contained essentially no ERE motifs. The percentage of ERa peaks 
bound to FOXA1 motifs decreased from 36.7% for the common peaks to 27.7% 
for the 10nM estrogen unique peaks, while the proportion of estrogen-free only 
peaks bound to FOXA1 remained near 37%. The proportion of ERa peaks bound 
to Foxa2 motifs also remained constant between the common peaks and the 
estrogen-free unique peaks, and fell to 20.1% of the peaks unique to the 10nM 
estrogen condition. These results indicate that ERa is not directly binding EREs 
in the absence of estrogen, but that response elements for pioneer factors such 
as Foxa2 and FOXA1 are most strongly associated with estrogen-free ERa 
binding, suggesting a mechanism other than direct recognition of ERE motifs by 
the estrogen receptor.  Having analyzed motif enrichment by ERa binding in 
SUM44, we then determined which genomic features were enriched by ERa 
binding in the estrogen-free and 10nM estrogen conditions in SUM44 shLacZ 
cells.  
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Motifs significantly enriched on or near ERa binding sites in SUM44 cells under 
either estrogen-free, estrogen-treated (10nM), or both conditions.  
Figure 7.3 ERa motif enrichment in SUM44 shWHSC1L1short and shLacZ 
cells. 
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3.2.3 ERa binding decreases upon WHSC1L1-short knockdown 
Given the evidence that WHSC1L1short is necessary for high levels of 
ERa expression in SUM44 cells, we next asked how ERa binding to chromatin is 
affected by knockdown of WHSC1L1short, both in overall binding intensity and 
the pattern of ERa binding to specific motifs, genomic features, or gene sets. We 
performed ERa ChIPseq on SUM44 shWHshort cells that were cultured in 
estrogen-free conditions for 72 hours and then either treated with vehicle or 
10nM beta-estradiol for 45 minutes before fixing for ChIP, with three biological 
replicates per condition. Unlike the SUM44 shLacZ cells, we were not able to 
detect any well-defined peaks in the estrogen-free conditions for any of the 
replicates. A few peaks were called, but the signal-to-noise ratio was low, eroding 
confidence in the results. 
A total of 12254 peaks were called in SUM44 shWHshort cells treated with 
10nM beta-estradiol. To determine the effect of WHSC1L1short knockdown on 
ERa binding in SUM44 in the presence of 10nM estradiol, we performed a 
differential occupancy analysis and differential binding analysis using the DiffBind 
package as described earlier. As shown in Figure 3.4a, 11212 ERa peaks were 
found to co-occupy the same regions in both shLacZ and shWHshort cells, with 
21864 peaks present only in shLacZ, and 1042 peaks present only in shWHshort 
cells. As shown by the MA-plot in Figure 3.4b, differential binding analysis found 
a total of 6320 significantly differentially bound peaks in shWHshort  
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Figure 3.4 ERa binding in SUM44 shWHSC1L1short vs shLacZ cells after 
treatment with 10nM beta-estradiol. 
a. Venn diagram of ERa binding sites in SUM44 shWHSC1L1short cells 
compared to shLacZ control cells. b. MA-plot showing the change in peak 
intensity (score) vs. mean peak intensity in SUM44 upon knockdown of 
WHSC1L1short compared to shLacZ control. 
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10nM estradiol vs shLacZ 10nM estradiol cells, and the majority of ERa 
binding sites showed a decrease in binding intensity in the shWHshort cells. Motif 
enrichment analysis of these peaks showed similar motifs enriched in the shLacZ 
and shWHshort SUM44 cells, however there were differences in the proportion of 
peaks binding each motif, and the third most enriched motif changed from Foxa2 
in shLacZ to Esrrb in shWHshort cells, both in 10nM estrogen conditions. As 
shown in the figure, the proportion of peaks bound to EREs increased from 
29.9% in shLacZ to 39.2% in shWHshort cells, and FOXA1 showed a similar 
increase from 49.7% to 57.5% of all ERa peaks in shLacZ and shWHshort, 
respectively. It is notable that FOXA1 was the most common motif enriched by 
ERa binding in SUM44 cells in all conditions. The proportion of peaks bound to 
promoters was also altered by WHSC1L1short knockdown. In SUM44 
shWHshort cells in the presence of 10nM estradiol, promoter enrichment was 
reduced from 4.96-fold to 3.1-fold, indicating that WHSC1L1short knockdown 
resulted in a smaller, but still considerably large, proportion of ERa binding sites 
localized to promoter regions in SUM44. 
3.3 Discussion 
Testing for genome-wide ERa binding by ChIPseq in SUM44 cells resulted 
in detection of high levels of ERa bound to chromatin in the absence of ligand. 
This contrasts with the reported results of ERa ChIPseq experiments in other 
ER+ cell lines such as MCF7. Most ERa breast cancer biology is based on 
experiments conducted on the MCF7 cell line, which has been reported to have 
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relatively little ERa bound in the absence of estrogen. Our results in SUM44 cells 
indicate that ERa binding to chromatin is much higher in SUM44 cells, 
suggesting that ER+ breast cancers may have varying levels of ERa bound to 
chromatin in low-estrogen conditions. While the presence of ERa bound to 
chromatin in the absence of exogenous estrogen does not indicate positive 
regulation of gene expression by ERa, indirect evidence from the RNAseq 
expression profiling data show that several genes bound by ERa in the absence 
of estrogen were expressed at high levels in SUM44 cells. Further experiments 
should be done to determine whether the ERa bound near these genes is 
actually positively regulating expression in an estrogen-independent manner. 
The observation that relatively few additional genes were bound by ERa 
after treatment with estrogen is unexpected, and suggests that most ERa in 
SUM44 cells is localized to the nucleus and bound to target regions on 
chromatin, and is activated by ligand binding, resulting in the recruitment of co-
factor promoting transcription, or the dissociation of inhibitory factors, also 
resulting in promotion of transcription. Additional ChIPseq experiments for co-
factors of ERa may result in elucidation of which mechanism is occuring at these 
sites in SUM44 cells. Overall, I conclude from these results that there is 
extensive binding of ERa in the absence of exogenous estrogen in SUM44 cells, 
and treatment of SUM44 with beta-estradiol results in increased binding intensity 
of the majority of the existing binding sites, with a relatively small number of 
additional binding sites observed after estrogen treatment. 
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DNA motif enrichment analysis at ERa binding sites resulted in enrichment 
of expected motifs, including ERE, FOXA1, ESRRB, and Foxa2. It is apparent 
when comparing the two treatment conditions that treatment with estrogen 
results in a large increase in binding intensity at ERE sites on chromatin. In the 
absence of estrogen, FOXA1 is the most abundant DNA sequence motif bound 
by the estrogen receptor. 
While the difficulty in detecting a sufficient number of ERa binding sites in 
SUM44 shWHshort cells in the absence of estrogen leaves our investigation of 
ERa binding incomplete, the almost complete abrogation of ERa protein in 
SUM44 shWHshort cells provides allows for the reasonable assumption that 
there was in fact little to no estrogen receptor actually present in the cells to bind 
to chromatin, which would explain the negative result. While it is impossible to 
interpret a negative, this does seem to be a plausible explanation. 
The successful measurement of ERa binding in SUM44 shWHshort cells 
in the presence of 10nM estrogen gives us some idea of the effect of WHSC1L1-
short knockdown on ERa binding to chromatin, although interpretation of the 
results is difficult when taking into consideration the earlier results showing that 
WHSC1L1-short is necessary for ERa expression in SUM44, and that SUM44 
proliferation responds negatively to treatment with even nanomolar amounts of 
estrogen. With that said, the DiffBind analysis of ERa binding in SUM44 
shWHshort cells treated with estrogen compared to SUM44 shLacZ cells treated 
with 10nM estrogen suggests that WHSC1L1-short knockdown does not alter the 
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location of ERa binding, but does result in a genome-wide decrease in ERa 
binding intensity. This appears to be a logical and unsurprising result of the 
decrease in levels of ERa protein upon WHSC1L1-short knockdown. 
Interestingly, there is evidence that an NSD-family member, WHSC1, is 
recruited to the ESR1 genomic locus by BRD3/4 in a breast cancer model cell 
line, and directly binds the ERa gene, promoting expression of ERa  in these 
cells (Feng, Zhang et al. 2014). WHSC1L1 has high protein homology with 
WHSC1 (NSD2), and our data suggest that WHSC1L1-short may be affecting 
ERa expression in a similar way, although we lack direct evidence of WHSC1L1-
short protein binding to the ESR1 locus. Also, WHSC1L1-short itself has been 
found to bind directly to the extra-terminal domain of BRD4 while also binding to 
chromatin in cancer cells (Rahman, Sowa et al. 2011). 
3.4 Materials and Methods 
3.4.1 Chromatin immunoprecipitation followed by Illumina sequencing 
For ChIP-seq analysis of ERa binding sites, we followed procedures 
originally developed by Carroll, Brown and co-workers (Carroll, Liu et al. 2005, 
Carroll, Meyer et al. 2006) (personal communications with Tom Westerling). Cells 
were cultured in 150 mm plates to ~90% confluence (approximately 1x108 cells). 
Cells were treated with 2 mM disuccinyl-glutamate (DSG) in PBS for 30 minutes 
at room temperature, then treated with 1% fresh formaldehyde for 2.5 minutes 
before quenching with 125 mM glycine for 5 minutes. Cells were washed with 
cold PBS, and chromatin was prepared using the Covaris High-Cell SDS 
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chromatin shearing kit with SDS buffer (520076) according to the manufacturer's 
recommended protocol. Chromatin was then sheared with a Covaris S220 
sonicator using standard settings for 8 minutes. Chromatin preparation was 
optimized for SUM-44 cells. 
ChIP was performed using the Magna ChIP A/G ChIP Kit (17-10085) with 
an antibody cocktail containing equal concentrations of the ERa antibodies from 
Thermo Scientific and Santa Cruz.  Sequencing libraries from ERa ChIP DNA 
were prepared with Rubicon ThruPLEX librarypreparation kits, and sequenced as 
35bp single-end reads on an Illumina Hi-Seq 2500. Libraries for three biological 
replicates were prepared and sequenced for each sample type. Read data for 
each sample was aligned with Bowtie2, and peakswere called with both the 
MACS version 2 and the homer tools FindPeaks peak callers. 
To generate consensus peaksets for downstream analysis, the called 
peaksets from eachpeak caller for each sample were input into DiffBind, which 
created consensus peaksetsconsisting of peaks present in at least 2 replicates 
for each sample type. These consensus peaksets were used for downstream 
analysis including differential occupancy and differential binding.  
3.4.2 RNA expression profiling 
Total RNA was prepared using a Qiagen RNeasy Plus Mini Kit and 
processed by the MUSC Genomics core for 2x101 cycles, paired-end RNA 
sequencing on an Illumina HiScanSQ. RNA integrity was verified on an Agilent 
2200 TapeStation (Agilent Technologies, Palo Alto, CA). A total of 100-200 ng of 
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total RNA was used to prepare RNA-Seq libraries using the TruSeq RNA Sample 
Prep kit following the protocol described by the manufacturer (Illumina, San 
Diego, CA). Sequencing was performed on an Illumina HiScanSQ. Samples were 
demultiplexed using CASAVA (Illumina, San Diego, CA). Fastq files were used to 
map reads to the human genome (hg19, UCSC) utilizing Tophat2 with default 
settings.  A total of 100-200 ng of total RNA was used to prepare RNA-Seq 
libraries using the TruSeq RNA Sample Prep kit following the protocol described 
by the manufacturer (Illumina, San Diego, CA). 
3.4.3 Bioinformatics and Statistical analysis 
Each ChIPseq experiment was repeated three times. Fastq files were 
aligned to the UCSC hg19 human reference genome assembly using Bowtie2. 
Aligned reads were converted from SAM to BAM format, sorted and indexed. 
BED format files were obtained from BAM files. Quality control tools including 
FastQC and Homer makeTagDirectory were employed to verify read quality and 
the strength of the ChIP signal (Heinz, Benner et al. 2010). After QC, aligned 
reads for ChIP and input samples were analyzed using MACS version 2 to call 
peaks (Feng 2011, Feng, Liu et al. 2012). Peaks were also called with Homer's 
findPeaks and MACS version 1.4. Called peak sets were utilized for downstream 
analyses including motif enrichment analysis via Homer's findMotifsGenome, and 
gene annotation with Homer's annotatePeaks. Bedgraph files output by MACS v2 
were converted to bigWig format for peak visualization on the UCSC Genome 
Browser. CEAS and Homer's annotatePeaks were used to determine which 
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genomic features were enriched under called peaks. Other tools were used for 
visualization and analysis of ChIPseq peakset data, including DiffBind to 
measure ERa peak occupancy and differential binding intensity (Ross-Innes, 
Stark et al. 2012). SeqMiner was used to perform unsupervised K-means 
clustering of peaks (Ye, Krebs et al. 2011).  To generate a consensus peakset for 
a specific experimental condition, the DiffBind package was used to generate a 
peakset consisting only of peaks called in two or more replicates. Consensus 
peak sets were then used for differential occupancy and differential binding 
analyses using DiffBind. SeqMiner was used to perform unsupervised k-means 
clustering of peaks. 
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CHAPTER 4    HISTONE H3K4ME3 METHYLATION IS 
AFFECTED GLOBALLY AND NOT LOCALLY BY 
WHSC1L1 KNOCKDOWN 
 
4.1 Introduction 
WHSC1L1 has been reported to have histone methyltransferase activity 
on lysines 4, 9, and 36 on histone H3, however only the long isoform of 
WHSC1L1 contains a catalytic SET domain capable of catalyzing the addition of 
a methyl group to a lysine on a histone tail (add cite)[He13, Rahman11}. 
Considering our findings that both total and short isoform-specific WHSC1L1 
knockdown resulted in changes in expression profiles in SUM44 cells, we 
considered it important to determine whether histone methylation levels are 
changing in response to knockdown of WHSC1L1-long or WHSC1L1-short in 
SUM44 shWH-total and shWH-short cells. Our initial aim was to investigate 
global methylation levels of lysines 4, 9, 27, and 36 on histone H3 by 
immunoblotting whole cell lysates with antibodies specific to mono-, di-, and tri-
methylated lysines on histone H3. If we identified changes in specific methylation 
marks on specific lysines on histone H3 in SUM44 shWH-total or shWH-short 
cells compared to shLacZ control, our plan was to proceed with ChIPseq using 
the same ChIP-grade antibodies used for immunoblotting to determine genome-
wide changes in methylation at high resolution. 
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4.2 Results 
4.2.1 WHSC1L1-short knockdown increases global levels of histone H3 
 WHSC1L1 has been reported to methylate histone H3 on lysines 4, 9, and 
36, although recent literature suggests that the main activity of WHSC1L1 is 
H3K36 dimethylation. However, understanding of WHSC1L1 substrates is still an 
active area of research. To investigate the mechanism of transformation by 
WHSC1L1, we hypothesized that knockdown of WHSC1L1 would alter histone 
H3 methylation levels. To test this, we looked for global changes in H3K36 and 
H3K4 methylation levels by western blot. Knockdown of WHSC1L1-short in 
SUM44 cells resulted in a large increase in total histone H3 levels, and a 
concomitant increase in H3K36me2 levels that was roughly proportional to the 
observed increase in total histone H3. 
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Figure 8.1 Global histone H3 methylation levels at lysines 4 and 36 in 
SUM44 shWHSC1L1short and shWHSC1L1total vs shLacZ control cells. 
Immunoblot of histone H3 subunits H3K4me2, H3K4me3, H3K26me2, and 
H3K36me3 in SUM44 shWHSC1L1short and shWHSC1L1total knockdown cell 
lines compared to shLacZ control. A total histone H3 antibody was also used as 
a control for total H3 levels in each sample.  
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 Figure 4.2 Histone H3K4me3 ChIPseq in SUM44 shWHSC1L1short vs 
shLacZ cells. 
a. Venn diagram comparing histone H3 lysine 4 trimethyl (H3K4me3) sites in 
SUM44 shWHSC1L1short vs shLacZ control cells. b. Heatmaps of genomic 
regions marked by H3K4me3 in SUM44 shWHSC1L1short vs shLacZ control 
cells. The heatmap x-axis origin is centered on the summit of the H3K4me3 peak, 
and shows the relative intensities of the peaks over a 10kb genomic window. 
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The SUM44 shWHtotal cells did not show a consistent increase in either 
total histone H3 or levels of the H3K36me2 mark. Histone H3K4me2 and 
H3K4me3 levels also increased in the shWHshort knockdown cells, but not the 
shWHtotal cells (Figure 4.1, right panel). Expression profiling corroborates the 
western data, showing an increase in histone levels in the shWHshort cells; the 
transcript levels of for at least one gene for each histone subunit increased upon 
knockdown of WHSC1L1-short (Table 4.1).   
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Table 4.1: Histone Transcripts significantly differentially expressed in 
SUM44 shWHSC1L1short cells vs. shLacZ control. 
 
  
gene symbol log2(fold change) FDR (B-H)
HIST1H4H1 1.538 0.052
HIST1H3H 1.524 0.075
HIST1H2BN 1.508 0.033
HIST1H3G 1.454 0.074
HIST1H1C 1.075 0.055
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4.2.2 H3K4me3 ChIPseq 
Given the observed increase in global H3K4me3 protein levels in SUM44 
shWHshort cells, we wanted to investigate H3K4me3 patterns in SUM44 cells, 
and then look for changes in H3K4me3 patterns in SUM44 WHSC1L1-short cells 
vs shLacZ control. H3K4me3 was measured in SUM44 shWHshort cells and 
shLacZ cells by ChIPseq, with two biological replicates per condition. We 
observed a total of 29599 peaks in SUM44 shLacZ cells, and a total of 35602 
peaks in SUM44 shWHshort. As shown in Figure 4.2a, the majority of the 
H3K4me3 sites detected in SUM44 cells were common to both shLacZ and 
shWHshort conditions. It should be noted that the mean peak intensities of the 
peaks unique to either the shWHshort or shLacZ cells were 4.7 and 4.4, 
respectively, while the overall mean peak intensity was 27.5, indicating that the 
unique H3K4me3 sites were in general not as strong as the sites common to 
both conditions. The heatmaps showing all H3K4me3 sites detected in SUM44 
shLacZ and SUM44 shWHshort cell lines (Figure 4.2b) show similar but not 
identical patterns of H3K4me3 sites. 
Having identified the sites of H3K4 trimethylation in SUM44 shLacZ and 
shWHshort cells, we next asked which genomic features were most enriched by 
H3K4me3 sites for each condition in SUM44 cells. We used the CEAS tool 
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released by Liu et al to annotate peaks for proximal genomic features based on 
peak location. The majority of H3K4me3 sites were primarily near transcription 
start sites (TSS) of genes (Figure 4.3a, Figure 4.3b). While intronic regions were 
enriched slightly more than promoter regions, Figure 4.3b shows that this is a 
result of the broad H3K4me3 peak extending from the promoter into the first 
intron. The profile plot shows clearly that the average H3K4me3 site is a bi-modal 
region approximately 2kb in width, with a "notch" of low intensity immediately 
upstream of the TSS. It should be noted that very few H3K4me3 sites were 
detected in distal intergenic regions, and also that the breakdown of genomic 
features with H3K4me3 marks is very similar in SUM44 shWHshort and shLacZ 
cell lines. 
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Figure 4.3 Genomic feature localization of histone H3K4me3 marks in 
SUM44 cells. 
a. Distribution of H3K4me3 marks across different genomic features in SUM44 
shWHSC1L1short and shLacZ cells, with the first column showing the proportion 
of the human genome each feature represents. H3K4me3 genomic locations 
determined by ChIPseq b. Histone H3K4me3 mean intensity profile of H3K4me3 
sites across a map of a gene, from 1kb upstream of the TSS to 4kb downstream. 
The 3 profiles represent the mean intensity of all H3K4me3 sites, and the blue 
and red curves represent H3K4me3 binding for the bottom 10% and top 10% of 
expressed gene loci, as measured by ChIPseq and RNAseq in SUM44 shLacZ 
cells. 
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Figure 4.4 Histone H3K4me3 patterns and mean intensity profiles for 
SUM44 shWHSC1L1short vs shLacZ cells. 
a. Histone mean occupancy profile plot for trimethylated histone H3 subunits in 
SUM44 shLacZ cells. The black trace shows the mean profile for all H3K4me3 
marks genome-wide, and the red and blue marks represent H3K4me3 profiles 
for the top 10% and bottom 10% of expressed genes, respectively. H3K4me3 
occupancy measured by 25bp single-end ChIPseq, and gene expression 
measured by 151bp paired-end RNAseq and absolute counts in SUM44 shLacZ. 
Profiles are representative of duplicate experiments, and plot data is from one of 
the experiments. b. Gene tracks showing H3K4me3 peaks (peaks shown using 
a wiggle file generated using the MACS2 peak caller). Profiles are from one 
experiments and are representative of duplicate experiments. 
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Trimethylation of histone H3 has been shown to be a mark of actively 
transcribed chromatin. The mean peak profile data together with the RNAseq 
expression profiling data we collected on the SUM44 shWHshort and shLacZ cell 
lines allowed us to determine the mean H3K4me3 peak profiles for groups of 
genes based on their expression by RNAseq (Figure 4.4a). Based on absolute 
expression (tags per million mapped reads) from RNAseq data, we took the top 
10% of expressed genes and the bottom 10% of expressed genes, and used 
these two gene sets to group the gene-annotated H3K4me3 ChIPseq data. The 
mean H3K4me3 peak profile for the top 10% of expressed genes in SUM44 
shLacZ cells (the red line) is similar in shape to the overall mean peak profile 
(black line), although the intensity is markedly greater. Conversely, for the bottom 
10% of expressed genes, the profile is flat (blue line), indicating that there is little 
to no H3K4me3 at or near the promoters of the least expressed genes in SUM44 
shLacZ cells. The results for SUM44 shWHshort cells are similar (data not 
shown). 
After determining that we had successfully detected H3K4me3 sites in 
SUM44 shLacZ and shWHshort cells, we next asked whether there were any 
H3K4me3 sites in SUM44 shLacZ cells that were significantly different in 
intensity in the shWHshort cells. To measure differential H3K4me3 intensity, we 
ran DiffBind comparing the SUM44 shWHshort H3K4me3 ChIPseq data to 
SUM44 shLacZ, however only 2 significantly differentially intense sites were 
  
107 
found (no MA-plot shown). A 1.7-fold increase was identified near the TSS of 
DST in SUM44 shWHshort, which was upregulated 1.8-fold in shWHshort cells 
by RNAseq, and a 1.4-fold increase in H3K4me3 near the TSS for BCAR3, which 
was not significantly differentially expressed. Figure 4.4b shows the H3K4me3 
profile for WHSC1L1 and TSKU, two genes significantly downregulated in 
SUM44 shWHshort cells. While these are just two examples out of tens of 
thousands, the profiles shown are representative of the majority of the observed 
peaks, and it can be seen qualitatively that there is little difference in H3K4me3 
pattern or intensity in SUM44 shWHshort cells compared to SUM44 shLacZ 
controls.  
4.3 Discussion 
Existing literature reports several substrates of WHSC1L1 activity on 
histone H3, including H3K4, H3K9, and H3K36. Recent publications focus on 
H3K36 as the primary substrate for WHSC1L1 methylation, however we wished 
to also investigate H3K4 as a substrate, as relatively little is known about 
WHSC1L1 activity. Our initial investigation into changes in global histone 
methylation levels resulted in an unexpected change in not only histone 
methylation, but in the global levels of total histone H3, as seen by the large 
increase in global histone H3, H3K36me2, H3K36me3, and H3K4me3 in SUM44 
shWHshort cells compared to shLacZ control. Firstly, the fact that methylation of 
both lysines 4 and 36 increased in response to knockdown of the short isoform of 
WHSC1L1 is intriguing as it may support the hypothesis that WHSC1L1-short is 
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acting in a dominant-negative fashion by preventing methylation of these histone 
lysines by WHSC1L1-long. Full interpretation of the effects of WHSC1L1 
knockdown on global histone methylation is difficult with the models used, as the 
effect of WHSC1L1-long knockdown is confounded by the concomitant 
knockdown of WHSC1L1-short in the shWHtotal SUM44 cells. 
While the observed increase in histone lysine methylation upon 
knockdown of WHSC1L1-short is intriguing, the global change in total histone H3 
calls into question the interpretation of the western data as an actual relative 
increase in histone lysine methylation at the tested residues. 
Together with the RNAseq expression data showing a significant increase 
in at least one transcript for every histone subunit upon knockdown of 
WHSC1L1-short, it appears that the overall histone levels incresed in the SUM44 
shWHshort cells. Whether the relative levels of histone H3K36me2, H3K36me3, 
or H3K4me3 increased is inconclusive at best based on the western data alone. 
In our attempt to identify specific H3K4me3 binding sites, we were able to 
successfully detect a large number of H3K4me3 sites in both SUM44 shLacZ and 
SUM44 shWHshort cells by ChIPseq. This is likely due to the quality of the 
"ChIP-grade" antibody available for this histone methyl mark, as well as the 
relatively narrow pattern of H3K4 methylation, in contrast to the much wider 
patterns characteristic of other histone methylation marks, such as H3K36 di- or 
trimethylation. The genomic features found in proximity to observed H3K4me3 
marks was consistent with published literature on H3K4me3: almost all marks 
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were found in the vicinity of gene loci, mostly within 5kb of the TSS, with a 
characteristic bi-modal pattern for many peaks located immediately upstream of 
the TSS. At the gross level, i.e. the number of H3K4me3 sites found, the mean 
profile of the marks, and the distribution of the genomic features where the peaks 
were located, there was surprisingly little difference between the SUM44 
shWHshort and the SUM44 shLacZ samples. This is consistent with the 
interpretation of the western data as a global increase in total histone levels in 
the SUM44 shWHshort cells, and not an increase in histone lysine methylation at 
lysine 4. 
In addition to the high levels of similarity in the number, peak profile, 
location, and enrichment of genomic features in the SUM44 shWHshort and 
shLacZ H3K4me3 ChIPseq data, the DiffBind differential binding intensity results 
indicated essentially no difference in H3K4me3 intensity between the two 
conditions. While 2 sites were detected as significantly increased in SUM44 
shWHshort cells relative to shLacZ, only one of them, the DST gene, exhibited a 
change in expression: a 1.8-fold increase concomitant with the slightly incresed 
H3K4me3 intensity, from 25.01 to 32.5. Inspection of individual loci significantly 
differentially expressed in SUM44 shWHshort cells relative to shLacZ control 
shows qualitative similarity in the patterns and intensities of H3K4me3 peaks for 
these genes, including WHSC1L1, TSKU, ESR1, and others. 
Based on the western data, together with the qualitative and quantitative 
results of the H3K4me3 ChIPseq analyses, I conclude that WHSC1L1 
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knockdown has no significant effect on the histone methylation patterns or 
intensity in SUM44 cells. While the results for these experiments looking for a 
change in H3K4me3 were negative, the results remain important in terms of 
ruling out lysine 4 on histone H3 as a substrate for WHSC1L1. 
Future work could include investigation of H3K36me2 ChIPseq to 
determine whether and where lysine 36 on histone H3 is differentially methylated 
upon knockdown of WHSC1L1-short. I failed to collect useful data for H3K36 
methylation by ChIPseq after several attempts with different experimental 
conditions. While I tried only one antibody, it was sold as ChIP-grade, and there 
were successful publications using the antibody for their ChIPseq work. I 
estimate that the two major factors that prevented a successful H3K36me2 
ChIPseq dataset were the lack of proper wash conditions when performing the 
ChIP, and possible difficulty in tuning the peak calling software to accurately call 
broad peaks. It should be noted however that I did not achieve sufficient signal-
to-noise ratios with my ChIP for the peak calling to be truly tested. 
A final point that needs to be made about these conclusions is that, given 
the negative result for H3K4me3 and the lack of results for a different histone 
lysine, I was not able to show with any certainty that knockdown of WHSC1L1 in 
SUM44 cells results in net changes in the proportion of histone H3 with 
methylation of one or more lysines. This leaves open the possibility that 
WHSC1L1-short is acting in a histone-independent manner to regulate 
expression of ESR1 and other target genes. While the data I have collected 
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showing strong nuclear localization of WHSC1L1 in several breast epithelial and 
breast cancer cell lines is suggestive of a nuclear protein as a target, it remains 
unclear what the primary mechanism of transformation by WHSC1L1 
overexpression might be. However, recent work in mouse leukemia cells does 
show that WHSC1L1-short is likely acting in a complex with BRD4 to recruit 
CHD8 to chromatin, resulting in chromatin conformation changes due to helicase 
activity and not histone methylation (Shen, Ipsaro et al. 2015). 
4.4 Materials and Methods 
4.4.1 Global histone methylation western blotting 
Experiments to determine global histone methylation levels were 
performed by lentivirally transducing SUM44 cells to generate SUM44 shLacZ, 
shWHtotal, and shWHshort cells as described earlier (p. 36-37), then collecting 
whole cell lysates after 72 hours of selection with puromycin. Whole cell lysates 
were loaded on 5-15% polyacrylamide gradient gels in SDS-based loading buffer 
containing beta-mercaptoethanol (reducing conditions), and run for 35 minutes at 
150V according to the manufacturer's protocol (Bio-Rad). The gels were 
transferred to PVDF membranes and immunoblotted with the following 
antibodies: H3K4me2, H3K4me3, H3K36me2, and H3K36me3. 
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4.4.2 Chromatin Immunoprecipitation followed by Illumina sequencing 
(ChIPseq) 
ChIPseq was performed as described above with some differences. 
SUM44 shWHshort and shLacZ cells were cultured to ~90% confluence, with 
puromycin selection for 72 hours post-infection with lentivirus to transduce the 
cells with the appropriate shRNA vector as described above. On the day of the 
experiment, the cells were fixed with 1% fresh formaldehyde for 2.5 minutes (no 
disuccinyl glutamate treatment) before following the Covaris SDS-based 
chromatin shearing protocol as described. Sheared chromatin equivalent to 
approximately 1x106 cells was loaded into each ChIP reaction in 1mL total 
volume, and 2 ug of H3K4me3 ChIP-grade antibody was used to 
immunoprecipitate the chromatin overnight at 4° Celsius. The wash steps also 
differed from the ERa ChIPseq protocol: after the magnetic Protein A/G beads 
were collected for each wash, the beads were washed once each with Low-Salt, 
High-Salt, and Lithium Chloride ChIP, and then two times with TE, all buffer 
solutions from the Millipore Magna-ChIP kit (Millipore).  
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CONCLUSIONS 
 
The work presented here has been an attempt to satisfy four general 
aims. First, we sought to confirm that WHSC1L1-short is the specific WHSC1L1 
isoform responsible for maintenance of a tumor phenotype in SUM44 breast 
cancer cells. While previous work by Yang and others in the Ethier lab had 
previously found that WHSC1L1-short appeared to be the WHSC1L1 isoform 
responsible for inducing a transformed phenotype in MCF10 cells, we have now 
shown that shRNA knockdown of WHSC1L1-short transcript in SUM44 cells 
does in fact have the greatest negative effect on SUM44 cell proliferation, 
suggesting the WHSC1L1-short is in fact the oncogenic isoform of WHSC1L1 in 
SUM44 cells (Yang, Liu et al. 2010). 
Second, we sought to observe transcriptome-level changes in gene 
expression in SUM44 shWHSC1L1-short cells relative to SUM44 shLacZ controls 
to determine whether knockdown of WHSC1L1-short, which lacks a catalytic 
domain, would significantly alter gene expression. As shown, we observed 
significant changes in gene expression in several hundred genes in SUM44, with 
an overall trend of upregulation upon WHSC1L1-short knockdown.  
Third, based on our observations that SUM44 expresses high levels of 
ERa, and that knockdown of WHSC1L1-short significantly downregulated 
expression of ERa transcript in SUM44, we sought to measure ERa binding to 
  
114 
chromatin in both SUM44 shLacZ (negative control) and SUM44 shWHSC1L1-
short cells. Our observations that ERa is bound to chromatin at thousands of 
sites in SUM44 cells in the absence of estrogen was an unexpected finding, and 
contrasts with the findings of other groups measuring ERa. 
Fourth, based the known activity of the long isoform of WHSC1L1 as a 
histone methyltransferase, we asked whether knockdown of WHSC1L1-short in 
SUM44 cells would alter histone lysine methylation patterns in SUM44 cells. 
Most literature on WHSC1L1 activity indicates that lysine 36 on histone H3 is the 
substrate for methylation by WHSC1L1 (di Luccio and Morishita 2012, Saloura, 
Vougiouklakis et al. 2016). However, we chose to investigate additional histone 
methyl marks that had been previously reported, including H3k4me3. While the 
results of the experiment testing whether WHSC1L1-short knockdown altered 
histone H3K4me3 levels in SUM44 cells did not result in any significant 
difference between the treatment and control samples, we did benefit by learning 
about the locations of histone H3K4me3 sites genome-wide in SUM44 cells. It 
should be noted that attempts were made to ChIP additional histone lysine 
methylation marks, including H3K36me2 and H3K36me3, however all 
experiments failed to achieve a sufficiently strong signal-to-noise ratio by ChIP, 
most likely due to technical errors and my failure to find the correct conditions for 
ChIP. While there was little change in H3K4me3 levels between the shWHshort 
and shLacZ cells, the occupancy analysis appears to agree with the western data 
in that the number of genomic loci with tri-methylated H3 increases by 
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approximately 6000 peaks. Figure 4.2a shows that the occupancy analysis found 
over 12000 areas with H3K4me3 in shWHshort cells that were not present in 
shLacZ.  Also, analysis of the distribution of H3K4me3 levels in shWHshort vs 
shLacZ cells suggests that WHSC1L1short knockdown increases weak 
H3K4me3 levels, while initially strong levels of H3K4me3 decrease. I have not 
yet figured out how to show whether this apparent change is statistically 
significant, but it may be an interesting finding, if in fact WHshort knockdown is 
causing more widespread H3K4me3 marks genome-wide, but at the same time a 
slight decrease in H3K4me3 levels at some promoters with high levels in shLacZ 
cells. This is slightly at odds with our claim that there is no significant decrease in 
H3K4me3 levels at promoters for genes significantly downregulated by 
WHSC1L1short knockdown.   
As mentioned in the introduction, researchers contributing to TCGA found 
that copy number alterations, specifically large amplifications, are the major 
mechanism of driving mutations in breast cancer at over 75% (Ciriello, Miller et 
al. 2013). This is strong evidence that changes in gene copy number are the 
primary mechanism of oncogene activation and tumor-suppressor inactivation in 
breast cancer. The Ciriello TCGA study identified Based on TCGA array CGH 
data, the amplifications most commonly found co-amplified with WHSC1L1 
amplifications are chromosomes 1, 16, 11, 17, and 20, in descending order of 
coincidence, occurring in 82%, 78%, 66%, 61%, and 60% of WHSC1L1-amplified 
individuals. The stark structural differences in loss of genomic integrity between 
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function-altering point mutations common in colon and uterine cancers and copy 
number changes found in cancers such as breast cancer raise an important 
question: do cancers driven by copy number changes rely on the activation of a 
greater number of oncogenes to maintain an oncogenic phenotype than cancers 
driven by point mutations? Understanding whether there are multiple driving 
oncogenes in an amplified region, or rather there is a single driving oncogene 
selected for in a large region surrounded by non-oncogenic “passenger'' genes 
incidental to the mechanism of mutation is an important question. Three reasons 
that understanding whether multiple genes in an amplicon (or across multiple 
amplicons) interact to drive cancer are amplicon formation, strategies for 
successful treatment of the primary tumor, and prevention of recurrent disease 
refractory to the initial treatment. With exceedingly few exceptions, such as the 
Gleevec for chronic myelogenous leukemias with Bcr-Abl fusions, a unifying truth 
of targeted cancer therapies (and cancer therapy in general) is that a drug-
resistant population of tumor cells will emerge and cause cancer recurrence at a 
probablility approaching one, given a large enough time scale. A characteristic 
feature of these recurrent tumor cells is the presence of a different driving 
oncogene or set of oncogenes from those driving the initial primary tumor. 
WHSC1L1 knockdown reduces SUM44 cell proliferation 
As shown in Figure 2.8, total knockdown of WHSC1L1 in SUM44 cells 
decreases proliferation, which WHshort knockdown results in a still greater 
decrease in proliferation. Because we did not investigate knockdown of the long 
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isoform of WHSC1L1 alone, it is possible that the milder decrease in cell 
proliferation observed in SUM44 shWHtotal cells was due to the decrease of 
WHshort, and that the greater decrease of WHshort in the shWHshort SUM44 
cells resulted in the greater decrease in proliferation observed. This cannot be 
determined conclusively without selective knockdown of WHlong alone, but the 
observed decreases in proliferation are proportional to the level of WHshort 
knockdown.   
The effects of WHSC1L1 knockdown on transcript expression 
Knockdown of WHshort in SUM44 shWHshort cells resulted in differential 
expression of both a greater number of different gene transcripts and larger 
differences in transcript levels than knockdown of WHlong and WHshort together 
in shWHtotal SUM44 cells. The observed 10-fold difference in the number of 
significantly differentially expressed genes (1130 vs 130 genes in shWHshort vs 
shWHtotal cells, respectively) suggests that transduction of SUM44 cells with an 
shRNA that knocked down both isoforms of WHSC1L1 dampened the effect of 
knockdown of each isoform individually, and that the effect of each WHSC1L1 
isoform on transcriptional regulation may be in opposition. This provides 
additional indirect support for our hypothesis that the short isoform of WHSC1L1 
may be acting in a dominant-negative fashion toward the long WHSC1L1 
isoform. However, as seen in Figure 2a, and as seen in the TCGA RNAseqV2 
BrCa data, the short isoform of WHSC1L1 is almost always expressed at higher 
levels than the long, not only in the cancer cells, but also in the normal matched 
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samples collected by TCGA to complement the tumor samples. If WHshort is the 
predominant isoform in normal tissue, the dominant-negative model for 
antagonism of WHlong activity becomes a poorer fit. Also, it should be mentioned 
that transcript level does not always correlate precisely with protein activity, 
which is not yet well characterized at a qualitative level for WHSC1L1, let alone 
with any quantitative accuracy in multiple tumor and normal tissue types. The fact 
that multiple WHshort protein molecules are likely present for every one molecule 
of WHlong suggests that perhaps two or more WHSC1L1short molecules 
complex with a single WHSC1L1long molecule, together with other chromatin 
modifying enzymes to form a “reader” complex that is capable of recognizing and 
binding a more diverse set of chromatin states than would a complex containing 
only a single WHlong molecule. This model would suggest that the catalytically 
inactive short isoform of WHSC1L1 is important for binding of WHlong to sites 
where it can methylate histone H3, and that WHlong binding to chromatin may be 
inefficient or less diverse in the absence of WHshort. These hypotheses could be 
tested by investigating protein-protein interactions between WHlong and 
WHshort, as well as measuring differential binding of WHlong to chromatin by 
ChIPseq in SUM44 shWHshort cells compared to shLacZ controls. While direct 
detection of the specific isoform bound to chromatin by ChIP would not be trivial, 
the existing model for knockdown of WHshort alone together with shLacZ control 
would serve as a good system for measuring the effect of WHshort levels on 
WHSC1L1 binding to chromatin. Interestingly, we have shown that WHlong 
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protein levels are increased in SUM44 shWHshort cells compared to shLacZ 
controls. It could be that the increase is an attempt at compensation for the lost 
chromatin binding capacity due to the absence of WHshort. Protein-protein 
interaction assays to detect binding of WHlong to WHshort would be essential to 
support this hypothesis of WHshort aiding WHlong binding to chromatin.   
WHSC1L1-short expression is necessary for ERa expression in SUM44 
cells 
Remarkably, expression of estrogen receptor alpha in the highly ER+ 
SUM44 cell line is dependent on overexpression of the short isoform of 
WHSC1L1. As shown, shRNA knockdown of WH-short and total WHSC1L1 both 
resulted in reduction of ERa expression at the transcript and protein levels. This 
suggests that the amplification of WHSC1L1 as part of the 8p11-p12 amplicon is 
necessary for overexpression of ERa in breast cancers with amplified WHSC1L1.  
 ER binds chromatin extensively in SUM44 estrogen-free cells 
A primary finding of our research was that the estrogen receptor binds 
chromatin extensively in SUM44 breast cancer cells in the absence of estradiol 
or other agonist. This observation, together with the observation that many ER 
target genes known to be expressed in ER+ breast cancer were actively 
transcribed in SUM44 in estrogen-free conditions, indicates ERa is both bound to 
EREs and is likely activating transcription of ER target genes in an estrogen-
independent manner in SUM44 cells. ERa activity at these sites in estrogen-free 
conditions should be confirmed by a reporter assay consisting of a vector 
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containing an estrogen response element (ERE) upstream of a reporter gene to 
attempt to measure agonist-free ERa activity in SUM44 cells. Knockdown of ERa 
with shRNA or siRNA vectors should also One key question that arises from 
these observations is whether WHSC1L1 amplification and overexpression in 
SUM44 results in a genome-wide shift toward euchromatin, increasing the 
number of exposed EREs and increasing the space in general for binding of ERa 
and other associated pioneer factors such as FOXA1 that preceed ERa binding 
to chromatin. To answer this question, a potentially important future experiment 
would be investigation of the effect of WHshort knockdown on chromatin 
conformation genome-wide (Hi-C) and at specific loci (3C or 4C).  
While I did not perform experiments which were able to measure 
WHSC1L1-short chromatin binding directly, recent work has shown that 
WHSC1L1-short links BRD4 and CHD8 by forming a complex, recruiting CHD8 
to chromatin. Residues C-terminal to the single PWWP domain on WHSC1L1-
short bind the ET domain of BRD4 while the N-terminal end binds CHD8 
(Rahman, Sowa et al. 2011, Shen, Ipsaro et al. 2015, Zhang, Zeng et al. 2016). 
While their work was performed in murine leukemia cells, they did show that this 
mechanism was required for tumor cell proliferation. 
 CHD8 is a helicase, and has been shown to act as a transcriptional 
repressor (Clapier and Cairns 2009, Ho and Crabtree 2010). This is consistent 
with our observation of a net increase in gene expression upon knockdown of 
WHSC1L1-short in SUM44 cells, and importantly, there is now direct evidence 
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for a model of chromatin modification modulated by the catalytically inactive short 
isoform of WHSC1L1, and it does not apparently involve inhibition of WHSC1L1-
long histone methylation activity. It will be very interesting to map WHSC1L1-
short vs WHSC1L1-long binding sites in SUM44 and other breast cancer cell 
lines to determine whether the BRD4/WHSC1L1-short/CHD8 complex binds the 
ESR1 locus directly. One hypothesis would be that upregulation of ERa 
expression by WHSC1L1-short expression is indirect, as the direct activity of 
WHSC1L1-short in this model is transcriptional repression.  
Final Conclusions 
In this dissertation I have presented work that focused on the role of 
WHSC1L1 overexpression in maintenance of a cancer phenotype in SUM44 
breast cancer cells, particularly the relationship between WHSC1L1 
overexpression and expression of the estrogen receptor. Significant findings 
include confirmation that overexpression of the short isoform of WHSC1L1 is 
necessary for maintenance of a cancer phenotype in SUM44 breast cancer cells, 
and that WHSC1L1-short is required for estrogen receptor alpha expression at 
the transcript and protein level in SUM44. Others have recently shown that the 
short isoform of WHSC1L1 acts as an adapter protein creating a complex 
including BRD4 and CHD8, two enzymes involved in chromatin remodeling 
(Shen, Ipsaro et al. 2015). WHshort knockdown has a greater effect on SUM44 
cell growth, overall differential gene expression, and ERa expression than 
WHtotal knockdown. The low number of significantly differentially expressed 
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genes in the shWHtotal cells is likely due to the fact that the shWHtotal vector 
reduced WHlong levels much more than WHshort; specific knockdown of 
WHshort resulted in an approximately 5-fold increase in the number of 
differentially expressed genes. This evidence that the short isoform of WHSC1L1 
has a greater effect on gene expression than the long isoform may provide clues 
about the function of WHSC1L1-short; we hypothesize that the short isoform is 
more promiscuous, able to complex with many different chromatin modifying 
proteins to form complexes with more diverse chromatin-modifying activity than 
the long isoform. As WHSC1L1-short is not able to directly catalyze methylation 
of histone lysine residues, its function may be instead to recruit several different 
chromatin modifiers with its single PWWP domain, perhaps with different 
activities. Also, while recent evidence shows WHSC1L1-short acting as a link 
between BRD4 and CHD8 to promote helicase activity, it may still be possible 
that WHSC1L1-long and WHSC1L1-short antagonize each other, and that 
knockdown of both isoforms results in a regulatory state where the effect of 
knockdown of either isoform alone is attenuated by the concomitant knockdown 
of the other. Positive determination of the effect of one isoform of WHSC1L1 on 
the other would require further experiments, including WHSC1L1 ChIPseq to first 
determine whether both isoforms of WHSC1L1 the same genomic loci. The 
global increase in histone H3 levels observed in the shWHshort cells may be 
explained by the buildup of G2-arrested cells after WHSC1L1-short knockdown. 
This may also be consistent with the apparent contradiction of slowed 
  
123 
proliferation together with positive enrichment of mitotic cell cycle and DNA 
replication KEGG pathways in exhibited by the shWHshort cells. The observation 
that alternate isoforms of H3 are upregulated upon knockdown of WHshort 
suggests that alternate isoforms of H3, such as H3.3, may be substituted for 
H3.1 in chromatin. For future work, chromatin conformation could be investigated 
by DNase-seq hypersensitivity assay or Formaldehyde-Assisted Isolation of 
Regulatory Elements followed by short read sequencing (FAIRE-seq) to 
determine both the overall state of chromatin in the cell and specific regions of 
altered chromatin conformation. One hypothesis to explain the lack of expected 
clustering by replicate and condition of the SUM44 shLacZ and shWHshort cells 
based on ERa occupancy, together with the observed identical mean peak profile 
shape and location in both shLacZ and shWHshort, indicate that the location of 
ERa binding sites do not change after WHSC1L1-short knockdown, either in the 
absence or presence of ligand. However, the change in mean peak profile 
intensity combined with the expected clustering of samples by condition when 
clustered by differential binding intensity is consistent with the significant 
reduction in ERa protein levels in the shWHshort cells, and indicates there is 
simply less ERa available to bind chromatin.  
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APPENDIX    SUM44 RNA-SEQ DIFFERENTIAL 
EXPRESSION RESULTS 
 
Table A.1 SUM44 WHSC1L1short shRNA knockdown differential gene-level 
transcript expression by RNAseq 
HGNC_gene_symbol log2fold-
change 
p-value FDR (q-
value) 
NELL2 4.21243 3.80E-18 2.74E-14 
CEND1 3.49112 3.79E-11 6.07E-08 
CNIH2 3.47971 1.12E-13 2.69E-10 
RRM2 2.83998 5.67E-09 3.89E-06 
LRRK2 2.80148 3.66E-22 5.28E-18 
VEPH1 2.73812 2.44E-14 7.03E-11 
DAB2 2.71662 1.75E-07 5.15E-05 
STAB2 2.69528 1.17E-07 4.12E-05 
RIBC2 2.63562 4.19E-10 5.49E-07 
E2F7 2.59767 1.92E-07 5.15E-05 
PCLO 2.56236 4.15E-08 1.92E-05 
MSRB3 2.44857 9.07E-08 3.35E-05 
RNF128 2.4245 2.15E-05 0.00220184 
BPIFA4P 2.38396 0.000135738 0.00854558 
E2F2 2.35443 1.63E-09 1.57E-06 
GFRA2 2.29534 0.000222107 0.0116441 
SACS 2.29352 8.53E-08 3.24E-05 
FAM169A 2.24946 2.38E-06 0.000429159 
STRA6 2.24448 3.34E-05 0.00305027 
C10orf114 2.22678 1.67E-07 5.13E-05 
CLSPN 2.21416 3.56E-08 1.77E-05 
TRIP13 2.21166 1.24E-17 5.97E-14 
HELLS 2.1998 8.23E-08 3.21E-05 
ETV1 2.17921 3.44E-05 0.00312274 
PLS3 2.17862 7.95E-05 0.00570208 
CDCA7 2.15269 1.82E-07 5.15E-05 
MCM10 2.15252 5.14E-06 0.000772727 
COL12A1 2.14029 4.97E-16 1.79E-12 
AMOTL1 2.12106 0.000218147 0.0115662 
RAPGEF4 2.11885 0.00017222 0.00989204 
HAS3 2.11234 0.00061495 0.0233309 
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ANKRD1 2.10533 0.000534165 0.0215644 
TYMS 2.10505 1.36E-06 0.000280438 
TK1 2.09423 3.53E-11 6.07E-08 
CORO1A 2.08402 7.00E-08 2.80E-05 
CHRNA5 2.06679 2.12E-06 0.000391642 
CACNA2D1 2.06284 4.49E-07 0.000102795 
FBXO43 2.05454 0.000128467 0.0081883 
FAM64A 2.04838 7.32E-05 0.00538199 
GHR 2.03573 9.15E-10 1.02E-06 
ASF1B 2.03353 1.24E-07 4.26E-05 
RAD51 2.02363 1.34E-05 0.00158828 
DHFR 2.02285 4.26E-08 1.92E-05 
FAM111B 2.02145 5.30E-06 0.000788439 
BPIFB1 2.00671 0.000146576 0.00891642 
B3GNT6 2.00413 0.000612379 0.0232946 
E2F8 1.99529 2.47E-08 1.27E-05 
ORC1 1.99393 4.27E-06 0.00069893 
SPC25 1.98276 1.83E-06 0.000361763 
RAD51AP1 1.96965 5.71E-08 2.42E-05 
NPAS3 1.96294 0.000196925 0.0108858 
ALOXE3 1.96017 4.91E-08 2.14E-05 
ATP10D 1.9431 5.48E-06 0.000806596 
NR4A3 1.93259 0.000492655 0.0203234 
ESCO2 1.93069 1.66E-05 0.00185966 
MNS1 1.93012 4.12E-05 0.00364282 
KIF18B 1.92156 0.000103273 0.00695743 
GTSE1 1.9193 4.18E-05 0.00367802 
CDC45 1.90854 1.45E-06 0.000294892 
SNX7 1.90619 0.00082274 0.0278438 
C1orf95 1.90532 1.35E-07 4.53E-05 
GPR3 1.89788 0.00057438 0.0222603 
CLEC3B 1.89377 0.000141175 0.00872416 
DMBX1 1.88504 2.09E-05 0.00215572 
RSAD2 1.87337 0.000626078 0.0235237 
BUB1B 1.87321 8.13E-05 0.00577361 
RDM1 1.87293 0.000202727 0.0109877 
RELT 1.87004 1.46E-07 4.66E-05 
SYT1 1.86779 6.17E-06 0.000898407 
CCKBR 1.85841 0.00288453 0.0642755 
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F13A1 1.85473 5.54E-05 0.00451004 
KIAA0101 1.85452 4.32E-05 0.00377257 
SYNE1 1.8534 4.68E-06 0.000733451 
DISP2 1.84749 0.000174295 0.00997145 
APOBEC3B 1.84033 3.00E-11 6.07E-08 
SPC24 1.83958 6.04E-05 0.00470738 
SRGAP2 1.83911 7.13E-09 4.47E-06 
MYBL2 1.82795 0.000272955 0.013385 
WDR17 1.82175 0.000587391 0.0224626 
HEG1 1.81633 1.87E-09 1.68E-06 
PCDH7 1.8129 1.42E-08 8.55E-06 
ARNTL2 1.80929 0.00230648 0.0552195 
UHRF1 1.80428 1.95E-05 0.00206532 
LAMB1 1.80115 7.59E-07 0.000160931 
TMPO-AS1 1.79864 2.34E-08 1.25E-05 
PLLP 1.79727 2.49E-05 0.00245859 
LOC100499484 1.79459 0.00163623 0.0435231 
CDCA5 1.77845 1.84E-05 0.00200501 
NCAPG 1.77712 0.000334681 0.0153665 
C18orf56 1.7771 0.00139205 0.0392744 
PRUNE2 1.7766 0.000880724 0.029324 
MGAT5B 1.77282 0.00156216 0.0424136 
TCF4 1.77213 2.22E-07 5.63E-05 
LRRC4C 1.76333 0.00470508 0.0857013 
LINC00284 1.7319 0.00172319 0.0449245 
EPHA7 1.72725 0.000670556 0.0246617 
DZIP1L 1.72517 0.00582697 0.0978301 
EXO1 1.7216 0.000372007 0.016656 
CDKN2C 1.7175 5.06E-06 0.000772727 
HMGN5 1.70272 2.95E-05 0.00274343 
AURKB 1.70203 0.000805746 0.0277091 
ZWINT 1.69974 1.75E-05 0.00193001 
ACBD7 1.69566 0.000573292 0.0222603 
CTGF 1.69559 0.000802603 0.0276821 
SKA3 1.69113 0.000280285 0.0136014 
KIF11 1.6878 0.000310681 0.0145425 
CCDC151 1.67986 9.46E-05 0.00649385 
CDC25A 1.67494 2.70E-05 0.00259668 
DTL 1.67022 0.000196123 0.0108858 
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BRCA2 1.66951 0.000268322 0.013385 
CMPK2 1.66942 0.00396343 0.0773217 
C6orf100 1.66925 0.00360706 0.0731402 
ZNF367 1.66746 8.97E-06 0.00117606 
LOC401242 1.66538 0.00603184 0.100186 
ELOVL7 1.66315 4.05E-09 3.43E-06 
GUCY1A2 1.65415 1.00E-05 0.00128818 
FRMPD4 1.65232 0.00442408 0.0820724 
HMGB2 1.6489 5.41E-05 0.0044586 
STIL 1.64763 0.000175105 0.00997819 
MLF1IP 1.64301 3.08E-05 0.00282949 
KIFC1 1.64178 0.000447726 0.0191539 
BLM 1.63668 0.000232559 0.0119743 
PBK 1.63265 0.00145117 0.0402408 
KATNAL1 1.62974 7.18E-05 0.00535713 
LINC00634 1.62042 0.000878117 0.0293051 
BIRC5 1.62007 0.00114451 0.0351821 
ELOVL6 1.61321 0.00011242 0.00746895 
MLLT11 1.61022 2.30E-08 1.25E-05 
RAD54L 1.6051 2.17E-05 0.00220508 
CDCA3 1.60233 0.00171634 0.0448546 
FAM72A 1.60116 0.00415025 0.079653 
PKD1L1 1.60049 0.000125604 0.00804815 
NXPE3 1.59837 9.43E-08 3.40E-05 
CPT1C 1.59824 0.00365639 0.0735205 
VASH2 1.59619 0.000440074 0.0189389 
SLC16A10 1.59333 4.64E-05 0.00392764 
CENPM 1.58991 5.79E-05 0.00458818 
HJURP 1.58918 0.00151072 0.0415033 
ROR1 1.58804 0.00555885 0.0954149 
ENC1 1.58503 2.05E-06 0.00038388 
TCF19 1.58376 5.68E-05 0.0045735 
ZNF488 1.5835 0.00140532 0.0394172 
NDC80 1.58312 0.0025405 0.0586961 
KIAA1524 1.57174 0.000261941 0.0131582 
CHML 1.56981 4.68E-06 0.000733451 
PCSK6 1.5635 0.000495931 0.0203699 
MXD3 1.55198 7.79E-07 0.000162678 
SLCO4A1 1.55118 1.49E-05 0.0017212 
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PSMB9 1.54766 1.98E-06 0.000381033 
HIST1H4H 1.53799 0.00213767 0.0523436 
FAM216A 1.53699 1.49E-05 0.0017212 
ANLN 1.5356 0.000354617 0.0161392 
PAG1 1.53523 0.000487998 0.0202466 
TRIM9 1.53459 1.52E-05 0.00173722 
ZNF878 1.53422 0.00656396 0.10638 
FBXO5 1.53193 0.00134622 0.0386623 
CENPA 1.53148 0.00138987 0.0392744 
TICRR 1.52862 0.000482592 0.0201085 
AP3S2 1.5267 0.010622 0.140751 
HIST1H3H 1.52444 0.00379429 0.0749141 
RHEBL1 1.52283 0.00120615 0.0366084 
BRIP1 1.52152 0.000453045 0.0193241 
POLE2 1.51632 0.00140968 0.0394629 
MAP1A 1.51623 0.000322183 0.0149354 
SYNM 1.51147 4.90E-07 0.000110272 
SYP 1.5098 0.000528093 0.0214465 
HIST1H2BN 1.50757 0.00107328 0.0334199 
TTLL7 1.50539 1.04E-09 1.07E-06 
LINC00669 1.50256 0.0031275 0.0670097 
IL15RA 1.49733 1.93E-05 0.00206003 
STMN3 1.49605 2.21E-07 5.63E-05 
TPX2 1.49366 0.00130417 0.0380611 
MICB 1.49203 0.000283499 0.0136696 
SYCE2 1.4889 0.00264164 0.0604811 
TMCC2 1.48821 0.00272606 0.0616683 
SPAG5 1.48725 0.00039802 0.0174947 
MMP16 1.48536 0.00759187 0.114864 
PKMYT1 1.48263 0.000255629 0.012886 
HMGCS1 1.48223 0.000149756 0.00903363 
C1QL1 1.47951 0.00682472 0.108656 
TROAP 1.47911 0.00227229 0.0549161 
KCNQ5 1.47873 0.0112826 0.145948 
STK10 1.47678 4.89E-09 3.71E-06 
BSN 1.476 1.90E-05 0.00204815 
CENPO 1.47353 2.59E-05 0.00252701 
CDH7 1.46987 0.0103487 0.139151 
SYT9 1.46887 0.00389381 0.0763696 
  
129 
VIM 1.4642 0.00363319 0.0732127 
OAS3 1.45889 1.08E-05 0.00136539 
CTNNAL1 1.45504 1.92E-07 5.15E-05 
HIST1H3G 1.45431 0.0037091 0.0739615 
FAM83D 1.45183 0.00422574 0.0804052 
BICD1 1.45055 0.000154892 0.00926059 
FAM81A 1.43651 0.00429035 0.0809607 
FOXM1 1.43532 0.00191119 0.0483397 
CCDC136 1.43476 0.000618213 0.0233319 
GDAP1 1.43443 6.32E-05 0.00486918 
ANP32E 1.43329 0.00126688 0.0374275 
NEIL3 1.43172 0.00219017 0.0532473 
PRC1 1.42942 0.000553965 0.021941 
POLQ 1.4288 0.00350656 0.0720144 
TACC3 1.42807 0.00115639 0.0354716 
CDK1 1.42427 0.00312154 0.0670097 
HPS5 1.42266 5.54E-07 0.000122867 
CDT1 1.42163 4.65E-05 0.00392764 
LRP8 1.42112 5.51E-05 0.00451004 
DISP1 1.41651 0.00254522 0.058711 
PRICKLE1 1.41359 0.00328285 0.0688921 
TEAD4 1.41279 6.43E-08 2.65E-05 
GOLIM4 1.41054 4.57E-10 5.49E-07 
ITGAM 1.41005 0.00121219 0.0367147 
CENPK 1.40904 0.0010227 0.0321225 
CENPI 1.39616 0.00558886 0.0956943 
DNA2 1.39102 3.01E-05 0.00278037 
CDKN2B-AS1 1.38575 0.00283838 0.0636406 
PTPN14 1.37918 3.57E-07 8.45E-05 
LYPD5 1.37429 0.00591896 0.0987657 
SHC4 1.36828 0.00120403 0.0366084 
SKA1 1.36414 0.00842536 0.122572 
ZNF788 1.36203 0.00246886 0.0574958 
RIMKLA 1.36098 0.00366338 0.0735584 
SLC36A1 1.3584 1.72E-07 5.15E-05 
SLC25A19 1.35254 9.02E-05 0.00624925 
SLCO2A1 1.34909 0.00217761 0.0531848 
SRGAP2D 1.34897 0.00011607 0.00763404 
GLYCTK 1.34777 0.00144644 0.0402408 
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SMC2 1.34758 0.00073352 0.0262619 
CTSL2 1.33719 0.000168736 0.00984888 
GPR19 1.33666 0.00433903 0.0812413 
RASSF8 1.33256 5.87E-05 0.00461277 
MPP1 1.33039 0.00592594 0.098768 
LOXL3 1.32639 9.51E-05 0.00649965 
ADAMTS12 1.3246 1.32E-05 0.00158229 
CIT 1.32238 0.00575065 0.0975052 
TBC1D8B 1.31873 0.000246892 0.0125776 
FAM111A 1.31674 2.04E-06 0.00038388 
POLR3G 1.31334 0.000313617 0.0145852 
CDC7 1.30899 0.00719454 0.112866 
CDC25C 1.30899 0.0046412 0.0848335 
EPB41L2 1.30892 8.15E-06 0.00114077 
WSCD1 1.3088 8.55E-06 0.00116287 
ANO2 1.30836 0.000364762 0.0164337 
ZDHHC23 1.30714 0.000272811 0.013385 
RFC3 1.30705 2.22E-05 0.00220508 
PART1 1.30661 0.00326768 0.0687662 
FANCD2 1.30194 0.000130859 0.00827454 
TUBA1B 1.30167 6.96E-05 0.00523211 
PLCE1-AS1 1.29855 0.00442896 0.0820724 
IL22RA1 1.29479 0.0112916 0.145948 
CENPL 1.29162 0.00035991 0.0162659 
SPARC 1.291 0.00174514 0.0453327 
C9orf40 1.28674 0.000334024 0.0153665 
CENPP 1.2857 0.00333844 0.0695525 
FANCI 1.28522 0.000895829 0.02969 
KIAA0319 1.28519 0.00908762 0.128953 
DNAJC6 1.27826 0.00161174 0.043185 
WDR76 1.27816 0.00056973 0.0222603 
LMNB1 1.27652 0.00442021 0.0820724 
TENM3 1.27557 2.75E-05 0.0026216 
KIF23 1.27492 0.00654836 0.106315 
GOT1 1.27195 3.56E-07 8.45E-05 
SGOL1 1.27164 0.00981822 0.135195 
MED12L 1.27128 0.00359296 0.0730603 
NCAPH 1.2682 0.00156986 0.0424629 
IFIH1 1.26653 7.24E-05 0.00535713 
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FLVCR1-AS1 1.26532 0.000488715 0.0202466 
GSG2 1.2608 0.00932975 0.131226 
MELK 1.2591 0.00475661 0.0861508 
RGL1 1.25704 0.0020207 0.0501419 
NCAPG2 1.25598 0.000199278 0.0108858 
CCNE2 1.25418 0.000248571 0.0126185 
SLC2A6 1.25393 0.00269182 0.0613752 
FEN1 1.25186 5.89E-05 0.00461277 
RASGRP3 1.2502 0.00378137 0.0748847 
TTK 1.24807 0.00542533 0.0940851 
SNAP25 1.24523 0.00213847 0.0523436 
ARHGAP11A 1.24436 0.00667043 0.106853 
MT2A 1.2407 0.000179724 0.0102011 
PEG10 1.23966 0.000203521 0.0109894 
FGFR2 1.23964 0.00421332 0.0804052 
ADORA2B 1.23881 0.00717623 0.112824 
CCDC85A 1.23181 0.00470801 0.0857013 
TBC1D4 1.22891 0.00106784 0.0333227 
TPTE2P1 1.22345 0.00575994 0.0975052 
LYPD6 1.22298 0.000550863 0.0218782 
IKBKE 1.22245 6.81E-05 0.00519156 
CHEK1 1.21995 0.00354467 0.0722823 
TP53I3 1.21655 1.34E-05 0.00158828 
PARPBP 1.20778 0.0102512 0.138252 
ATF3 1.20099 0.0092082 0.130024 
APLN 1.20076 0.00943574 0.13233 
ZNF460 1.20004 0.0112235 0.145594 
RAI14 1.19974 0.0104243 0.139428 
ENOX1 1.19774 0.0022959 0.0550749 
MCM2 1.19532 0.000233878 0.0119993 
H2AFX 1.19495 2.93E-06 0.000509257 
SYNE2 1.19341 2.21E-05 0.00220508 
PCDHGC3 1.19248 0.00195901 0.049204 
CDC6 1.1918 0.00274991 0.061946 
LOC148709 1.19048 0.000367006 0.0164832 
TBC1D1 1.18803 0.00138987 0.0392744 
ADAM22 1.18628 0.00856017 0.123908 
WDR62 1.18366 0.000302027 0.0143879 
SFXN5 1.18257 2.00E-07 5.25E-05 
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PSIP1 1.1788 6.10E-05 0.00472438 
ERCC6L 1.17439 0.00718575 0.112851 
ORC6 1.17059 0.00115998 0.0355062 
ZNF432 1.16956 0.0112298 0.145594 
NES 1.16363 0.00415475 0.079653 
STMN1 1.15981 0.00352936 0.0722767 
MSMO1 1.15712 0.0001416 0.00872416 
GINS4 1.15463 0.00122765 0.036873 
KIAA1161 1.15442 7.48E-05 0.00544352 
KIF20B 1.14914 0.00472847 0.0859011 
HSPA2 1.14892 0.00029214 0.0140393 
STAMBPL1 1.14599 0.00440893 0.0820724 
SMAD6 1.14515 0.00577055 0.0975052 
ZNF695 1.14392 0.0114789 0.147496 
ZAK 1.14138 0.00399503 0.0777279 
IL1RAPL2 1.13827 0.00776292 0.116506 
FANCA 1.13776 0.000545559 0.0217828 
MYO16 1.13616 2.75E-06 0.000489791 
TTC7B 1.13094 0.000522317 0.0212719 
RCBTB2 1.13051 0.0034343 0.0708331 
MTFR2 1.12883 0.00270036 0.0614055 
XPR1 1.12682 2.07E-05 0.00215572 
LMNB2 1.1253 0.00363238 0.0732127 
TMEM180 1.12517 0.00501175 0.0896457 
RNASEH2A 1.12331 0.00312808 0.0670097 
ARHGEF39 1.1233 0.00339913 0.0704099 
ARHGAP33 1.12216 0.00129731 0.0380149 
ROR2 1.11949 0.00233754 0.055703 
KCNK3 1.11803 0.00127222 0.0375084 
C5orf34 1.11595 0.00654136 0.106315 
AP4B1 1.11471 0.000413901 0.0180825 
ATAD2 1.11468 0.00153405 0.0418871 
TPM3P9 1.11462 0.00527955 0.0925041 
OXCT1 1.11188 0.00087225 0.0291769 
CEP85L 1.10679 0.000538071 0.0215644 
DOCK5 1.10673 1.49E-06 0.000299161 
B3GALTL 1.10549 0.000759062 0.0267565 
STARD8 1.10307 0.00569285 0.0972439 
ACYP1 1.10082 0.0013407 0.0386579 
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RRM1 1.1006 0.00127488 0.0375101 
LRRCC1 1.09998 0.00154147 0.0420101 
LDOC1 1.09681 0.000658698 0.0243499 
NRM 1.09563 0.003198 0.0679872 
AURKA 1.09561 0.0078983 0.117878 
HCN3 1.09549 0.000190964 0.0107544 
CENPN 1.09439 0.00305498 0.0662311 
CCDC15 1.08925 0.0103564 0.139151 
RASAL2 1.08451 8.55E-05 0.0059575 
MCM5 1.08177 0.00122347 0.036858 
LHX2 1.08097 0.00227918 0.0549161 
ANKRD30B 1.08061 0.00204493 0.0504825 
ZBED5-AS1 1.08044 0.000585539 0.0224514 
TAP2 1.07963 2.58E-05 0.00252701 
HSPA4L 1.07936 0.00237957 0.0563529 
GEN1 1.07929 0.00883438 0.126594 
CXCL16 1.07705 0.0042431 0.0804052 
HIST1H1C 1.07451 0.0022785 0.0549161 
CCNF 1.07165 0.0013581 0.0387745 
PFKP 1.07161 0.000445683 0.0191233 
STON2 1.07137 0.000584715 0.0224514 
CENPH 1.07021 0.00320672 0.0679872 
COPG1 1.06877 3.80E-07 8.83E-05 
TTF2 1.06464 0.00019974 0.0108858 
INSIG1 1.06341 7.95E-05 0.00570208 
GMNN 1.06081 0.00090496 0.0298554 
PCDHA3 1.06073 0.00125854 0.0374111 
MAD2L1 1.06069 0.00475642 0.0861508 
NCAPD2 1.05714 0.00198333 0.04947 
LATS2 1.05455 0.000617733 0.0233319 
OSBPL6 1.05191 0.0043811 0.0818166 
KPNA5 1.05001 0.00296643 0.0651936 
EAF2 1.04897 8.27E-05 0.00581924 
PPFIBP1 1.0486 0.000811074 0.0277091 
PLK4 1.04719 0.00990011 0.135667 
ZWILCH 1.0419 0.00379651 0.0749141 
FAM21A 1.03942 0.0111362 0.145032 
DENND5B 1.03869 3.02E-06 0.000518602 
BORA 1.03691 0.00370138 0.0739451 
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IFIT5 1.03606 0.00030994 0.0145425 
CEP97 1.03549 0.00248319 0.0576491 
ACAT2 1.03521 0.00424976 0.0804052 
IBA57 1.03176 4.51E-05 0.00390026 
FDPS 1.0311 0.000154302 0.00926059 
DBF4B 1.02899 0.00517653 0.0914746 
TNFAIP8L1 1.02888 0.00735494 0.113773 
CLPB 1.02868 0.00158704 0.0427671 
PIK3R1 1.02581 0.00136089 0.0387745 
CDK6 1.02504 0.000918539 0.0301653 
ZIC3 1.02038 0.0069399 0.109844 
NHS 1.01472 0.00156523 0.042417 
LOC643837 1.01321 0.00050201 0.0205028 
MMS22L 1.00884 0.00430797 0.0809998 
SYNGR3 1.00769 0.0103983 0.139428 
CLCN5 1.00767 0.00247193 0.0574958 
DONSON 1.00762 0.000817951 0.0278245 
STIM2 1.00461 0.00477112 0.0863052 
LRRC49 0.999362 0.00228166 0.0549161 
PRKCA 0.997279 0.00810991 0.119673 
FLVCR1 0.996571 0.00133002 0.0385037 
UPF3B 0.99657 0.00124061 0.0371076 
PDE4DIP 0.99464 8.79E-06 0.00117368 
SCAMP5 0.989379 8.55E-06 0.00116287 
ATP5D 0.989282 0.000971004 0.0311781 
ATP11C 0.989165 0.000116711 0.00763404 
SLC4A8 0.987678 0.000643432 0.0238467 
MAPK8IP1 0.985241 0.00197495 0.0494319 
PHACTR2 0.984499 0.00107646 0.0334469 
NBN 0.982813 0.00779616 0.116837 
SQLE 0.981725 0.00119771 0.0365061 
KPNA2 0.980041 0.00038626 0.0170819 
STARD9 0.979853 0.00574852 0.0975052 
SKA2 0.976684 0.00123945 0.0371076 
EBP 0.973094 0.000226484 0.0117454 
NUP205 0.972971 0.00235896 0.0561206 
FREM2 0.971049 0.00352695 0.0722767 
DDX60 0.967736 0.00965747 0.134148 
DBF4 0.967432 0.00302239 0.0657609 
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SCLT1 0.962529 0.00389873 0.0763696 
LCORL 0.961218 0.000845222 0.0284709 
SAP30 0.960177 0.00218022 0.0531848 
FOXN2 0.959233 0.00820911 0.120887 
KNTC1 0.955058 0.00446362 0.0826085 
ASAP1 0.954513 0.00473091 0.0859011 
FAM160A1 0.954195 0.000394948 0.0174127 
BEX5 0.952618 0.00183262 0.0468926 
PHTF2 0.95204 0.000221774 0.0116441 
CNTRL 0.95052 0.00310037 0.0669132 
RYR2 0.949209 0.0107828 0.142064 
C17orf53 0.947903 0.0065971 0.106387 
PSMB10 0.94751 0.00099819 0.031698 
E2F1 0.942328 0.00176954 0.0458016 
PANK1 0.941239 0.00967632 0.134148 
LRR1 0.940095 0.00237314 0.0563529 
DHCR7 0.938694 0.00201883 0.0501419 
UNC13B 0.938372 0.00722613 0.113238 
AIM1 0.934966 0.000683839 0.0248335 
MCM3 0.933803 0.00125444 0.0373664 
SEC23A 0.933332 0.000572138 0.0222603 
MASTL 0.931323 0.00198031 0.04947 
OSBPL11 0.930779 0.000457512 0.0194571 
CEP152 0.92563 0.00164058 0.0435258 
ITPR2 0.924488 0.00515802 0.0913785 
SLCO3A1 0.922575 0.0112118 0.145594 
HLA-H 0.92257 0.00581684 0.0978301 
LCP1 0.922476 0.000225643 0.011744 
SMC1A 0.922008 0.00464269 0.0848335 
HIP1 0.919469 0.00505672 0.0900033 
DEK 0.91851 0.0100922 0.136877 
STXBP1 0.913497 0.00013753 0.00862073 
TCP11L1 0.913222 0.00146313 0.0404874 
MCM6 0.912942 0.00968039 0.134148 
THOP1 0.911996 2.65E-05 0.00256082 
ANKRD13B 0.908889 0.00482919 0.0870281 
MGST3 0.908832 0.000626558 0.0235237 
TMEM198 0.908174 0.00430928 0.0809998 
DPP3 0.907333 2.19E-05 0.00220508 
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ALDH3B1 0.904533 0.00408863 0.0788046 
FAM3C 0.898821 0.0017174 0.0448546 
LDLR 0.898813 0.00490429 0.0880512 
METTL7A 0.897796 0.00193931 0.0488793 
PPIL1 0.897542 0.00734216 0.113773 
LIPE 0.895762 0.00488366 0.0877901 
DUT 0.894969 0.00391162 0.076518 
LPIN1 0.894869 0.00126606 0.0374275 
SLC41A2 0.886086 0.000210028 0.011251 
CCDC77 0.884743 0.000429008 0.0186295 
EZH2 0.883777 0.0104835 0.139428 
MCM7 0.883153 0.00578255 0.0975052 
ZNF525 0.881039 0.00662989 0.10644 
FRY 0.880216 0.000694095 0.0251426 
MAML2 0.879751 0.00212667 0.0523211 
FAM198B 0.877871 0.00555357 0.0954149 
LOC646214 0.876825 0.00834677 0.121797 
APOL3 0.876128 0.000981077 0.0312924 
FA2H 0.875996 0.000237048 0.0121189 
DOT1L 0.87506 0.000312784 0.0145852 
FANCM 0.873804 0.0106628 0.141033 
HAUS2 0.87332 0.00124832 0.037261 
SLX4 0.872313 0.00348205 0.0716129 
E2F3 0.871111 0.000424493 0.0184892 
DLAT 0.86987 0.000935702 0.0304515 
PRPS1 0.866535 0.000171505 0.00989204 
ALDOC 0.861118 0.011084 0.144482 
POLA2 0.858399 0.00822441 0.120887 
ANAPC15 0.853716 0.0104443 0.139428 
GPR98 0.853153 0.00751422 0.11469 
INCENP 0.852699 0.00184028 0.0469284 
SFN 0.846951 0.003149 0.067258 
TEAD1 0.84671 0.00744045 0.11432 
ITGB8 0.846213 0.0109975 0.143745 
TNS1 0.845767 4.52E-05 0.00390026 
MIS18BP1 0.842141 0.00853974 0.123736 
DTYMK 0.842114 0.00450241 0.083113 
ALYREF 0.840344 0.00301522 0.0657609 
HMGCR 0.83901 0.0116396 0.149163 
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MCU 0.838668 0.00393122 0.0767972 
REPS2 0.836786 0.00548433 0.0945978 
IMPA1 0.835749 0.00576945 0.0975052 
CISD1 0.832802 0.000768806 0.0269681 
FASTKD1 0.832448 0.00082131 0.0278438 
PFKM 0.825855 7.42E-05 0.00543109 
LIG1 0.825672 0.0031153 0.0670097 
TRAF3 0.82546 0.00335643 0.0698263 
PCNA 0.82383 0.0102489 0.138252 
GTDC1 0.823574 0.00512039 0.0910242 
TMEM38B 0.82204 0.00070606 0.0255119 
POP1 0.820319 0.00515933 0.0913785 
MVD 0.81786 0.00838812 0.122153 
DDX12P 0.815977 0.0101705 0.137422 
APOL2 0.813713 0.004373 0.0817712 
AFG3L2 0.813325 3.87E-05 0.00346126 
LAGE3 0.808539 0.00440211 0.0820724 
CHAF1A 0.807995 0.0041809 0.0800457 
PAK2 0.805508 0.00374451 0.074359 
MDH1 0.805157 0.000221333 0.0116441 
TYRO3 0.803125 0.00467705 0.0853532 
GLMN 0.800999 0.00952083 0.133135 
MARVELD2 0.799318 0.000123562 0.00795264 
MYO9A 0.798361 0.0100031 0.136437 
PPIC 0.796195 0.00122459 0.036858 
MVK 0.7949 0.00112846 0.0347628 
SNX8 0.794746 0.00544836 0.0942964 
ATP2B4 0.789523 0.00837673 0.12211 
ALDH9A1 0.788591 0.000738307 0.0262819 
TDRKH 0.785267 0.000546949 0.0217828 
POLA1 0.783385 0.010526 0.139736 
ACOT7 0.781429 0.0032318 0.068318 
NCAPD3 0.78138 0.0104249 0.139428 
DNPH1 0.780592 0.00183446 0.0468926 
LETM2 0.780285 0.000847819 0.0284919 
SLC25A30 0.779687 0.00494913 0.0887458 
ECSIT 0.777683 0.00246869 0.0574958 
UBE2S 0.777395 0.00926788 0.130583 
PPP2R1B 0.776173 0.00979057 0.135072 
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ACVR1C 0.776148 0.00547402 0.0945978 
PARP2 0.770941 0.000795059 0.0275538 
AGL 0.770928 0.00594784 0.0990185 
TCTA 0.7695 0.0105521 0.139954 
DNAJC9 0.76932 0.00127939 0.0375662 
ATP6V0A1 0.769104 0.00238045 0.0563529 
MYO1D 0.766001 0.0013333 0.0385215 
APAF1 0.765506 0.0072659 0.113383 
RTTN 0.762866 0.00455752 0.0838083 
C12orf4 0.762633 0.001496 0.0412387 
ITGA2 0.761037 0.00692178 0.109781 
LINC00294 0.760652 0.0080984 0.119626 
FAM155B 0.759197 0.00682823 0.108656 
ZSWIM5 0.758671 0.00353752 0.0722823 
EGLN3 0.757974 0.0116645 0.14922 
L2HGDH 0.75742 0.00733715 0.113773 
TUBB4B 0.75554 0.0114192 0.146992 
PKN3 0.755475 0.0105111 0.139667 
8-Mar 0.755372 0.0024726 0.0574958 
CDK8 0.754501 0.00752563 0.11469 
HAUS5 0.754245 0.00823408 0.120887 
ARMC6 0.750857 0.00321765 0.0681188 
ABHD6 0.750138 0.00406586 0.0785757 
ZKSCAN2 0.749712 0.00553468 0.0953327 
C4orf21 0.748688 0.00595628 0.0990446 
RBM12B 0.739692 0.00995353 0.136079 
BTBD1 0.738006 0.000411777 0.0180444 
MYH10 0.733254 0.0033014 0.069081 
ZNF860 0.729381 0.00916348 0.129759 
CFL2 0.728647 0.00608608 0.10097 
NFKB2 0.72576 0.00865095 0.124472 
BHLHB9 0.721765 0.0108408 0.142291 
PSMB8 0.720348 0.00111459 0.0345572 
NDRG2 0.712113 0.00924005 0.130346 
PPP1R21 0.7104 0.00385788 0.0758786 
BTN2A2 0.708798 0.00782178 0.117099 
RCAN1 0.702042 0.00852376 0.123736 
CHCHD3 0.700728 0.00441955 0.0820724 
TAP1 0.69879 0.00327208 0.0687662 
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DSN1 0.695578 0.00733289 0.113773 
CYCS 0.693735 0.00160582 0.043112 
KCNC4 0.692126 0.00227357 0.0549161 
IPO9 0.690808 0.0104382 0.139428 
KCTD10 0.690664 0.0106927 0.141224 
GPR137C 0.69026 0.010854 0.142291 
CBX6 0.68811 0.00293986 0.065106 
CHTF18 0.685385 0.00678615 0.108345 
GOT2 0.680253 0.00917141 0.129759 
OPA3 0.67799 0.00411763 0.0791519 
MYO19 0.673648 0.00239487 0.0564165 
PATL1 0.665251 0.00759968 0.114864 
TMEM237 0.662799 0.01079 0.142064 
EPB41L4A 0.660656 0.00766258 0.115556 
SUPT16H 0.655083 0.00462781 0.0848335 
ASAP2 0.654086 0.0072879 0.113589 
ZNFX1 0.652344 0.00967653 0.134148 
DNAJC2 0.651909 0.00503274 0.0896873 
TRIM14 0.649032 0.0103859 0.139417 
SLC25A13 0.648802 0.00303582 0.0659147 
PLCE1 0.646939 0.0117451 0.149982 
EPT1 0.645487 0.00482054 0.0869808 
ACSS3 0.643994 0.0112995 0.145948 
IDH3A 0.640344 0.00995957 0.136079 
SUCLG1 0.640029 0.00950905 0.133099 
VCL 0.637432 0.0075231 0.11469 
PITRM1 0.62763 0.00210566 0.0518927 
ADIPOR2 0.626442 0.00624264 0.103093 
LUZP1 0.626004 0.00996736 0.136079 
TPI1 0.619397 0.0027967 0.0628038 
WASF1 0.613017 0.00961064 0.134001 
VAC14 0.610859 0.00661277 0.10644 
ZNF330 0.599251 0.00877919 0.126065 
CNTROB 0.599228 0.00298276 0.0653561 
TDRD7 0.595862 0.00990896 0.135667 
OGDH 0.590377 0.00452009 0.0833326 
HCFC2 0.585451 0.0094978 0.133071 
TOMM40L 0.580473 0.0100885 0.136877 
PHF14 0.577677 0.00862322 0.124445 
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PET112 0.564802 0.0108977 0.1427 
HARS 0.563603 0.00964264 0.134148 
TOP3A 0.550843 0.0110756 0.144482 
PPARD 0.546019 0.00463373 0.0848335 
SMAD1 0.51098 0.0104543 0.139428 
MRPS5 0.498317 0.0113952 0.146945 
TEAD2 -0.51487 0.010084 0.136877 
VMP1 -0.525157 0.00683604 0.108661 
PCYOX1 -0.534758 0.0108543 0.142291 
TM9SF2 -0.551405 0.00918264 0.12979 
TPD52L1 -0.551863 0.0109513 0.143271 
ALG13 -0.558571 0.0108566 0.142291 
LSM1 -0.560658 0.00676267 0.10809 
PTTG1IP -0.562381 0.00900943 0.127969 
ARIH2 -0.567511 0.00629499 0.103601 
REEP3 -0.568439 0.007997 0.118634 
RING1 -0.576308 0.00361211 0.0731402 
PCDH1 -0.578252 0.00733503 0.113773 
ANAPC16 -0.586422 0.00402794 0.0781985 
FOXP1 -0.589257 0.00773092 0.116465 
TRAPPC6A -0.589967 0.0104809 0.139428 
DNAL4 -0.590388 0.0033622 0.0698456 
SEMA4B -0.590463 0.00631848 0.103678 
CLDN7 -0.590846 0.00966514 0.134148 
GGCX -0.591447 0.00805453 0.119344 
PCMTD2 -0.593706 0.00927492 0.130583 
ZNF83 -0.600686 0.0093565 0.131346 
DYNLL1 -0.605153 0.00755825 0.114864 
HNRNPA0 -0.606201 0.00637436 0.104194 
FAU -0.609184 0.00761534 0.114964 
RWDD3 -0.61603 0.00301387 0.0657609 
FIS1 -0.616842 0.00525174 0.0922221 
USP28 -0.621547 0.00849442 0.123452 
SEPN1 -0.621943 0.00885268 0.126594 
GSKIP -0.622023 0.00785095 0.117292 
GPAA1 -0.622218 0.00796694 0.118634 
CMC1 -0.625762 0.0117219 0.149818 
UBA52 -0.626161 0.00985896 0.135368 
COPS7A -0.62678 0.00455563 0.0838083 
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TMED4 -0.628338 0.00354145 0.0722823 
GPR108 -0.631619 0.00369093 0.0739057 
SHARPIN -0.63432 0.00298289 0.0653561 
TCEB2 -0.634656 0.0106969 0.141224 
ZNF512B -0.636311 0.00341044 0.0705429 
SKP1 -0.6383 0.00741304 0.11406 
ATRAID -0.638875 0.00739643 0.113926 
SLC2A1 -0.642261 0.0108345 0.142291 
STK16 -0.645447 0.0042458 0.0804052 
TNFRSF25 -0.645652 0.00826455 0.121087 
ALS2CL -0.64641 0.00627646 0.103415 
POLM -0.647383 0.00972788 0.134465 
MBTD1 -0.648554 0.0100628 0.136877 
TTC17 -0.649491 0.00132277 0.0384483 
ZSCAN18 -0.652059 0.00230959 0.0552195 
ENKD1 -0.653845 0.0100339 0.136728 
NUDT13 -0.65433 0.00885303 0.126594 
AMZ2P1 -0.657589 0.00407569 0.0786603 
TCAIM -0.659247 0.00893095 0.127105 
DDRGK1 -0.659547 0.00294859 0.065126 
DUSP22 -0.662962 0.00775607 0.116506 
RBKS -0.665498 0.00583574 0.0978301 
CPD -0.667658 0.000913188 0.0300581 
TMEM219 -0.668638 0.00537227 0.0934318 
LUC7L -0.669889 0.00430245 0.0809998 
SERP1 -0.671544 0.00529996 0.0926177 
DEF6 -0.672511 0.00724965 0.113383 
ETHE1 -0.672795 0.0104708 0.139428 
CBLN3 -0.67354 0.0052188 0.0917555 
UBL3 -0.673737 0.0112117 0.145594 
ENGASE -0.676026 0.00798815 0.118634 
LOC100129034 -0.676315 0.00274884 0.061946 
EPS8L1 -0.676471 0.00426751 0.0806352 
FAAH -0.676552 0.00520053 0.0915947 
TAX1BP1 -0.67729 0.00184237 0.0469284 
RNASET2 -0.679953 0.000643193 0.0238467 
LTBP4 -0.683268 0.00264293 0.0604811 
TC2N -0.68638 0.00776596 0.116506 
RGL2 -0.687284 0.00758205 0.114864 
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NIT2 -0.692607 0.00135561 0.0387745 
TMEM66 -0.695948 0.00320498 0.0679872 
FAM110A -0.696041 0.00706229 0.111275 
NFYA -0.696527 0.00134527 0.0386623 
DNAJC4 -0.697157 0.00130998 0.0381536 
CLSTN1 -0.698406 0.00168014 0.0441212 
AUP1 -0.698681 0.00272809 0.0616683 
MANBA -0.700245 0.010115 0.136927 
SNRNP70 -0.703713 0.00531093 0.092697 
SMIM14 -0.703983 0.00877235 0.126065 
SMIM22 -0.704028 0.00697881 0.110322 
UBE2E1 -0.704097 0.00520331 0.0915947 
C1RL -0.707492 0.00799283 0.118634 
NFATC4 -0.707754 0.00796626 0.118634 
MAPK13 -0.70802 0.000187302 0.0105896 
DHPS -0.710303 0.00649032 0.10573 
FAM109A -0.710465 0.00148084 0.040899 
MAT2A -0.711014 0.000979504 0.0312924 
ANKRA2 -0.713877 0.00135981 0.0387745 
SIL1 -0.714805 0.00102159 0.0321225 
PPP1R26 -0.715578 0.00193886 0.0488793 
COMMD1 -0.715906 0.00357366 0.0727704 
C12orf57 -0.716093 0.00151933 0.041564 
PEA15 -0.716277 0.00859402 0.124148 
TNFSF13 -0.721931 0.00739378 0.113926 
C6orf120 -0.722664 0.000538364 0.0215644 
SLC25A20 -0.723847 0.00572056 0.0975052 
MAN2B1 -0.729352 0.0065723 0.10638 
C6orf57 -0.729614 0.0028949 0.064407 
SH3PXD2A -0.730632 0.00203072 0.0503039 
RPL9 -0.73244 0.00424924 0.0804052 
SRD5A3 -0.733646 0.00449173 0.0830221 
ENDOV -0.733733 0.00173729 0.0452102 
NTAN1 -0.733956 0.0024173 0.056852 
OSTC -0.734835 0.00648564 0.10573 
PPP1R35 -0.735139 0.0058812 0.0982495 
TXNIP -0.735814 0.00213806 0.0523436 
SDC3 -0.735982 0.000831742 0.0280825 
CERS6 -0.737071 0.00337683 0.0700487 
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ATP8B1 -0.738388 0.00111902 0.03462 
R3HDM4 -0.741467 0.000726288 0.026112 
FAM173B -0.743019 0.00228614 0.0549322 
ICK -0.744444 0.000904234 0.0298554 
SLC3A2 -0.744648 0.00760077 0.114864 
NUMB -0.744829 0.000281141 0.0136014 
BCDIN3D -0.745141 0.011204 0.145594 
TMBIM6 -0.745235 0.000269625 0.013385 
GLUD2 -0.746813 0.00272903 0.0616683 
CAMKK1 -0.747365 0.0110506 0.144308 
C11orf54 -0.747462 0.00611799 0.101383 
SKP1P2 -0.748108 0.00376127 0.0745891 
SSPN -0.748503 0.00363466 0.0732127 
IDH1 -0.749834 0.00548545 0.0945978 
RPL13 -0.750182 0.0106327 0.140764 
BNIP3L -0.750726 0.000225545 0.011744 
IFT43 -0.750762 0.00077859 0.0271134 
PPM1N -0.750788 0.010459 0.139428 
ISYNA1 -0.752398 0.0114572 0.147349 
RGS14 -0.753254 0.0107313 0.141549 
SNHG6 -0.753648 0.00433723 0.0812413 
AP1G2 -0.756317 0.000736944 0.0262819 
TNRC6C-AS1 -0.756954 0.00502262 0.0896873 
APMAP -0.757439 0.00726056 0.113383 
USB1 -0.757476 0.00203739 0.0503826 
RPL18A -0.758494 0.0058599 0.0981209 
SIPA1 -0.758946 0.00757836 0.114864 
LOC100131564 -0.760848 0.00658383 0.106387 
TAGLN -0.761401 0.00330623 0.069081 
PLA2G6 -0.761688 0.00577708 0.0975052 
PRKRA -0.764518 0.00309083 0.0668074 
FAM211B -0.764595 0.00631238 0.103678 
C11orf35 -0.764705 0.00775711 0.116506 
STX16 -0.76475 0.000464703 0.019647 
GLUL -0.765688 0.0101148 0.136927 
ELOVL5 -0.767557 0.00295545 0.065126 
HOMER3 -0.76844 0.00076162 0.0267812 
BCL3 -0.770339 0.0075938 0.114864 
PCSK4 -0.772646 0.00808193 0.119505 
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ARHGAP30 -0.77346 0.00894035 0.127113 
SLC9A3R2 -0.77442 0.00302124 0.0657609 
ARHGAP4 -0.774753 0.00497185 0.0890425 
LYRM1 -0.774837 0.00197038 0.0494033 
NPAS1 -0.775122 0.00654367 0.106315 
SUMO3 -0.776232 0.00333499 0.0695525 
GPR160 -0.776507 0.00674711 0.107961 
AMN1 -0.778197 0.00245931 0.0574958 
OSGEPL1 -0.778293 0.00565185 0.096658 
LINC00116 -0.778489 0.00737229 0.113797 
AGFG1 -0.779107 0.00983993 0.135332 
SPAG4 -0.780924 0.00620709 0.102741 
LRIG1 -0.784525 0.00528063 0.0925041 
LRP3 -0.786132 0.00887968 0.126751 
MFSD6 -0.786283 0.000581683 0.0224228 
HOXC13 -0.786923 0.00423348 0.0804052 
ZNF680 -0.791276 0.00746694 0.114388 
PQLC3 -0.792632 0.00182039 0.0466986 
VAT1 -0.792656 0.00659124 0.106387 
KIF16B -0.794054 0.00515734 0.0913785 
CLINT1 -0.794242 0.000210253 0.011251 
SSR4 -0.796862 0.00177813 0.0459415 
KAZN -0.797089 0.00636506 0.104194 
LOC100507557 -0.797089 0.0098469 0.135332 
TLE2 -0.806614 0.00265407 0.0606398 
MFN1 -0.808489 0.000600305 0.0228958 
LAMA3 -0.808917 0.00799834 0.118634 
EHF -0.809108 0.00974873 0.134624 
ADAM15 -0.810991 0.000269626 0.013385 
GOLGA8A -0.814434 0.00542962 0.0940851 
RPS13 -0.815761 0.00731629 0.113773 
EGFL7 -0.818887 0.010085 0.136877 
SURF1 -0.820833 0.000808346 0.0277091 
RPS23 -0.82189 0.00784097 0.117265 
RPS20 -0.821986 0.000928502 0.0302855 
C19orf53 -0.823042 5.57E-05 0.00451079 
PP7080 -0.823324 0.00759773 0.114864 
SLC35E2B -0.823619 5.77E-05 0.00458818 
CYTH2 -0.823959 0.00307359 0.0665345 
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ERGIC3 -0.824316 0.00016366 0.00959143 
SLC35E2 -0.825064 0.00121773 0.0368051 
MPST -0.826162 0.00403007 0.0781985 
EML2 -0.826403 0.010294 0.138699 
GRIN1 -0.827285 0.0117566 0.149995 
C11orf1 -0.828439 0.00180149 0.0463787 
FADS3 -0.830256 0.000757639 0.0267565 
NCK2 -0.830456 0.00573139 0.0975052 
GBAS -0.832773 0.0116648 0.14922 
ESR1 -0.833012 0.0098884 0.135643 
FBXL17 -0.833737 0.00479413 0.0866128 
RPS29 -0.833929 0.00295884 0.065126 
FHL3 -0.834033 0.00682102 0.108656 
SRPK3 -0.834408 0.00538069 0.093462 
POU2F3 -0.835585 0.00555931 0.0954149 
PLEKHG5 -0.836838 0.00189983 0.0482215 
RPS4X -0.83824 0.00971453 0.134409 
PNPLA2 -0.838618 0.00890801 0.127029 
LOC100652768 -0.839354 0.0063212 0.103678 
EIF3E -0.839801 0.00264095 0.0604811 
TMEM198B -0.841137 0.00580212 0.097721 
THBS3 -0.843698 0.000677463 0.0247617 
TMOD3 -0.846224 7.61E-05 0.00551427 
SPSB2 -0.847041 0.0018099 0.0465122 
KIFC2 -0.847671 0.000963249 0.0309981 
PTPRF -0.849735 0.00027135 0.013385 
RPS7 -0.85417 0.00145143 0.0402408 
GLI4 -0.856252 0.00644573 0.105241 
IGSF8 -0.856391 0.000559294 0.0220913 
TBC1D16 -0.858075 0.000141465 0.00872416 
ZP3 -0.859352 0.00261647 0.0601621 
KRCC1 -0.859706 0.000156303 0.00927333 
MINPP1 -0.859797 0.000756881 0.0267565 
TMEM9 -0.86155 0.000111397 0.00743527 
FAM174B -0.861821 0.00164237 0.0435258 
SPPL2A -0.861866 0.000306717 0.0144508 
ARL1 -0.86219 0.00161453 0.043185 
ERVK13-1 -0.864365 0.00315507 0.0672879 
TMEM123 -0.866658 0.00954391 0.133199 
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RPL5 -0.866791 0.00269477 0.0613752 
NOTCH3 -0.86744 1.25E-05 0.00152959 
RAB4A -0.871258 0.00406128 0.0785757 
NANOS1 -0.876729 0.000798801 0.0276171 
PABPC1L -0.877514 0.00745373 0.11432 
GPR153 -0.877674 0.00102254 0.0321225 
RPL18 -0.877678 0.00577307 0.0975052 
EPHB4 -0.878061 0.000635186 0.023724 
ULK1 -0.878251 0.000161979 0.00953161 
LGALS3 -0.879487 0.000341112 0.0156121 
GLUD1 -0.880882 0.00194658 0.048977 
PRSS30P -0.882084 0.00694096 0.109844 
NR4A2 -0.882205 0.000734102 0.0262619 
LINGO1 -0.883165 0.00014379 0.00882136 
CCBP2 -0.883665 0.000534171 0.0215644 
TMCO3 -0.883675 0.00432373 0.0811656 
EEF1A1 -0.886904 0.00980511 0.135144 
FAM210B -0.887675 0.00705402 0.111267 
RPL38 -0.888778 0.00370316 0.0739451 
NEBL -0.889141 9.34E-06 0.00121341 
RPL32 -0.890337 0.00278466 0.062631 
EPB41L4A-AS1 -0.892122 0.00621765 0.102798 
CELSR1 -0.892809 0.000960605 0.0309936 
CD81 -0.894731 9.97E-05 0.00675046 
PFKFB3 -0.896034 0.000197835 0.0108858 
CAT -0.898054 0.000210708 0.011251 
TMEM179B -0.90201 0.000303386 0.0143879 
SLC11A2 -0.903617 0.00017117 0.00989204 
NRCAM -0.904292 0.000117023 0.00763404 
RPS6 -0.904893 0.00291765 0.0647136 
PVRL4 -0.905668 0.00295329 0.065126 
THNSL2 -0.90745 3.95E-05 0.00351259 
AIFM2 -0.907618 0.00285349 0.0637811 
LOC642852 -0.90798 0.00157546 0.0425344 
RPS27A -0.913186 0.000579379 0.0223938 
PTER -0.913332 0.000157105 0.0092827 
IRF2BP2 -0.915342 0.000979648 0.0312924 
PRODH -0.916159 0.00517745 0.0914746 
STX1A -0.919568 0.0036103 0.0731402 
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RPL23 -0.922254 0.00858591 0.124148 
MMP17 -0.92237 0.00823164 0.120887 
SUMF1 -0.922475 0.000293425 0.0140542 
HSPB1 -0.924254 0.0074468 0.11432 
GNPTG -0.925549 0.00291421 0.0647136 
RPS15A -0.928909 0.00185864 0.0472594 
LFNG -0.930159 0.00176133 0.045671 
MYO15B -0.930245 0.000818311 0.0278245 
PIGS -0.931796 0.000128927 0.0081883 
CSAD -0.932528 0.00383014 0.0754359 
COL1A1 -0.934014 0.00317492 0.0676112 
RPL23P8 -0.935384 0.00747409 0.114388 
EFEMP2 -0.937716 0.00752085 0.11469 
OLFM2 -0.938714 0.00864377 0.124472 
RPS18P9 -0.940563 0.00239201 0.0564165 
CD44 -0.948044 0.0023223 0.0554316 
EFCAB4A -0.949582 0.00270583 0.061433 
GPR155 -0.950683 0.00048027 0.0200697 
RFWD2 -0.950991 0.000121636 0.0078638 
RGS19 -0.952292 0.000200093 0.0108858 
STARD10 -0.952548 0.00853274 0.123736 
EPHX1 -0.952892 0.00423729 0.0804052 
RPS18 -0.953405 0.00132913 0.0385037 
MXRA7 -0.95488 0.000743098 0.0263873 
GNS -0.955849 0.000882749 0.029324 
MOSPD1 -0.95857 0.00222498 0.0540026 
MAP4K1 -0.958994 0.0081834 0.120634 
ID2 -0.96038 0.00583324 0.0978301 
RPS12 -0.962015 0.000772408 0.0270287 
NAMPT -0.96587 0.000358702 0.0162623 
MYOM1 -0.967669 0.00885991 0.126594 
GOLGA8B -0.972983 7.25E-05 0.00535713 
S100A1 -0.973124 0.00418634 0.0800457 
C3orf35 -0.976364 0.00253433 0.0586475 
CHAD -0.980183 0.00657448 0.10638 
CCDC64B -0.981041 0.000270551 0.013385 
GUCY2EP -0.981757 0.0114161 0.146992 
RPS27 -0.983833 0.000475237 0.0199171 
SPDYC -0.986111 0.000677379 0.0247617 
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IQCK -0.987574 0.000218215 0.0115662 
RPL34 -0.989094 0.00537247 0.0934318 
MLPH -0.990662 8.44E-05 0.00590906 
RPL31 -0.994335 0.00342567 0.0707562 
NAAA -1.00096 0.00095382 0.0309712 
DCST2 -1.00229 0.000566348 0.0222603 
ALDH2 -1.00486 0.0016326 0.0435231 
RPL26 -1.00673 0.00136784 0.0388957 
DDX11L2 -1.00957 0.00520051 0.0915947 
TRIL -1.00985 5.34E-05 0.00442803 
TMC4 -1.01021 2.86E-06 0.000502644 
MAPK10 -1.01055 0.00829117 0.121354 
KRTCAP3 -1.01401 0.000198177 0.0108858 
RIN2 -1.01653 0.00140473 0.0394172 
LINC00893 -1.01855 0.00238948 0.0564165 
XBP1 -1.02005 0.00373145 0.0742019 
STC2 -1.02426 0.00167991 0.0441212 
EEF1E1 -1.02847 0.00143709 0.0400746 
PGRMC1 -1.02867 0.000460188 0.0195133 
LOC440311 -1.02959 0.00575095 0.0975052 
FGFR3 -1.03173 0.00913771 0.129536 
ARHGEF25 -1.03224 6.97E-05 0.00523211 
HPN -1.03565 0.000680143 0.0247617 
CCDC40 -1.03763 0.00245145 0.0574675 
LOC100131320 -1.04094 0.00102121 0.0321225 
ZFAS1 -1.04399 0.000381436 0.0169205 
DNAI1 -1.04411 0.00140208 0.0394172 
GTF2A2 -1.04747 1.21E-05 0.00148756 
CNTD1 -1.05455 0.00326283 0.0687662 
GLTSCR2 -1.05611 0.000957423 0.0309936 
ST6GALNAC6 -1.05756 0.00101193 0.0320636 
RPL37A -1.05787 0.000810393 0.0277091 
GSDMB -1.05808 0.000922746 0.030166 
COL18A1 -1.06388 0.0016597 0.0437439 
FGF11 -1.06417 0.0019053 0.0482754 
SKAP1 -1.07015 0.000274104 0.0133958 
LINC00087 -1.07727 0.00218941 0.0532473 
ARFGAP3 -1.07924 6.72E-07 0.000146826 
HGD -1.08141 0.0032528 0.0686612 
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SLC1A5 -1.0819 0.00106387 0.0332708 
SNHG5 -1.08403 0.00064159 0.0238467 
BAIAP3 -1.08448 0.000777146 0.0271134 
PRRT1 -1.08472 0.00311484 0.0670097 
RPL37 -1.08698 0.000473369 0.0198967 
ASAH1 -1.08783 0.00164929 0.043629 
RHOU -1.09457 0.00806803 0.119422 
LINC00514 -1.0977 0.0082502 0.121 
PCBP2 -1.09863 3.34E-06 0.000566984 
ALG14 -1.09957 2.51E-07 6.23E-05 
MXI1 -1.10286 0.00625731 0.103217 
VIPR1 -1.10562 2.27E-06 0.000414299 
KNDC1 -1.10712 0.00459628 0.0844134 
SLC6A9 -1.10858 0.003636 0.0732127 
SYTL1 -1.10956 0.000145241 0.00887265 
VWCE -1.11062 0.00261443 0.0601621 
TSPAN31 -1.12185 3.74E-08 1.80E-05 
FTH1 -1.12387 0.00287664 0.0641989 
SLC27A1 -1.12522 1.97E-06 0.000381033 
BCL6 -1.12537 0.000664745 0.0245106 
AKR1C3 -1.13002 0.00934875 0.131346 
LOC100133669 -1.13215 0.000471711 0.019885 
VTCN1 -1.13271 0.000570443 0.0222603 
NOD2 -1.13338 0.000713588 0.0257195 
FLJ10038 -1.13574 0.00502692 0.0896873 
RINL -1.13591 0.00313895 0.0671428 
ABCC11 -1.13606 0.00661872 0.10644 
GNG7 -1.13941 0.00112258 0.0346558 
TPM2 -1.14109 0.00126124 0.0374143 
RPL27 -1.14336 0.000538473 0.0215644 
RNF152 -1.1521 0.000228973 0.0118319 
FCGRT -1.15335 0.00142114 0.0397066 
LOC100289495 -1.16127 0.000435681 0.0188625 
DLG5 -1.16893 5.34E-05 0.00442803 
ADCY1 -1.16941 0.00833988 0.121797 
RAB12 -1.17078 4.98E-06 0.000771838 
MYB -1.17293 0.00587418 0.0982461 
MMP14 -1.17492 0.00830269 0.121399 
KPNA7 -1.17495 0.00702075 0.110863 
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DGKQ -1.17759 8.23E-05 0.00581668 
DFNB59 -1.17925 0.00330501 0.069081 
SCNN1B -1.19126 0.00686366 0.10898 
DUSP5 -1.19835 1.54E-05 0.00174887 
C5orf63 -1.19878 0.00953257 0.13317 
CAPN9 -1.19918 0.00199056 0.0495646 
C20orf26 -1.20264 0.00734726 0.113773 
RPL15 -1.20638 9.21E-05 0.00635042 
IL13RA1 -1.21327 7.02E-09 4.47E-06 
CD24 -1.22673 0.00405396 0.0785564 
IDUA -1.22883 4.66E-05 0.00392764 
LINC00340 -1.22975 0.00155119 0.0421952 
FAM107B -1.23296 2.79E-05 0.00262869 
CACNA2D4 -1.23473 0.00536865 0.0934318 
ANXA2P1 -1.23522 0.00284772 0.0637508 
TSPAN6 -1.23784 1.27E-05 0.00153859 
10-Sep -1.23823 8.71E-06 0.00117368 
SLC9A2 -1.2391 0.00024965 0.0126288 
CYP4X1 -1.24223 0.000785157 0.0272762 
ATP6V1C2 -1.24454 0.000921935 0.030166 
TMEM240 -1.25763 0.00411635 0.0791519 
VMAC -1.25997 5.01E-05 0.00419769 
GSTA4 -1.2635 8.44E-06 0.00116287 
GSDMC -1.2643 1.43E-07 4.66E-05 
FAM117B -1.26511 0.00011521 0.00761919 
NAALADL2 -1.26865 0.00372262 0.0741284 
TPT1 -1.26894 0.000140403 0.00872416 
LGI2 -1.27317 6.85E-05 0.00519978 
ANXA2P2 -1.27443 4.63E-05 0.00392764 
CALML6 -1.27533 0.000305648 0.0144476 
FUT1 -1.27992 0.00343984 0.070846 
FLJ34503 -1.28047 0.010323 0.138961 
WIPF1 -1.28489 0.00244699 0.0574564 
VEGFA -1.30779 5.76E-05 0.00458818 
ZAP70 -1.31493 0.00368738 0.0739057 
ANXA2 -1.3162 2.08E-05 0.00215572 
SPON2 -1.32275 0.00103764 0.032521 
AGAP11 -1.32404 5.15E-06 0.000772727 
DEPTOR -1.32841 0.000869314 0.0291463 
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LOC399715 -1.33005 0.00117599 0.0359201 
TMEM52 -1.33427 6.38E-05 0.00488968 
GOLM1 -1.34756 0.00163455 0.0435231 
GAS5 -1.35295 1.98E-05 0.00207867 
NFU1 -1.35364 0.00151136 0.0415033 
BSCL2 -1.35398 0.000679912 0.0247617 
MET -1.35988 0.000375836 0.0167236 
ASS1 -1.36127 8.06E-05 0.00575433 
IL20RA -1.36143 4.57E-06 0.000731719 
SSPO -1.36149 1.70E-05 0.00188096 
PPM1J -1.36201 0.000493389 0.0203234 
ANKRD30A -1.36259 4.02E-06 0.000666107 
AKR1B1 -1.36303 0.000984507 0.0313325 
ENG -1.36409 0.000121361 0.0078638 
PCP2 -1.36979 1.02E-05 0.00130445 
SLC30A8 -1.38176 0.000570072 0.0222603 
CAPN12 -1.38288 3.41E-06 0.000571444 
TSKU -1.38485 0.000108727 0.00729075 
PRKAG2-AS1 -1.38838 0.00557222 0.0955229 
UBXN10 -1.39664 0.00151787 0.041564 
CEACAM5 -1.39667 0.00302417 0.0657609 
CSF3R -1.39992 0.00636767 0.104194 
APOD -1.40486 3.23E-07 7.90E-05 
YBX2 -1.41296 0.00666073 0.106816 
LINC00672 -1.41381 0.00389263 0.0763696 
CPNE7 -1.42467 0.00379845 0.0749141 
FLJ23867 -1.42536 9.96E-05 0.00675046 
SLCO2B1 -1.44026 0.00253379 0.0586475 
GSTA2 -1.4422 0.0089238 0.127105 
ZNF558 -1.44307 1.86E-07 5.15E-05 
RND2 -1.45169 0.00968637 0.134148 
RBM20 -1.45878 0.0113078 0.145948 
TLR9 -1.4597 0.0115101 0.147635 
CCDC146 -1.46238 0.000155446 0.00926059 
AKAP6 -1.46666 0.00138119 0.0391981 
SLC5A7 -1.47417 0.00736741 0.113797 
UPP2 -1.478 0.000499226 0.020447 
CBFA2T3 -1.48284 0.00165862 0.0437439 
CLEC1A -1.48307 0.0115076 0.147635 
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AKR1C1 -1.5032 0.000630652 0.0236159 
NAGS -1.50455 0.00707616 0.111372 
CECR1 -1.51333 4.33E-06 0.00070148 
GPR87 -1.51427 0.00159296 0.0428466 
UCN2 -1.52429 0.000960957 0.0309936 
OPRL1 -1.53427 0.00179402 0.046269 
GABRD -1.54356 1.18E-05 0.00147866 
TMSB15A -1.55548 0.0112936 0.145948 
COL3A1 -1.55974 0.00726684 0.113383 
FBLN2 -1.56662 0.00864173 0.124472 
CPAMD8 -1.57964 2.79E-05 0.00262869 
BCRP3 -1.58448 0.000302937 0.0143879 
SLPI -1.6058 0.000148993 0.00902533 
C20orf203 -1.6066 0.0101706 0.137422 
STAT4 -1.60983 0.00885457 0.126594 
CEACAM6 -1.64313 0.0016832 0.0441212 
RASD2 -1.64983 6.44E-06 0.000927914 
LINC00930 -1.65614 0.00130043 0.038029 
LINC00304 -1.65717 6.95E-07 0.000149632 
MUCL1 -1.66151 0.000280596 0.0136014 
TMEM59L -1.68435 0.00398697 0.0776758 
LOC100289187 -1.68549 0.000354867 0.0161392 
XYLT1 -1.68764 0.00528774 0.0925161 
KRT38 -1.69434 0.0066281 0.10644 
CHI3L2 -1.70273 0.000373164 0.0166561 
KRT17 -1.73186 0.00485103 0.0873125 
C6orf141 -1.7349 1.59E-05 0.00178818 
SPINK8 -1.82077 0.000197177 0.0108858 
CLEC7A -1.82225 3.86E-05 0.00346126 
LRRC32 -1.8311 1.21E-05 0.00148756 
PEBP4 -1.87085 0.000439683 0.0189389 
AZGP1 -1.96749 1.93E-07 5.15E-05 
ATAD3C -1.97713 1.67E-08 9.62E-06 
ABCC12 -1.98199 7.85E-06 0.00111419 
GJC3 -1.98811 8.91E-06 0.00117606 
PDE2A -2.00118 4.58E-09 3.67E-06 
TBX4 -2.03199 0.000193358 0.0108468 
RASIP1 -2.06261 1.49E-05 0.0017212 
AGT -2.07213 7.88E-06 0.00111419 
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LEMD1 -2.07605 0.000171779 0.00989204 
RASD1 -2.09605 1.85E-05 0.00200859 
KRT16 -2.11607 0.000332786 0.0153665 
IZUMO1 -2.15674 2.91E-05 0.00272747 
AKR1C2 -2.20714 1.67E-07 5.13E-05 
SHISA9 -2.71682 3.08E-10 4.44E-07 
PRSS3 -3.10627 5.24E-09 3.78E-06 
LRRK2 2.76706 3.30E-12 4.45E-08 
FRMPD4 2.74108 2.32E-07 0.000802072 
SNPH 2.50413 2.09E-06 0.00270252 
GPR158 2.378 3.92E-05 0.0154172 
LOC645638 2.35482 1.99E-05 0.0112465 
SYNE1 2.21137 2.21E-06 0.00270252 
CYP2C8 2.1685 6.23E-05 0.0204647 
STRA6 2.16048 7.40E-06 0.00532797 
STAB2 2.1565 4.68E-05 0.016587 
CNIH2 2.11714 0.000126763 0.0284583 
ABI3BP 2.0586 0.00010475 0.0271209 
RAD21L1 1.98781 5.53E-05 0.018631 
RCBTB2 1.98087 1.27E-08 8.54E-05 
C1orf95 1.98026 3.59E-07 0.000806297 
NELL2 1.94265 0.000149532 0.032487 
TRIM22 1.91057 0.000175449 0.0363583 
F13A1 1.9037 2.17E-05 0.0112465 
NXPE3 1.87834 1.02E-06 0.00152124 
CAMK2N2 1.85558 0.000238771 0.0428833 
REPS2 1.84049 0.000182849 0.0367608 
PKD1L1 1.81587 4.48E-05 0.016587 
PFN1P2 1.78891 0.00129276 0.112345 
COLEC12 1.76561 0.00195515 0.134955 
SYT1 1.76509 0.000101975 0.0269334 
GPER 1.74572 2.45E-05 0.0117748 
PART1 1.72574 2.82E-05 0.0126725 
SLC26A3 1.71116 0.00218333 0.140784 
ALDOC 1.6669 0.000193919 0.0373155 
ADAMTS12 1.64802 7.52E-06 0.00532797 
DHFR 1.63849 0.00110611 0.106424 
GHR 1.62505 2.98E-07 0.000802072 
CXCL17 1.61766 0.00118091 0.109702 
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MPP1 1.58976 0.000867624 0.0933047 
SCGN 1.57411 0.0012729 0.111561 
KIAA1324L 1.5658 0.000235159 0.0428833 
CES1 1.54048 0.00126269 0.111561 
IL1RAPL2 1.53265 0.000939602 0.0977896 
PFKFB1 1.51988 2.77E-07 0.000802072 
PCDHGC3 1.51562 0.000584842 0.0748657 
HMGN5 1.51503 0.00115085 0.108459 
TRO 1.50536 3.89E-05 0.0154172 
FAM111B 1.50047 0.000116779 0.0271209 
LOC729041 1.47244 0.000619766 0.0752095 
CCDC151 1.46632 0.00127546 0.111561 
ELOVL6 1.45665 0.00196953 0.134955 
SLC2A6 1.45617 0.000341334 0.0553948 
C15orf48 1.42316 0.00120608 0.110862 
SRGAP2 1.4009 0.00115948 0.108459 
CCDC136 1.37201 0.00171398 0.127298 
APOL3 1.34773 0.000841647 0.0921706 
TTLL7 1.34727 4.55E-07 0.000876191 
VEPH1 1.33362 0.000528223 0.0712776 
GATA3-AS1 1.32512 0.00168728 0.126265 
OXCT1 1.32086 2.17E-05 0.0112465 
MLLT11 1.30676 8.06E-05 0.0221502 
ZBED5-AS1 1.29923 4.01E-05 0.0154172 
ABCA5 1.29692 7.72E-05 0.0221184 
WDFY3-AS2 1.28864 0.00124644 0.111561 
METTL7A 1.28604 4.61E-05 0.016587 
OBSCN 1.26239 0.000237519 0.0428833 
TTC18 1.21929 0.0021345 0.139571 
FAM111A 1.21626 0.000111736 0.0271209 
PLCD4 1.20247 5.40E-05 0.018631 
INSIG1 1.1982 0.000669736 0.0798349 
NBPF10 1.19497 0.000438354 0.065607 
FFAR2 1.18962 0.000605555 0.0748657 
STK10 1.18577 0.000249119 0.0435797 
KRT7 1.17234 0.000448825 0.0658022 
LRP8 1.14967 0.000430357 0.065607 
SORBS1 1.14157 0.00149835 0.118028 
STX1B 1.12764 0.00135159 0.112906 
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GIPR 1.12483 0.000872783 0.0933047 
MAGEH1 1.08837 0.000436995 0.065607 
LOC729737 1.07951 0.00125317 0.111561 
TMEM64 1.0724 0.00211917 0.139245 
APOL1 1.07145 0.00115923 0.108459 
KMO 1.06589 0.00259884 0.148332 
CLN6 1.06275 0.00219962 0.14109 
CMYA5 1.05754 0.00181007 0.12969 
GOLGA2P5 1.0374 2.60E-05 0.0120785 
SCAMP5 1.02841 0.00132963 0.112906 
C9orf96 1.02596 0.00178834 0.129511 
DOC2A 1.00935 0.000497226 0.0705013 
MYO16 0.998879 3.91E-05 0.0154172 
MVK 0.974622 2.30E-05 0.0114715 
NOTCH2NL 0.968749 0.000916966 0.0964964 
COL12A1 0.958922 0.00188419 0.133579 
ENPP5 0.957253 0.00051543 0.0712776 
COQ10A 0.946274 0.00104552 0.103366 
PTPN14 0.945855 0.00145369 0.116555 
LPIN1 0.933355 0.00126339 0.111561 
AP4B1 0.93218 0.00231812 0.143265 
ELOVL7 0.927248 0.00232847 0.143265 
SLC36A1 0.917707 0.00136242 0.112906 
COPG1 0.916752 2.54E-06 0.00285427 
C1orf51 0.900304 0.000734128 0.0819686 
LOC145837 0.895014 0.000600821 0.0748657 
LCP1 0.887433 0.0020753 0.137787 
ALDH3B2 0.881453 0.0020559 0.137776 
PTPRU 0.871198 0.000578919 0.0748657 
PC 0.870815 0.00224889 0.142889 
GOLIM4 0.863273 0.00134631 0.112906 
FKBP10 0.859984 0.000547749 0.0730513 
PFKM 0.853081 3.73E-05 0.0154172 
BTN2A2 0.83724 0.000454313 0.0658022 
EML3 0.828823 0.00100139 0.100663 
SPIN3 0.81381 0.00240469 0.144295 
ALDH3B1 0.784482 0.000969513 0.098673 
TOMM40L 0.782841 0.000358117 0.0574267 
NUCB1 0.766174 0.000705174 0.0818853 
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PDE4DIP 0.754244 0.00179908 0.129592 
SLC25A35 0.713699 0.00235886 0.143773 
PLEKHA5 0.673017 0.00255097 0.148332 
SLC26A2 0.668646 0.0016709 0.126265 
KIAA1598 -0.642883 0.00250821 0.148182 
CALM2 -0.664414 0.001518 0.118881 
TMEM9 -0.683076 0.000606014 0.0748657 
PCNP -0.734345 0.00201943 0.136692 
MISP -0.738468 0.00256098 0.148332 
SEH1L -0.743447 0.00257151 0.148332 
S100A14 -0.748624 0.00172944 0.127298 
DYNLT3 -0.754159 0.00215045 0.139935 
GMFB -0.758642 0.00250101 0.148182 
JDP2 -0.760815 0.000663094 0.0797489 
PQLC3 -0.774298 0.00259749 0.148332 
YIPF4 -0.780146 0.00105293 0.103366 
RPS19 -0.781687 0.00105285 0.103366 
GLUL -0.786898 0.00157996 0.122311 
CACNA1I -0.791745 0.00229149 0.143265 
CLDND1 -0.83151 0.000974277 0.098673 
RPS5 -0.832131 0.00207652 0.137787 
AK3 -0.83293 0.00068064 0.080177 
MEX3D -0.841342 0.0021844 0.140784 
RPS11 -0.849103 0.00196027 0.134955 
OSTC -0.851914 0.00138304 0.112906 
SPOPL -0.852034 0.000340508 0.0553948 
STK17A -0.85637 0.00255334 0.148332 
WHSC1L1 -0.856384 0.000948247 0.0977896 
STX8 -0.861365 0.00059298 0.0748657 
LGALS3 -0.862214 0.000435065 0.065607 
PAFAH1B2 -0.881254 0.000174684 0.0363583 
FAM173B -0.902263 0.000376932 0.0595395 
CNIH -0.904576 0.0023178 0.143265 
PKP4 -0.9048 7.61E-05 0.0221184 
MGLL -0.914809 0.000255664 0.0441511 
RPS16 -0.916005 0.000736318 0.0819686 
C1orf198 -0.918594 0.00186932 0.133226 
SLC1A4 -0.922634 0.000286029 0.0484305 
RSL24D1 -0.932577 0.0017577 0.128478 
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VMA21 -0.934748 6.48E-05 0.0207928 
CCDC71L -0.938266 0.00233345 0.143265 
IRF2BP2 -0.962077 0.000287635 0.0484305 
TNFAIP8 -0.964265 0.00131034 0.112906 
C5orf15 -0.965323 0.00111409 0.106431 
RAB12 -0.966198 0.0013243 0.112906 
CPNE3 -0.987221 0.000684511 0.080177 
SMIM20 -0.987408 0.00176454 0.128478 
SOX4 -0.987627 3.91E-06 0.00344533 
EIF3E -1.01053 0.00105898 0.103366 
PTAFR -1.01554 0.00246364 0.146837 
JUND -1.01715 1.29E-05 0.00828583 
SLC1A5 -1.01762 0.00165503 0.125951 
MTHFD2 -1.01767 0.000451547 0.0658022 
CLIC4 -1.02756 0.00258871 0.148332 
FCHO1 -1.02766 0.000121693 0.0277832 
TSPAN6 -1.02919 0.00222055 0.141758 
CDK14 -1.03464 6.83E-06 0.00532797 
MYC -1.03621 0.000523983 0.0712776 
FAM167A -1.03802 0.00233068 0.143265 
EEF2 -1.03928 0.00136674 0.112906 
EEF1E1 -1.04186 0.000906826 0.0961807 
TES -1.05203 0.00120985 0.110862 
CAMK2N1 -1.05481 0.00195236 0.134955 
AHR -1.05641 0.00139916 0.113435 
EPB41L4A-AS1 -1.07519 0.00159936 0.123105 
AZGP1 -1.07615 0.000529158 0.0712776 
CHST8 -1.07682 0.00168704 0.126265 
IQCK -1.08487 0.000111643 0.0271209 
CPT1A -1.08946 2.00E-05 0.0112465 
CDC42SE2 -1.09201 9.05E-05 0.0243893 
SLC39A10 -1.09217 0.00148624 0.117763 
CXXC5 -1.09429 0.000114125 0.0271209 
HSPB1 -1.11089 0.00200732 0.136558 
SIAH1 -1.11234 1.99E-05 0.0112465 
GADD45B -1.12989 0.000187237 0.0370354 
PIK3CD -1.13908 0.00237842 0.144295 
IER3 -1.14482 0.000853719 0.0927387 
OSGIN1 -1.1722 0.00137588 0.112906 
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ZFAS1 -1.17705 0.00155992 0.121458 
ETNK2 -1.17949 0.00146366 0.11666 
ARL4C -1.18118 0.0022851 0.143265 
GAS5 -1.18155 0.00031828 0.0529288 
TAF9B -1.2217 7.03E-05 0.0215157 
FKBP4 -1.2236 0.00134798 0.112906 
FHL2 -1.23093 0.00239666 0.144295 
GALNT3 -1.24396 0.000520415 0.0712776 
IGFBP4 -1.24483 0.0019435 0.134955 
AKR1B10 -1.25354 0.00190907 0.134634 
EGR1 -1.27487 0.00241027 0.144295 
EIF4EBP1 -1.30086 0.00016633 0.035563 
CPAMD8 -1.31017 1.23E-05 0.00825541 
HR -1.31181 0.00172091 0.127298 
SNHG5 -1.33353 0.000115947 0.0271209 
B3GNT3 -1.33353 0.000759262 0.0838299 
MYB -1.34323 6.85E-05 0.0214595 
PDE2A -1.34822 0.00162782 0.124583 
LFNG -1.35933 4.09E-06 0.00344533 
NPNT -1.3873 0.000496431 0.0705013 
RASL11A -1.3894 0.000565692 0.0739793 
CA8 -1.3981 0.000220382 0.0418105 
CEBPB -1.44585 7.72E-05 0.0221184 
VTCN1 -1.44926 0.000380134 0.0595395 
MTHFD1L -1.45764 0.000247692 0.0435797 
KLF4 -1.46551 0.00197374 0.134955 
GJA1 -1.47487 0.00233989 0.143265 
TIAM1 -1.48433 0.000189713 0.0370354 
RNF165 -1.54648 0.00258722 0.148332 
TMEM240 -1.55546 0.000714406 0.0819686 
INSM1 -1.56465 0.000951035 0.0977896 
EGFL6 -1.56486 0.00211119 0.139245 
RAET1E -1.58735 0.00261504 0.148627 
LIMCH1 -1.59506 0.000112518 0.0271209 
GFRA1 -1.60909 0.000720935 0.0819686 
DGAT2 -1.60923 0.00107788 0.104454 
GPR87 -1.61354 0.000725571 0.0819686 
C18orf32 -1.6184 0.00204502 0.137732 
SLC6A9 -1.64652 6.08E-07 0.00102368 
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LOC100133669 -1.68275 3.85E-06 0.00344533 
FLRT3 -1.71496 4.03E-06 0.00344533 
TAT -1.7276 0.000611376 0.0748657 
FOXP2 -1.80867 0.00124289 0.111561 
C3 -1.82133 0.00140636 0.113435 
DHRS2 -1.8366 0.000178911 0.0365141 
ANXA1 -1.8424 0.000231267 0.0428833 
GPR124 -1.85838 0.000561842 0.0739793 
TFF2 -2.25491 0.000144108 0.0318219 
KRT16 -2.30423 7.97E-05 0.0221502 
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Breast cancer is the most common cancer and the second leading cause 
of cancer death in women. While ER-positive breast cancer subtypes are initially 
well-managed by targeted therapies targeting estrogen signaling, many women 
are suffering from recurrence of a more aggressive, hormone insensitive cancer 
5 or more years after initial remission. Late recurrence of hormone resistant 
breast cancer in patients who were previously successfully treated with anti-
estrogen therapies worsens overall long-term outcomes, and specific oncogenic 
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mutations may be driving late recurring aggressive disease in these patients. 
More complete characterization of the oncogenome of a tumor may allow for the 
possibility of customized therapy targeting each patient's specific oncogene-
activating mutations, and in doing so increase the probability of durable 
remission over the long term. Basic research on cell lines modeling different 
breast cancer subtypes enables discovery and characterization of novel driving 
oncogenes and their context in a breast cancer subtype model. 
The Wolf Hirschhorn Syndrome Candidate 1-Like 1 gene (WHSC1L1) is 
one of approximately 50 genes in the chromosome 8p11-p12 amplicon, an 
amplified region of the short arm of chromosome 8 found in 12-15\% of human 
breast cancers, as well as other cancer types such as lung. Amplification of the 
8p11-p12 region is most often found in breast cancers of the luminal B subtype. 
WHSC1L1 is a member of the NSD family of histone lysine methyltransferases, 
SET domain-containing proteins which catalyze the addition of a methyl group to 
lysines on the amino-terminal tail of histone H3 subunits. The WHSC1L1 gene 
expresses two known isoforms which code for two distinct proteins, WHSC1L1-
long and WHSC1L1-short. The short isoform of WHSC1L1 codes for the first 647 
of the 1437 amino acids present in the long isoform, and lacks the catalytic SET 
domain and several PHD and PWWP chromatin interacting domains, containing 
a single PWWP domain and a recently characterized acidic transactivation 
domain. 
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In both normal and tumor breast tissue, WHSC1L1-short is expressed at 
greater levels than WHSC1L1-long. Several breast cancer cell lines established 
in the Ethier lab harbor WHSC1L1 amplifications and also overexpress both 
isoforms of WHSC1L1. The SUM44 cell line is a highly ER-positive cell line 
model of luminal B breast cancer isolated from a pleural effusion metastasis of a 
patient with aggressive disease. It is known that the short isoform of WHSC1L1, 
WHSC1L1-short, is a potent driving oncogene in SUM44 cells, however the 
specific mechanism of WHSC1L1-short as an oncomodifier is not known. 
To investigate WHSC1L1-short function as an oncogene in SUM44 cells, 
we developed an shRNA knockdown model that specifically knocked down 
expression of WHSC1L1-short through its unique 3' UTR sequence 
(shWHSC1L1-short), and a model that knocked down both WHSC1L1 isoforms 
(shWHSC1L1-total). We found that knockdown of both total WHSC1L1 and 
WHSC1L1-short alone negatively affected SUM44 proliferation, and that 
WHSC1L1-short knockdown had a larger effect than knockdown of both 
isoforms. 
After finding that WHSC1L1 expression was required for typical 
proliferation rates of SUM44 cells, we performed genome-wide expression 
profiling of SUM44 WHSC1L1-short and total WHSC1L1 knockdown cell lines 
relative to a control SUM44 line transduced with shRNA against lacZ. Again we 
found that knockdown of the WHSC1L1-short alone had a greater affect than 
total WHSC1L1 knockdown, this time on the number of significantly differentially 
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expressed genes; 1131 genes were found to be differentially expressed in the 
WHSC1L1-short knockdown cells relative to shLacZ control, while 238 genes 
were differentially expressed in the total WHSC1L1 knockdown SUM44 cells 
relative to shLacZ control. Interestingly, the ESR1 gene, which codes for the 
estrogen receptor alpha protein, was significantly downregulated by WHSC1L1-
short knockdown. This was confirmed by immunoblotting with ERa antibody. 
While total WHSC1L1 knockdown also had a negative effect on ERa protein 
levels in SUM44, knockdown of WHSC1L1-short alone almost completely 
abrogated ERa in SUM44 as measured by western blot. We subsequently found 
that SUM44 cells were extremely sensitive to treatment with beta-estradiol, and 
that proliferation actually decreased upon as little as 100 picomolar beta-estradiol 
treatment, with dose-dependent decreases in proliferation as estrogen 
concentrations increased. We also found SUM44 cells to be relatively insensitive 
to Tamoxifen. 
Knockdown of WHSC1L1-short reduced proliferation of SUM44 cells in 
estrogen-free conditions, and treatment of SUM44 shWHSC1L1-short cells with 
increasing concentrations of beta-estradiol resulted in a marginal increase in 
proliferation up to 100pM beta-estradiol, then proliferation decreased with 
increasing beta-estradiol concentrations similar to results seen in SUM44 shLacZ 
control cells.  
After observing that WHSC1L1-short overexpression was required for 
expression of ERa in SUM44 cells, we asked whether knockdown of WHSC1L1-
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short affected genome-wide binding patterns of the estrogen receptor in SUM44 
cells. Interestingly we found that ERa was binding to thousands of genomic loci 
in the absence of exogenous estrogen. Treatment with high doses (10nM) of 
beta-estradiol for 45 minutes resulted in an approximately even increase in ER-
alpha binding across sites already bound in the absence of estrogen, with some 
additional weak binding sites, but no significant changes in the pattern of ERa 
binding. No ERa binding sites were detected in SUM44 shWHSC1L1-short cells 
under estrogen-free conditions, and weak ERa binding was detected in SUM44 
shWHSC1L1-short cells treated with 10nM beta-estradiol at loci where strong 
ERa binding was observed in control SUM44 cells, suggesting that WHSC1L1-
short knockdown was reducing ERa expression levels, which made less ERa 
available to bind to chromatin in SUM44 shWHSC1L1-short cells. 
Our investigation of WHSC1L1 oncogenic activity in SUM44 cells resulted 
in the interesting observation that the short isoform of WHSC1L1 is required for 
expression of the estrogen receptor alpha in these cells, and that ERa is bound 
extensively to chromatin without activation of ERa by estrogen. SUM44 is a 
model for luminal B breast cancer, and is highly ER-positive, and expresses little 
to no progesterone receptor (PR). While the implications of ERa expression 
dependence on WHSC1L1-short overexpression in SUM44 cells are not yet 
clear, the extensive binding of ERa to estrogen response elements (ERE's) in the 
absence of exogenous estrogen and the negative proliferative response of 
SUM44 to estrogen indicate that WHSC1L1 amplification and overexpression 
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may alter the biology of the estrogen receptor in breast cancers harboring 
WHSC1L1 amplification and overexpression. Additionally, the differences seen in 
ERa binding to chromatin and the negative response of SUM44 cells to ERa 
agonists illustrate the importance of researching ER-positive breast cancer using 
additional cell line models rather than consistently using MCF7 cells to represent 
ER-positive disease. 
The dominant role of the catalytically-inactive short isoform of WHSC1L1 
in regulating ERa expression and maintaining the proliferation rate of SUM44 
cells suggests that catalytically inactive isoforms of chromatin modifying enzymes 
can be important regulators of gene expression. Interestingly, recent work has 
shown that WHSC1L1-short is likely not regulating target gene expression 
through histone methylation, but instead is acting as a co-factor for a different 
chromatin-binding complex, the BRD4-CHD8 complex, which has been shown to 
be recruited to superenhancer regions (marked by histone acetylation) by 
WHSC1L1-short, which results in activation of pTEFb through BRD4 and directly 
activates target gene transcription. It will be important to avoid assumptions 
about binding substrate identities of catalytically inactive isoforms of future 
chromatin modifiers of interest, as the catalytically inactive isoforms of these 
genes may also bind to chromatin substrates unrelated to the substrate of the 
catalytically active isoform. 
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